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Abstract 
 
Antisera raised against recombinant human CYP4Z1 (4Z1), mouse Aryl 
hydrocarbon receptor (AhR), and C.elegans Latrophilin (LpH) proteins were 
titred over the course of several bleeds.  The sensitivity of the antibodies shows 
an increase over the course of several immunizations, with the minimum 
amount detected being 1 ng of 4Z1, 0.3 ng of Ah-R, and 0.3 ng of LpH.  
Terminal bleeds were taken for the AhR and LpH antisera.  The AhR antisera 
detects proteins in rat and mouse liver cytosol consistent with previous reports 
of the AhR. LpH is predicted to be localized in a membrane compartment on 
the basis of its primary structure, so sub-cellular fractions of C.elegans were 
isolated and tested, revealing a protein of ~113 kDa in a crude membrane 
preparation.  This protein was not solubilized in < 1% Emulgen 913, but was 
soluble in 2% dodecylmaltoside. 
A fresh 15k supernatant treated with 2% dodecylmaltoside showed a strong 
band of LpH protein at ~113 kDa.  However, 66 kDa band was detected when 
the samples were stored overnight at –80°C due to presence of a G protein 
coupled receptor proteolysis site (GPS) between position M536 and C547 of 
LpH, which is a characteristic feature in the LpH protein family. 
In order to study the expression of the CYP 4X1 in mouse tissues, RNase 
protection assays were performed.  Different tissues were assayed at the same 
time and the same riboprobe was used to hybridise all the samples. The CYP 
4\x1 probe was shown to be full length (-ve control).  However, the +ve control 
(RNase positive) shows an absence of signal when hybridised to the yeast 
tRNA demonstrating the specificity of the signal in the samples.  Several RNA 
 11
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 12
samples were hybridised with mouse cyp4X1 gene probe, such as aorta, brain 
and heart and liver.  The mouse cyp4X1 gene appears to have 12 exon from the 
genomic sequence and encodes a protein which high identity with the human 
and rat cyp4X1 gene.  The full-length of the probe was 424 b.p and the 
protected fragments were 177 b.p.  The murine cyp4X1 was not expressed in 
control liver, but is expressed in brain at high level. 
Cyp4X1 gene was also investigated in aorta tissue and found to be expressed at 
low levels.  Known inducers of hepatic cytochrome P450 were used 
(Ciprofibrate, TCDD, PB, and dexamethasone), but had no induction effect in 
the samples. 
Western blotting of brain confirmed that the cyp4X1 protein is expressed in 
brain, and quantification showed that this is a major cytochrome P450 in brain. 
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Chapter 1                      Introduction 
 
 
1.1 Cytochrome P450 
The cytochrome P450 enzymes are a super family of hemoproteins, which contain 
a thiolate-bound heme protoporphyrin IX prosthetic group and catalyse the 
oxidation of a large variety of substrates, including endogenous lipids and 
Xenobiotics.  They were described as a microsomal carbon monoxide binding 
pigment (Omura and Sato 1962).  Cytochrome P450 was discovered by 
Klingenberg and Garfinkle in 1958 as a new kind of pigment in rat liver 
microsomes (Klingenberg 2003), and it was characterised as a P450 hemoproteins 
by Omura and Sato (Klingenberg 2003).  At first, it was thought that the P450 
protein was a single protein. However, it later became apparent that there were 
several different P450s with differing substrate and physiochemical characteristics 
(Lewis 2001). 
A characteristic of all cytochrome P450 proteins is that in the reduced state they 
bind carbon monoxide giving a unique absorption maximum at 450 nm (Garfinkel 
1958) (Jecoate 1978).  The name of cytochrome P450 was derived from this unique 
absorption and named by Omura and Sato(Omura and Sato 1962; Omura and Sato 
1964). This spectral characteristic is due to the presence of the thiolate ligand 
which not found in most other heme proteins with histidine-derived imidazole 
ligand (Ortiz de Montellano 1997).  For instance, absorption of the ferrous-CO 
complex in myoglobin occurs at 423 nm and not at 450 nm  (Ortiz de Montellano 
1997). 
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The cytochrome P450 enzymes play an important role in the mixed function 
oxidase (MFO) system which consists of cytochrome P450, NADPH-P450 
cytochrome P450 reductase and a lipid component (phosphatidylcholine), in the 
detoxification of xenobiotic substances in a wide variety of species.  In order to 
distinguish between cytochrome P450s and other redox proteins such as 
cytochrome (a, b, and c), heme-thiolate enzymes were recently described (Lewis 
2001).  
The complete reaction can be summarized as follow, where RH is a drug substrate 
and ROH is the metabolite: 
   Cytochrome P450 
NADPH + RH + O2 + H
+
                                                     NADP
+
 + H2O + ROH. 
 
 
 
Cytochrome P450 is present in most living organisms, both plants and animals 
(Nelson et al. 1996).It has a molecular weight of approximately 50-60 kDa (Skett 
2001) , but shows an apparent mobility of 48-55 kDa on SDS-PAGE.  
Proteins of the cytochrome P450 superfamily occur as soluble or             
membrane-associated forms.  The soluble form is found in bacteria, whereas the 
membrane-bound form occurs in yeast and higher organisms, particularly in the 
endoplasmic reticulum and mitochondrial membranes (Lee 2003).  
CYP450 proteins usually contain approximately five hundred amino acids with 
haem as the prosthetic group (Hoch and de Montellano 2001).  The haem group in 
CYP450 is non-covalently bound to an apoprotein (Skett 2001),  but recently, it 
was found that some CYP4 family members are covalently linked to their 
prosthetic haem group by an ester linkage(Zheng et al. 2003). 
 18
Al-Anizy M                                                                                            Introduction 
In mammals, it was initially thought that P450 enzymes were found only in the 
liver and endocrine organs.  However, they were subsequently found in the kidney, 
prostate, breast (Williams et al. 2000), brain, skin and intestine (Gonzalez and Lee 
1996) ((Hellmold et al. 1998) ; (Hakkola et al. 1998).  
The liver is well-studied because it contains the greatest concentration of 
cytochrome P450 enzymes, and most of our knowledge regarding drug 
metabolism was obtained from studying the enzymes in liver.  
The typical function of cytochrome P450 is the mono-oxygenation of various 
substrates by introducing oxygen into a wide variety of substrates and structural 
classes of compounds (Porter and Coon 1991).  A cytochrome P450 catalytic cycle 
has been proposed  (Guengerich 1991) (Guengerich and Johnson 1997) 
(Guengerich et al. 1998) (Ortiz de Montellano 1997) (Mansuy 1998).  Although 
some parts of this mechanism are poorly understood, it is still accepted by most 
workers to date.  It participates in a wide variety of additional reactions, including 
epoxidations, dealkylations, deaminations and dehalogenations.  The cytochrome 
P450 system is responsible for biotransformation of drugs, environmental 
pollutants, pesticides and industrial chemicals (Simpson 1997), FiJ1.1.  
CYP450 enzymes can catalyse a vast variety of exogenous and endogenous 
substrates simultaneously due to its substrate specificity and overlapping reactions.  
For example, P450 can convert fatty acids to their Ȧ and/or Ȧ-1 hydroxylated form 
(Gibson et al. 1982) (Bains et al. 1985), or be involved in drug metabolism (by the 
CYP2D subfamily) (Distlerath et al. 1985)  
 
 19
Al-Anizy M                                                                                            Introduction 
Fig 1.1 The Functional Roles of Cytochrome P450s.  The Figure has been taken from 
Simpson (Simpson 1997) 
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1.2 Nomenclature of P450 
The nomenclature system introduced originally by Nebert et al (1987) proposes 
that all members of a family share >40% identity at the amino acid sequence level 
(e.g. CYP2A6 and CYP2B6), and members of a sub-family share >55% identity 
(e.g. CYP2A6 and CYP2A7) (Coon et al. 1992) (Nelson et al. 1996).  The CYP 
prefix is used to describe a P450, followed by an Arabic number for the family 
(e.g. CYP4), a letter for the sub-family and a number for individual gene (e.g. 
CYP4A1) and italicized names refer to genes ( e.g. CYP4A1)..   
To date, 265 CYP450 Families have been identified, of which 18 families and 43 
subfamilies are from mammals (http://drnelson.utmem.edu/famcount.html). 
There are now over 400 known members of the cytochrome P450 family in such 
diverse organisms as mammals, fish, insects, nematodes, plants, yeast, fungi and 
bacteria (Nelson 1999),
 
but the substrate specificities for only a few of these are 
known.  
 
 
1.3 Function of cytochrome P450 
Cytochrome P450 plays an important role in the metabolism of endogenous 
chemicals and the detoxification of natural toxins, drugs and xenobiotics.  
The main function of CYP450 is the mono-oxygenase activity whereby it 
introduces one atom of oxygen into a substrate but there are others functions 
depending on the substrate such as N-hydroxylation, N-oxidation, oxidative 
deaminations, S-dealkylations,  
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O-dealkylations, aliphatic and aromatic hydroxylation (Mansuy 1998).  CYP450 
enzymes catalyze many steps of sterol biosynthesis, metabolism of fatty acids, 
sterols, and the vast majority of drugs and xenobiotics.  Furthermore, they are 
responsible for the metabolism of xenobiotics to metabolites responsible for toxic 
or carcinogenic effects (Josephy 1997).  The vast number of catalytic reactions is 
due to the diversity and overlapping specificities of CYP450 enzymes.  For 
example, CYP1, CYP2 and CYP3 are responsible for metabolism of exogenous 
compounds, whereas other families such as CYP4 are responsible mainly for 
endogenous metabolism with some exogenous substrates such as phthalate ester 
(Lewis 2001).  
CYP450s from 13 mammalian gene families are involved in the metabolism of  
endogenous substrates that are physiologically important in the biosynthesis of 
thromboxanes (CYP5), prostacyclins (CYP8A), steroid hormones (CYP11, 
CYP17, CYP19 and CYP21), bile acids (CYP7A, CYP8B and CYP27A) and 
calcitriol (CYP27A and CYP27B) (Eggertsen et al. 1996)   (Shinki et al. 1997) 
(Shinki et al. 1997) (Hedlund et al. 2001).  
 
1) - Metabolism of exogenous compounds 
The role of CYP450 in the oxidation of foreign chemicals is that by converting 
these hydrophobic chemicals into hydrophilic forms (water soluble) by introducing 
polar groups, such as hydroxyl, the chemicals become easier to excrete or 
metabolize by other enzymes (Smith et al. 1998).  In humans, three CYP450 
families (CYP1, CYP2, and CYP3) are responsible for this phase-I metabolism of 
foreign compounds and  
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particularly they have an important role in the metabolism of drugs (Parikh et al. 
1997) (Murray 1999).  Some CYP450s such as CYP2D6, 2C19 and 3A4 were 
found to be involved in metabolism of a vast range of medicines (van der Weide 
and Steijns 1999) (Hasler 1999).  
 
2) - Biosynthesis and biotransformation of endogenous chemicals 
CYP450s are involved in catalyzing pathways of endogenous metabolism in both 
animals and plants (Lewis 2001). CYP51 has been shown to catalyze steroid 
hormone biosynthesis (Pikuleva 1999).  The biosynthesis and metabolism of 
steroids was found to be a major endogenous function of P450 (Lewis et al. 1998) 
(Nelson 1999).  The catalysis of cholesterol biosynthesis via CYP51 forms the first 
step in the formation of many steroid hormone derivatives, such as progesterone, 
pregnenolone, cortisol, testosterone, and estradiol (Takemori and Kominami 
1984).  Several CYP450s were found to be involved in the production of bile acid 
from cholesterol (Hasler 1999) (Pikuleva 1999).  Some CYP450s are involved in 
the metabolism of Vitamin D3 to the physiological active form, 1,25-
dihydroxyvitamin D3 in the animal tissues (Omura 1999).  CYP450 is involved in 
the synthesis and metabolism of eicosanoids (Omura 1999),  and in mammals, the 
CYP4 family is responsible for metabolizing fatty acids such as lauric acid, 
palmitic acid, myristic acid and arachidonic acid (Capdevila 1999).  Moreover, it 
was found that some CYP450s metabolize arachidonic acid (Capdevila and Falck 
2001) to produce epoxyeicosatrienoic acids (EETs, dihydroxyeicosatetraenoic 
acids (DiHETEs) and 19 and 20-hydroxyeicosatetrienoic acids (19- and 20-HETE) 
(Hoagland et al. 2001) (Yue et al. 2004).  The arachidonic acid metabolites are 
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thought to play an important role in the pathogenesis of hypertension  (Harder et 
al. 2000),  (Capdevila et al. 2000) (Holla et al. 2001),   
(Capdevila and Falck 2001),  (Hoagland et al. 2001)  and  (Llinas et al. 2004). 
Recently, it has been reported that non-fatty acid substrates are metabolized by 
CYP4A (Okita and Okita 2001).  
 
1.4 Redox Partners  
Redox partners are essential enzymes required for CYP450 function.  Two types 
of electron transfer protein are involved in the oxidation and reduction of CYP450, 
cytochrome P450 reductase and cytochrome b5.  The presence of cytochrome 
P450 reductase is essential for cytochrome P450 catalytic reactions (Dierks et al. 
1998). Cytochrome P450 reductase is a 68 kDa flavoprotein that has of two flavins 
prosthetic groups, FMN and FAD, and it is found in the mammalian endoplasmic 
reticulum (Strobel 1978).  FMN and FAD are found at in equal amounts in the 
cytochrome P450 reductase  (Strobel 1978).  The pathway of electron transfer is 
starting from NADPH to FAD to FMN and finally to P450 haem  (Shen et al. 
1989). 
Cytochrome b5 is a heme enzyme present in the endoplasmic reticulum and has a 
molecular weight of approximately 17 kDa  (Schenkman and Jansson 1999).  This 
protein facilitates many reactions including fatty acid desaturation, fatty acid 
elongation and cytochrome P450 monooxygenation (Schenkman and Jansson 
1999).  Cytochrome b5 was purified from liver  (Strittmatter 1978).  
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The role of cytochrome b5 in the CYP450 catalytic reaction is not well understood 
and still controversial.  It is known that some P450s can be stimulated by either b5 
or by the absence of heme b5  (abo-b5) with a lack of electron transfer, whereas 
some P450s were reported to mediate the reaction by cytochrome b5 (Yamazaki et 
al. 2001). Other studies found that cytochrome b5 was not involved in electron 
transfer to the cytochrome P450, but that it played an important role in the 
conformational effect (Loughran et al. 2001).  The transfer of electrons by 
cytochrome b5 to cytochrome P450 was not a direct step, but involved apo-b5 in 
the presence of holo-b5 formation (Guryev et al. 2001).  NADPH-cytochrome 
P450 reductase and cytochrome-b5 affect rate of metabolism and substrate 
specificity (Loughran et al. 2000).  For example, cytochrome b5 is important for 
 Ȧ-hydroxylation of endogenous fatty acid, arachidonic acid, to its physiologically 
important product (20-HETE) by CYP4A4 and CYP4A7 (Okita and Okita 2001). 
 
1.5 Mechanism of action 
Based on a number of observations a cyclic reaction was proposed by Estabrook et 
al (1971) for cytochrome P450 catalysed oxygenation reactions.  The reaction 
begins when the substrate binds to the active site of the cytochrome P450 to form a 
substrate ferric hem complex FiJ 1.2.  Two electrons are donated to cytochrome 
P450 by the reducing co-factor NADPH.  NADPH is a two electron donor but 
cytochrome P450 can only accept one electron at a time. NADPH-cytochrome 
P450 reductase which possesses two flavins prosthetic groups, has the ability to 
accept two electrons from NADPH and simultaneously transfer one electron each 
to two different cytochrome P450 molecules.  The ratio of NADPH-cytochrome 
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P450 reductase to cytochrome P450 molecules present in liver microsomes is 
about 20:1. 
It is during the first electron donation that the iron atom present in the cytochrome 
P450 is reduced to the ferrous state (Fe
+2
) and molecular oxygen binds to the 
cytochrome P450 complex.  A second electron is then donated to the cytochrome 
P450 from NADPH-cytochrome P450 reductase.  This is followed by electron 
rearrangement, insertion of an oxygen atom and product release with the 
generation of water or hydrogen peroxide (Guengerich et al. 1998)  (Plant 2003) 
The P450 absorption can be detected by measuring the difference in the spin state 
of heme iron (Josephy 1997).  As a result of heme ligation, cytochrome P450 has 
two types of states known as low spin state and high spin state(Josephy 1997). 
It is known that the heme group is a very strong chromophore and is affected by 
the nature of the heme ligand, the iron oxidation state and the presence of the 
protein substrate.  A change from the low spin state to the high spin state leads to a 
blue shift of maximal absorption in the optical spectrum (Jefcoate 1978)  (Ortiz de 
Montellano 1997).  Based on the P450 spectrum differences, three types of P450 
difference spectrum have been identified, Type-I, Type-2 and Type-3 (Lewis 
2001).  The Type-I difference spectrum has a maximum absorption at 
approximately 385-390 nm and a trough at approximately 420 nm (Josephy 1997). 
This difference spectrum represents the binding stage of a compound that 
displaces the distal ligand (H2O) and causes a low to high spin shift (Josephy 
1997). The Type-2 difference spectrum has a maximum absorption of 
approximately 425-435 nm and trough at 390-405 nm and represents the 
compound coordinating with the ferric heme. 
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The Type-III difference absorption is a reversal of Type-I (mirror image) with a 
maximum absorption at approximately 420 nm and a trough at 388-390 nm 
(Josephy 1997). 
 
 
 
 
 
 
 
 
 
FiJure. 1.2 Catalytic cycles for cytochrome P450 reactions (adapted from Plant N. 2003). 
Six steps in cytochrome P450 catalytic reactions are shown by numbers. Fe3+= oxidised 
cytochrome P450, Fe2+= reduced cytochrome P450, b5= cytochrome b5, RH=substrate, 
ROH=product, and e- = electron. 
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1.6 Classification of cytochrome P450 enzymes 
Cytochrome P450 enzymes are classified according to their protein sequence 
similarity (Nebert and Nelson 1991) and divided into gene families and 
subfamilies. 
265 families have now been identified, of which 18 families and 43 subfamilies 
are from mammals (http:// drnelson.utmem.edu/famcount.html.).  Cytochrome 
P450 enzymes can be divided into three classes on the basis of the redox partner. 
Class I P450s use a flavoprotein which contains FAD and iron-sulfur protein as 
electron transporters and this class is found in some bacteria and most mammalian 
mitochondrial P450s.  Class II P450, need a flavoprotein which contains FAD and 
FMN as electron transporters and this class is found in microsomes.  Class III 
P450s can gain electrons from the substrate without interacting with redox partners 
(self-contained system) and can be found in bacteria, mammals and plants (Ortiz 
de Montellano 1995) (De Mot and Parret 2002).  Class IV P450 has recently been 
identified. In these, the substrate has a flavoprotein reductase domain, an iron-
sulfur cluster and a cytochrome P450 enzyme (Roberts et al. 2002). 
In the last decade CYP450 studies have been expanded rapidly and hence it was 
essential to classify the CYP450s to families and subfamilies  
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1.7 Cytochrome P450 4 family 
CYP4 family is one of the oldest cytochrome P450 families and is thought to have 
evolved about 1.25 billion years ago (Simpson 1997) 
 
after the formation of the 
steroid biosynthetic genes (Simpson 1997) (Okita and Okita 2001).  CYP4 proteins 
were highly conserved during evolution and have been isolated from both 
mammals and invertebrates (Nelson 1998).  A highly conserved sequence of 13 
residues at around position 315.  (I helix) is a shared characteristic of this family 
(Bradfield et al. 1991). 
The cytochrome P450 gene family was first identified after the sequencing and 
cloning of CYP 4A1 by Hardwick et al (1987) (Hardwick et al. 1987). 
In humans, the CYP4 family consists of six sub-families (CYP4A, CYP4B, 
CYP4F, CYP4V, CYP4X and CYP4Z) (Demontellano et al. 1992) (http:// 
drnelson.utmem.edu/famcount.html.) (Capdevila et al. 2000) (Rieger et al. 2004). 
This family is thought to be related to cholesterol metabolizing enzymes, which 
are involved in maintaining membrane integrity in early eukaryotes (Simpson 
1997).  In mammals, the CYP4 enzymes are thought to be involved in the 
metabolism of endogenous substances including arachidonic acid, prostaglandins 
(PGs), and leukotrienes (LTs) (Capdevila and Falck 2001), (Kikuta et al. 2002). 
To date, the CYP4 family contains 18 subfamilies of which three were identified 
in mammals; CYP4A, CYP4B and CYP4F  (Nelson et al. 1996) (Simpson 1997). 
Most CYP4 genes are expressed in liver, kidney and lung and their expression is 
often known to be induced by peroxisome proliferators. 
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Members of the CYP4A family are responsible for the metabolism of fatty acids to 
Ȧ and Ȧ-1 hydroxylated forms, which is a preferable site for all CYP4 family 
(Roman 2002) (Needleman et al. 1986), and are involved in drug 
biotransformation like CYP2D6, 2C19 and 3A4 (van der Weide and Steijns 1999). 
CYP4 family is divided into subfamilies which of three subfamilies, CYP4A, 
CYP4B and CYP4F, are identified in mammalian species, Table 1.1.  Furthermore, 
two uncharacterized new members of the CYP4 family have been identified in this 
laboratory and named CYP4X1 and CYP4Z1 (Savas et al. 2005).  Two genes of 
CYP4Z1 sub-family were identified and isolated from human tissues (4Z1, 4Z2P), 
which one are a gene and the other pseudogene (Rieger et al. 2004).  The position 
of these genes (CYP4Z1 and CYP4Z2P) in the chromosome were found to be 
localized on chromosome 1P33 in head to head orientation in a distance of 166 kb 
(Rieger et al. 2004).  CYP4V subfamily has been identified by EST (expressed 
sequence tag) analysis as additional mammalian subfamily exists in the CYP4s. 
Recently, CYP4X1 has been identified in rats with a unique location in the brain 
and it is thought to play an important role in neurovascular function(Bylund et al. 
2002).  
 
CYP4 Family Species Located 
 
CYP4A 
 
CYP4B 
 
CYP4F 
 
Human, Rabbit, Rat, Mouse, Guinea Pig 
 
Human, Rabbit, Rat, Mouse 
 
Human, Rat 
 
Table 1.1 The mammalian CYP4 family. Members of the CYP4 family and the species 
as described by Lewis (2001). 
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1.8 The CYP4A subfamily 
This subfamily is the well-studied among all of the CYP4 family subfamilies since 
it was identified by Hardwick et al 1987, due to its inducibility by many foreign 
chemicals (Omiecinski et al. 1999).  The first CYP4 protein, CYP4A1 was isolated 
and characterised by Gibson et al in 1982 (Gibson et al. 1982) formerly designated 
as P452.  In the liver it forms only 1-4% of the total P450 isozymes (Sharma et al. 
1988).  
Currently, 24 proteins of the CYP4A subfamily have been identified in 
mammalian species including human(Kawashima et al. 1992), rabbit (Johnson et 
al. 1990) (Matsubara et al. 1987),  rat  (Kimura et al. 1989)  (Imaoka et al. 1990), 
mouse and guinea pig (Bell et al. 1993), Table 1.2. 
The CYP4A subfamily are known to metabolize endogenous fatty acids, 
eicosanoids and prostaglandins (PGs) (Lewis and Lake 1999)  (Capdevila et al. 
2002), and also some exogenous fatty acids such as phthalate ester mono-(2-
ethylhexyl)-phthalate (Lewis 2001).  Moreover, the CYP4A subfamily is involved 
in the metabolism of arachidonic acid to the active metabolite, 
hydroxyeicosatetraenoic acid (HETEs), an Ȧ-hydroxylated metabolite of 
arachidonic acid, and cis-epoxyeicosatrienoic acids (EETs) which have 
physiological importance in the blood flow of the kidneys, cornea and brain 
(Kroetz et al. 1997; Capdevila et al. 2000; Capdevila and Falck 2001; Okita and 
Okita 2001).  Although endogenous fatty acids, such as lauric acid are the main 
substrates of CYP4A forms, it has been reported that some non-fatty acids are 
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metabolised by CYP4A forms, e.J. all trans-retinoic acids can be metabolised to 
18-hydroxy retinoic acid by CYP4A11(Marill et al. 2000).  It was found that 
CYP4A1 gene expression can be induced by peroxisome proliferators, e.g. 
clofibrate (2-(4-chlorophenoxy)-2-methylpropionate), and that the major 
expression was in the liver and the kidney. 
Recently, a new member of CYP4A subfamily CYP4A21 was identified and 
isolated from pig liver and found to hydroxylate a steroid nucleus, particularly the 
alpha-hydroxylation of chenodoxycholic acid (Lundell et al. 2001). 
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Table 1.2:  Members of the CYP4A subfamily identified in different species 
 Species GenEMBL References 
CYP4A1 Rat M14972 
M33937 and M57718 
(Hardwick et al. 1987)  
(Kimura et al. 1989) 
CYP4A2 Rat M33938 and M57719 (Kimura et al. 1989)} 
CYP4A3 Rat M33936 (Kimura et al. 1989) 
CYP4A4 Rabbit J02818 
L04758 
(Palmer et al. 1993) 
(Matsubara et al. 1987) 
CYP4A5 Rabbit M28655 
X57209 
(Johnson et al. 1990) 
(Yokotani et al. 1991) 
CYP4A6 Rabbit M28656 
L04755 
(Johnson et al. 1990) 
(Muerhoff et al. 1992) 
CYP4A7 Rabbit M28657 (Johnson et al. 1990) 
CYP4A8 Rat M37828 (Stromstedt et al. 1990) 
Cyp4a10 Mouse X71478 (Bell et al. 1993) 
CYP4A11 Human S67580 (Imaoka et al. 1993) 
Cyp4a12 Mouse X71479 (Bell et al. 1993) 
CYP4A13 Guinea 
Pig 
X71481 (Bell et al. 1993) 
Cyp4a14 Mouse Y11639-Y11642 (Heng et al. 1997) 
CYP4A15 Koala AF252263 (Ngo et al. 2000) 
CYP4A16 Cat U91789 Gebremedhin, Lange et al., 
unpublished 
CYP4A17 Hamster No accession number  Bell, unpublished 
CYP4A18 Hamster No accession number Bell, unpublished 
CYP4A19 Hamster No accession number Bell, unpublished 
CYP4A20* Human AC026935 (replaced by 
AL450996, from genome) 
Mclay, unpublished 
CYP4A21 Pig AJ278474 (Lundell et al. 2001) 
CYP4A22 Human AL390073 (from genome) Mclay, unpublished 
CYP4A23 Pig AF384031 Van Es et al., unpublished 
CYP4A24 Pig AJ318096 (Lundell 2002) 
CYP4A25 Pig AJ318097 (Lundell 2002) 
*Now named 4Z1. 
Twenty-four CYP4A members are summarised in the Table (1.2). The accession numbers of 
CYP4A members are also shown in the table. The accession numbers of CYP4A20 and CYP4A22 
are from the human genomic sequence.  
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Typically, CYP4A is involved in the metabolism of endogenous fatty acids via Ȧ-
hydroxylation of long or medium fatty acids to short chain dicarboxylic acids 
which helps to prevent fatty acid accumulation in the liver (Okita and Okita 2001). 
The majority of this oxidation in the fatty acid was found to be in the omega (Ȧ) 
site and to some extent in the Ȧ-1 site.  
The most important catalytic oxidation by the CYP4A subfamily is that involved 
in the oxidation of the long chain poly unsaturated endogenous fatty acid, 
arachidonic acid.  Arachidonic acid can be metabolised by CYP4A1 to produce 
20-HETE, a vasoconstrictor, which is thought to play an important role in 
physiological functions (Powell et al. 1998; Nguyen et al. 1999; Capdevila and 
Falck 2001; Okita and Okita 2001) and is also involved in the pathogenesis of 
hypertension (Roman et al. 2000).  Inhibition of CYP4A expression (CYP4A1, 
CYP4A2 and CYP4A3) was found to reduce male rat hypertension which 
indicates a strong correlation between CYP4A expression and hypertension (Wang 
et al. 2001). 
In vivo, the hydroxylation of medium and long chain saturated fatty acids 
represents an important secondary pathway for fatty acid metabolism in 
hepatocytes during times when there is an increase in lipolysis and fatty acid 
transport to the liver (Okita and Okita 2001). 
In the kidney, the arachidonate CYP4A metabolites are hypothesised to be 
involved in the regulation of renal salt and water excretion (Lapuerta et al. 1988) 
(Schwartzman et al. 1990).  This makes the CYP4A subfamily the most well 
studied of all the CYP4 subfamilies. 
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In an E.coli expression system, it was found that the CYP4A enzyme activity was 
very high on long chain fatty acids and prostaglandins (PGE1) with a low rate of 
lauric acid metabolism (Roman et al. 1993).  Furthermore, studies in COS-1 cells 
revealed hydroxylation of PGE1 and PGA1 by CYP4A4 (Roman et al. 1993; Okita 
and Okita 2001).  The rabbit CYP4A5 was found to metabolize lauric acid and 
palmitic acids (Hosny et al. 1999).  CYP4A6 expressed in COS cells exhibited 
metabolism of lauric acid, but not prostaglandins (Roman et al. 1993). CYP4A7 
was able to metabolise lauric and arachidonic acids with low activity to PGE1 and  
PGA1 (Okita and Okita 2001). 
In humans, it is reported that CYP4A11 is the predominant lauric acid                 
Ȧ-hydroxylase in human liver, but the major Ȧ-hydroxylation of arachidonic acid 
was catalysed by CYP4F2 and to a lesser extent by CYP4A11 in human kidney 
(Powell et al. 1998) (Lasker et al. 2000).  CYP4A21 has been identified to catalyze 
the 6Į-hydroxylation of chenodeoxycholic cid to 3Į, 6Į and 7Į-trihydroxy-5ȕ-
cholanoic cid in pig liver (Lundell et al. 2001).  Furthermore, CYP4A21 was not 
able to hydroxylase lauric acid (Lundell et al. 2001; Okita and Okita 2001). 
Regulation of the CYP4A sub-family appears to be controlled by an orphan 
nuclear receptor, the peroxisome proliferators activated receptor (Llinas et al.) and 
most inducers of these enzymes are also involved in peroxisomal proliferation 
(Honkakoski and Negishi 2000) (Jeffery et al. 2004).  The CYP4A sub-family has 
been identified to be induced by many compounds that have been known as PPs. 
The PPs compounds include hypolipidemic agents (clofibrate and ciprofibrate), 
phthalate plasticizers (diethylhexylppthalate DEHP), solvents and lubricants 
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(perfluorooctanoic acid), non-steroidal anti-inflammatory drugs (aspirin and 
ibuprofen) and the steroid dehydroepiandesterone (DHEA)(Okita and Okita 2001). 
The induction of CYP4A sub-family is mediated by the activation of the PPARĮ, 
which heterodimerizes with RXR and binds to response elements in the target 
genes (Issemann et al. 1993) (Issemann et al. 1993). 
So far, no induction of CYP4A in brain has been found with ligands for PPARĮ. 
(Although most of this ligand is acids, which dont cross the BBB)  
 
1.9 CYP4B and CYP4F subfamilies 
The CYP4B subfamily contains the least members (4B1) of all the CYP4s (Nelson 
et al. 1996).  CYP4B1 has been expressed in human (Nhamburo et al. 1989), 
mouse (Imaoka et al. 1995), rats and rabbits (Gasser and Philpot 1989).  In mouse, 
the cyp4b1 was cloned from kidney cDNA library (Imaoka et al. 1995).  In rabbit, 
CYP4B found to be induced in the liver by  phenobarbital (PB).  However, no 
expression of CYP4B was found in rat liver (Gasser and Philpot 1989).  CYP4B1 
protein has been reported to hydroxylate short and medium chain length fatty acids 
(Fisher et al. 1998).  In mouse, it is thought that cyp4b1 is responsible for 
carcinogenesis in renal microsomes of male mice (Imaoka et al. 1995).  
Several forms of CYP4F subfamily have been identified in human and rat (Nelson 
et al. 1996), sea bass (Sabourault et al. 1999) (Bylund et al. 1999).  
The typical function of CYP4F is hydroxylation of a wide variety of fatty acid 
substrates such as eicosanoids including leukotrienes (LTBs) and prostaglandins 
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(PGs), arachidonic acid and HETEs (Kikuta et al. 1999) (Bylund et al. 2000) 
(Hashizume et al. 2001) (Bylund et al. 2003). 
 
1.10 CYP450 in the brain 
Brain tissue contains a very high amount of fat which causes difficulties in 
detecting low amounts of protein.  The brain can be exposed to neurotoxicant 
products such as xenobiotic metabolism from the liver and neurotransmitter 
system products (Lowndes et al. 1994).  
CYP450s (CYP4A and CYP2C) were found in brain tissue at very low levels 
(Warner et al. 1991). 
The content of CYP450 proteins in the brain is 0.5-2% of that in the liver 
(Hedlund et al. 2001)  (Alexander et al. 1998).  In most brain regions, the yield of 
P450 after extraction by hydrophobic chromatography is between 20 and 50 
pmol/J and it is higher in cerebellum (300 pmol) (Warner et al. 1991).  
Many cytochrome P450s are detected in the brain using in situ hybridization, 
immunohistochemical, catalytic activity and RT-PCR analysis with Southern blot  
quantitation have been the most used techniques (Table 1.3), which can show the 
tissue-specific brain P450 expression instead of general distribution (Strobel et al. 
2001). 
The low level of cytochrome P450 means that Western and immuno histochemical 
analysis have frequently given misleading results, because of the low signal, and 
confusion of noise with signal.   
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CYP4 CYP3 CYP2 CYP1 Family 
4A      4B       4F 3A 2A  2B  2C  2D  2E  2F 2G  2J 1A1     1B1 Subfamily 
 4        1           4 5  3                         1        2          1       Number of member 
                 4F4 
                    4F5 
                    4F6 
3A9   Northern blot 
detection 
4A2 
4A3 
4A8 
3A1 
3A2 
              2C6  2D1 2E1 
              2C7  2D4 
              2C11  2D5 
              2C12  2D18 
              2C13 
              2C23 
1A1         2B1 
    1A2         2B2   
RT-PCR detection 
4A3 
4A8 
                      2D1 2E1 
                         2D4 
 Western blot and 
protein sequence 
detection 
 
Table 1.3 CYPs of families 1-4 in Rat Brain (Adapted from Hedlund E, 2003). 
 
 
 
Detection of CYP450 in the brain tissues was not possible in the past.  However, it 
is now easily detected using several techniques such as RT-PCR (Warner et al. 
1991), Northern blotting techniques, Immunohistochemistry, RNase protection 
assay and In situ hybridization techniques.  
The presence of CYP450 at low levels in brain tissue does not mean that these 
enzymes are unimportant in the physiology or toxicology of the brain. 
For example Aromatase, a cytochrome P450 enzyme which catalyses the 
conversion of androgens to estrogens in a specific brain area is present at a very 
low levels in the brain but play an important role in brain physiology (Sanghera et 
al. 1991) (Warner and Gustafsson 1994). 
Cytochrome P450 plays an important role in biosynthesis and metabolism of 
neurosteroids, vasoactive eicosanoids, retinoids and cholesterol in the brain 
(Hedlund et al. 2001) (Lund et al. 1999) as well as metabolism of dopamine and 
anandamide, brain neurotransmitter (Bornheim et al. 1995; Hiroi et al. 1998). 
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A high amount of fatty acids are present in the brain, including polyunsaturated 
fatty acids docosahexaenoate and arachidonate, which are of physiological 
importance in the brain (Bylund et al. 2002). 
Several CYP activities or mRNA have been reported in the nervous system, 
predominantly of types metabolising fatty acids and xenobiotics (sub-classes 
CYP2C,-2D, -2E and 4).  CYP450s (CYP2C7, 2C11, 2E1, 4A3, and 4A8) can be 
induced by solvents such as ethanol (Warner and Gustafsson 1994).  
A new CYP450 subfamily, CYP46, has also been identified in multiple subregions 
of mouse brain (Lund et al. 1999). 
Different CYP450s isoform and amounts are expressed in different cell types in 
the brain (Farin and Omiecinski 1993; Lowndes et al. 1994).  For example, 
CYP2E1 was found to be expressed in neurons but not in glia (Hansson et al. 
1990) (Anandatheerthavarada et al. 1993). 
In human, only two subfamilies of CYP4 have been identified in the brain, 
CYP4A and CYP4F (Bylund et al. 2002).  CYP4A protein identification was 
carried out by Western blotting and it was found that CYP4A protein function 
could be detected using  
CYP4A antiserum in brain and prostate (Stromstedt et al. 1994).  It is also known 
that antisera can cross-react, whereas RT-PCR/ protections are much more 
specific. 
CYP4A is expressed in the brain at low levels (Warner and Gustafsson 1994) and 
(Stromstedt et al. 1994).  However, fatty acid hydroxylation (Ȧ-side chain) occurs 
at high levels in the brain so another, as yet unidentified, P450 enzyme may be 
responsible for this. 
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The amount of the CYP4A content in the brain is 0.1% of that in the liver 
(Stromstedt et al. 1994). 
The members of the CYP4 family present in brain include CYP4A1 (isolated from 
human libraries by PCR), and CYP4A3 (Yun et al. 1998).  Both of these genes are 
expressed in brain tissues such as cerebral cortex, cerebellum and brain stem. 
Finally, CYP4X1 expression has been identified in the brain stem, hippocampus, 
cortex, cerebellum and vascular endothelial cells of Sprague-Dawley rat (Bylund 
et al. 2002).  In the same study, CYP4X1 shows 41-51% identity with that of 
CYP4A, CYP4B and CYP4F subfamily.  CYP4X1 was found to be highly and 
specifically expressed in the rat brain tissues (Bylund et al. 2002).  The role of 
CYP4X1 is not yet known, but it may play a role in neurovascular function. 
 
1.11 General P450s expressed in brain tissue 
Apart from the CYP4 family, several other P450s has been identified in brain. 
CYP2C and CYP2D are expressed in the brain and CYP2D6 is involved in the 
metabolism of neurotransmitters such as dopamine and anandamide (Hiroi et al. 
1998) (Smith and Sachse 2001).  One gene from the CYP7 family (CYP7B) has 
been found to be expressed in rat and mouse hippocampus (Stapleton et al. 1995) 
(Warner et al. 1989) (Akwa et al. 1993) (Rose et al. 1997).  CYP7B has been 
shown to preferentially catalyse the hydroxylation of the neurosteroid DHEA, with 
a significant activity against pregnenolone.  CYP7B1 is strongly expressed in rat 
and mouse hippocampus and is responsible for the metabolism of DHEA, 
pregnenolone and 25-hydroxycholesterol to 7Į-hydroxy product.  Another 
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CYP450 which is highly expressed in mouse brain is CYP2J9 (Qu et al. 2001) and 
the role of this P450 is as yet unknown. 
A specific expression of CYP4X1 has been identified in neurons such as the brain 
stem, hippocampus, cortex, cerebellum and vascular endothelial cell  (Bylund et 
al. 2002). 
The function of CYP4X1 is not known yet, but it thought that this P450 might play 
un important role in neurovascular function (Bylund et al. 2002). 
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1.12 Expression of CYP4A genes  
CYP4A1 is expressed in the liver and kidney of the rat and can be induced by 
peroxisome proliferators such as clofibrate [2-(4-chlorophenoxy)-2-
methylpropionate].  The CYP4A subfamily genes are between 10-15 kb in size 
and transcribe to mRNAs of about 1.5 kb long. Expression of CYP4A may be 
tissue-specific and sex specific.  
 
1.12.1 Expression of CYP4A genes in Rat 
CYP4A was first identified and isolated in the rat (Tamburini et al. 1984).  The 
CYP4A family has four members, CYP4A1, CYP4A2, CYP4A3 and CYP4A8. 
Two of them have been identified from genomic clones (CYP4A1, CYP4A2) and 
the other two are cDNA (CYP4A3 and CYP4A8).  The rat CYP4A1, CYP4A2 and 
CYP4A3 are found in the liver and kidney tissues and can be induced by exposure 
to peroxisome proliferators such as clofibrate.  The high induction of this gene is 
found in the liver (Kimura et al. 1989).  In the liver, CYP4A1 and CYP4A3 
mRNA expression is found in the centrolobular region (Bell and Elcombe 1991), 
whereas in the kidney, expression is localised in the proximal convoluted tubule 
(Bell and Elcombe 1991).  CYP4A1 is also expressed in extrahepatic tissues such 
as lung at very low levels (Stromstedt et al. 1994).  However, this does not agree 
with work by Bell et al (Bell et al. 1992).  
The CYP4A2 gene is expressed in a sex-specific manner in rats, with no 
expression in the female liver or kidney (Sundseth and Waxman 1992). 
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In males, CYP4A2 is expressed at low levels in the liver and induced strongly by 
clofibrate.  In male kidney, CYP4A2 is highly expressed in untreated animals with 
low levels of induction by clofibrate(Kimura et al. 1989). 
The sex specificity of CYP4A2 is regulated by the different growth hormone 
profiles between the sexes (Waxman et al. 1991).  In the male liver, continuous 
exposure to growth hormone leads to inhibition of the CYP4A2 gene (Sundseth 
and Waxman 1992).  
CYP4A3 is expressed in the lung, prostate, cerebellum, brain cortex, 
hypothalamus-preotic area and brainstem, but is not expressed in the seminal 
vesicle (Stromstedt et al. 1994).  CYP4A3 is expressed in liver and kidney and is 
strongly induced by peroxisome proliferators (Kimura et al. 1989).  
CYP4A8 is expressed in the prostate, kidney and retina (Stromstedt et al. 1994). 
Expression of CYP4A8 was found to be localised in the proximal tubules of the rat 
kidney using in situ hybridisation methods.  This gene is not expressed in the liver 
(Stromstedt et al. 1994).  Stromstedt et al, used castrated rats and androgen 
releasing implants to induce the CYP4A8 gene.  In castrated rats, CYP4A8 
expression in the prostate was completely abolished, however expression was 
restored by testosterone treatment.  
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1.12.2 Expression of CYP4A genes in Mouse 
To date, three members of the cyp4a family (cyp4a10, cyp4a12, and cyp4a14) 
have been identified in the mouse (Henderson et al. 1994) (Bell et al. 1993) (Heng 
et al. 1997).  Cyp4a10 was identified by Bell et al (1993) using PCR to clone a 
partial murine cyp4a10 cDNA fragment.  Specific primers were used to generate 
PCR product from a highly conserved sequence (exon 8 and 12) homologue to the 
CYP4A1 gene.  A full-length rat CYP4A1 cDNA probe was used to isolate the 
full-length murine cyp4a10 cDNA from mouse liver and it was found to be 
identical to the partial PCR fragment cloned by Bell et al, 1993).  It was found that 
cyp4a10 was highly induced using methylclofenapate (Sanghera et al.) in mouse 
liver and kidney (Bell et al. 1993).  The deduced cDNA of cyp4a10 encodes 509 
amino acids and the full-length cDNA was approximately 1.6 kb. 
Sequence alignment showed that mouse cyp4a10 and cyp4a14 were similar to rat 
CYP4A8 and CYP4A2 respectively.  
The other cyp4a genes expressed in the mouse liver are cyp4a12 and cyp4a14.  
The mouse cyp4a12 gene is highly expressed in the male liver and kidney and is 
not induced by treatment with MCP.  In female liver and kidney, the cyp4a12 is 
expressed at low levels, but it is highly induced following treatment with MCP 
(Bell et al. 1993).  This means a cyp4a12 shows a sex specific expression pattern. 
Cyp4a12 is found on chromosome 4 in a region synteric with human chromosome 
1. 
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1.12.3 Expression of CYP4A genes in Rabbit 
Four rabbit CYP4A genes (CYP4A4, CYP4A5, CYP4A6 and CYP4A7) have been 
identified (Nelson et al. 1996).  CYP4A1 is expressed in the aorta of rabbits and is 
not inducible by treatment with ciprofibrate (Irizar and Ioannides 1995).  CYP4A4 
is expressed in liver, lung, small intestine and uterus of pregnant rabbits (Palmer et 
al; 1993a) and is induced by treatment with progesterone (Matsubara et al. 1987).  
CYP4A5 is expressed in liver and kidney and is induced at very low levels in the 
liver following treatment with clofibrate (Roman et al. 1993). 
Induction of CYP4A5 in the liver by clofibrate was found to be slightly induced, 
but no induction of this gene was found in the kidney (Roman et al. 1993). 
CYP4A6 was found to be highly induced by treatment with clofibrate (Yokotani et 
al. 1989) (Roman et al. 1993). 
CYP4A7 is expressed in the liver, kidney and small intestine, whereas induction of 
this gene by clofibrate leads to expression of this gene in the liver but not kidney 
(Yokotani et al. 1989) (Roman et al. 1993). 
 
1.12.4 Expression of CYP4A genes in Human 
A single gene in the human CYP4A family (CYP4A11) has been identified so far. 
Human CYP4A11 is located on chromosome 1 (Bell et al. 1993) and the cDNA 
was isolated from a kidney cDNA library (Imaoka et al. 1993) (Palmer et al. 
1993).  Human CYP4A11 is highly expressed in the kidney and also found in liver 
and lung (Palmer et al. 1993) (Imaoka et al. 1993). 
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1.12.5 Expression of CYP4A genes in Guinea Pig 
Only a partial cDNA clone of CYP4A13 has been cloned from guinea pig liver 
(Bell et al. 1993).  The sequence of the cloned guinea pig CYP4A13 is similar to 
rat and mouse genes, 77% and 82% respectively.  CYP4A13 was found to be non-
inducible in both male and female guinea pig treated with peroxisome proliferators 
(Bell et al. 1993). 
 
1.13 The novel P450s 4Z1and 4X1 
Our laboratory has cloned two novel human cytochrome P450, known as CYP4X1 
and CYP4Z1.  However, nothing is known of the function of these two P450s; the 
substrate specificity of these P450s is likely to be of interest.  
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1.14 Black Widow Spider Venom (BWSV) 
Over the last decade the venom of black widow spider has been intensively 
studied.  This is because the black widow spider (BWS) venom has a component 
named Į-latrotoxin, which has been shown to be extremely useful for studying 
synaptic transmission.  Clinically, black widow spider bites are not a significant 
health problem for humans because they rarely cause serious disease.  In severe 
cases, the patient has a generalized muscle pain, abdominal cramps, blood 
pressure, and tachycardia (Muller 1993).  The active components of the venom of 
black widow spider are high molecular weight proteins compared with other spider 
venoms (Frontali et al. 1976).  Seven separate venom components were isolated by 
further ion exchange and hydrophobic fractionations(Krasnoperov et al. 1997).  
These components are named Į-latrocrustatoxin (Į-LCT), Į-latroinsectotoxin, ȕ-
latroinsectotoxin (ȕ-LIT), Ȗ-latroinsectotoxin (Ȗ-LIT), į-latroinsectotoxin (į-LIT), 
İ-latroinsectotoxin (İ-LIT) and Į-latrotoxin (Į-LTX).  Only Į-LTX is a vertebrate 
toxin (Knipper et al. 1986).  Į-latrotoxin (Į-LTX) is a high molecular weight 
protein (120 kDa) on SDS-PAGE  (Sudhof 2001) (Frontali et al. 1976).  
Į-latrotoxin stimulates exocytosis only after binding to specific neuronal receptors 
(Tzeng and Siekevitz 1979).  Two classes of receptors for Į-latrotoxin have been 
identified in brain, neurexin (Ushkaryov et al. 1992) (Ushkaryov et al. 2004) and 
latrophilin (CIRL)(Davletov et al. 1996) (Krasnoperov et al. 1996) (Tobaben et al. 
2002).  Neurexin binds Į-LTX in the presence of Ca²+ , whereas latrophilin or 
CIRL (Calcium Independent Receptor for Latrotoxin) binds Į-LTX without the 
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presence of Ca²
+
 [calcium independent] (Sugita et al. 1998) (Ichtchenko et al. 
1999)  (Petrenko et al. 1999). 
Recently, a third Į-LTX receptor, protein-tyrosine phosphatase-ı, has been 
identified that binds toxin in a Ca²
+
 -independent manner (Krasnoperov et al. 
2002).  
The mechanism of the interaction between the latrotoxin and these receptors 
(latrophilin and neurexin) has still not been fully understood.  It was proposed that 
these receptors serve as targeting sites to bring the toxin to the necessary location 
on the cell surface.  The nematode C.elegans is used as a model system to examine 
the relationship between the BWSV and the latrophilin receptors. 
 
1.14.1 Latrophilin/CIRL (LPH) 
Į latrophilin is a neurotoxin from black widow spider venom, which causes 
massive exocytosis of synaptic vesicles (Lelianova et al. 1997).  The Latrophilin 
receptor was isolated from rat (Bittner 2000) and bovine brain membranes by 
affinity chromatography (Davletov et al. 1996) (Krasnoperov et al. 1996).  Three 
closely related forms of latrophilin are expressed in vertebrates (Sugita et al. 
1998).  These forms of latrophilin are latrophilin-1, latrophilin-2, and latrophilin-3.  
When these forms are expressed in various tissues, only latrophilin-1 and 
latrophilin-2 bind to Į-LTX at nanomolar concentrations, whereas the latrophilin-3 
protein cannot bind the toxin (Ichtchenko et al. 1998).  LpH 1 and LpH 3 are 
highly expressed in mammalian brain, wherease LpH 2 is expressed ubiquitously 
(Sugita et al. 1998) (Ichtchenko et al. 1999) (Matsushita et al. 1999).  All of the 
latrophilins are G-protein coupled receptors with large intra and extracellular 
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domains and all have the same domain structure (Lelianova et al. 1997)  (Henkel 
and Sankaranarayanan 1999).  However, the C.elegans latrophilin is 
uncharacterised.  FiJ 1.3, shows the structural domains of latrophilin (Sugita et al. 
1998) (Modified from Sugita et al, 1998).  Latrophilin consists of four domains: 
lectin-like domain, olfactomedin-like domain, the domain which shows homology 
with G-protein coupled receptor BAI1-3 a brain specific angiogenesis inhibitor 
and cysteine rich domain (Sugita et al. 1998) (Danilevich et al. 1999). 
The cysteine rich sequence is thought to be responsible for a proteolytic cleavage 
signal during the maturation of G-protein-linked receptor (Krasnoperov et al. 
1999)  (Ichtchenko et al. 1999).  All of these domains are located in the 
extracellular plasma membrane and contains ~ 500 amino acids.  The intracellular 
part has seven transmembrane regions of latrophilin, similar to the 
calcitonin/secretin family of G-protein coupled receptors.  It also contains a long 
intracellular C-terminal tail, which is approximately 500 amino acids in length.  
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Figure 1.3 Domain structures of latrophilin/CIRL 
Four domains are present in the extracellular region, while no domains in the intracellular region. 
The seven transmembrane regions are similar to those in the calcitonin/secretin receptor family.  
[Modified from Sugita et al, 1998]. 
 
 
Latrophilin and neurexin IĮ are known to bind the mammalian-specific Į-LTX. 
Therefore, homologues of these receptors in C.elegans may be responsible for the 
latrotoxin effects in C.elegans. 
The C.elegans latrophilin homologue was compared with the rat latrophilin 
homologue and showed several conserved domains.  FiJure 1.4, shows alignment 
of the C.elegans latrophilin domains and rat latrophilin domains.  These domains 
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are the galactose-binding lectin at residues (51-133), a hormone receptor motif at 
residues (181-240), a GPS (G-protein-coupled receptor protease cleavage site) 
motif at residues (493-541), a seven-transmembrane domain of the secretin family 
at residues (548-799), and a sequence of four conserved cysteine residues at   
(815-870).  
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493-541 
7-TM 
secretin 
 
548-799 
4 Cys 
 
 
815-870 
Hormone 
receptor 
motif 
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Galactose 
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1 1014
1 
1466
A
B
FiJure 1.4  Domain structure of the latrophilin.  
(A) shows the C.elegans homologue. A galactose-binding lectin domain (51-133 is shown by a 
black box, hormone receptor motif (181-240) is shown by solid grey box. The G-protein-coupled 
receptor proteolytic site domain (493-541) is shown by black colour on a grey background. The 
seven transmembrane domain (7-TM secretin) (548-799) is shown by black dots on a white 
background, that similar to those of the calcitonin/secretin receptor family. A domain of four 
conserved cysteine residues (815-870) is shown by black lines on a white background. (B) shows 
the rat latrophilin homologue.  Protein conserved region is shown by alignment of image (A) and 
(B). Labelling numbers (1-1014) and (1-1466) show total amino acid size of C.elegans and rat 
latrophilin respectively.      
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In order to understanding the function of Į-latrotoxin, LpH 1 and neurexin 1 
knock-out mice has been produced and demonstrated that both LpH 1 and 
neurexin were a major latrotoxin receptors in brain (Tobaben et al. 2002).  
The role of latrophilin in vivo and the natural ligand of the receptors are unknown.  
Recent work in this laboratory has shown that it mediates the action of black 
widow spider venom, and so it is important to find out if latrophilin has a similar 
mechanism of action in C.elegans.  The development of antibodies against this 
protein is an essential first step for subsequent functional analysis.  
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1.15 Aryl hydrocarbon receptor (AhR)    
Aromatic hydrocarbons can be classified into two types based on their chemical 
structure. Type-I are halogenated aromatic hydrocarbons (HAHs) and Type-II are 
non-halogenated polycyclic aromatic hydrocarbons (PAHs).  
The AhR gene is present in all vertebrates and even in Caenorhabditis elegans 
(Hahn 2002) (Nebert et al. 2004). 
The Aryl hydrocarbon receptor is a soluble protein present in most organs and 
cells that shows high affinity specific binding to certain planar aromatic 
compounds, such as polycyclic aromatic compounds (e.g., 3-methylcholanthrene) 
and halogenated aromatic compounds (e.g., TCDD [2,3,7,8 tetrachlorodibenzo-p-
dioxin]) and initiates the coordinated expression of human CYP1A1, CYP1A2 and 
CYP1B1 (Hedlund et al. 2001) (Bell and Poland 2000) (Poland et al. 1991) 
(Poland and Glover 1990) (Poland and Glover 1987). 
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor 
belonging to the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of 
transcription factors. 
This bHLH/PAS family plays an important role in the regulation of circadian 
rhythms, activation of xenobiotic responses and cell fate determination.  The PAS 
represents the first letters of the three members of the family PER (product of 
Drosophila Period gene), ARNT (AH receptor nuclear translocator) and SIM 
(product of Drosophila Single-minded protein ) (Crews 1998) (Korkalainen et al. 
2004). 
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The most potent inducing agent for AhR is the environmental pollutant and 
carcinogen TCDD, which is a very strong CYP4A1 inducer.  It has also been 
known some endogenous ligand such as flavonoids in the dietary (Ashida 2000), 
indols and tryptophan  
derivatives and benzoflavones (Denison and Nagy 2003).  Furthermore, some 
urine products such as indirubin and indigo were found to be  very potent inducers 
of AhR than TCDD in a yeast assay system (Adachi et al. 2001). 
AhR can be induced by either environmental pollutant such as TCDD (Huff et al. 
1994) or diet (Denison and Nagy 2003) (Denison et al. 2002). 
Typically, the mechanism of AhR action starts when the ligand binding to AhR 
receptor induces nuclear translocation (Gasiewicz and Bauman 1987) and then 
makes a complex with bHLH/PAS protein, ARNT (heterodimerization) (Reyes et 
al. 1992).  This heterodimerization recognizes and binds specific DNA sequence, 
dioxin responsive elements (DREs), within gene promoter regions and modulates 
subsequent gene transcription (Fujisawasehara et al. 1987).  
Recently, a number of endogenous AhR ligands have been reported to have a high 
affinity toward AhR. Most of these chemicals are tryptophan derivatives       
(Fujii-Kuriyama and Mimura 2003).  
AhR ligands such as TCDD are involved in the induction of some CYP450s such 
as CYP1A1 and CYP1B1 in most body tissues, but in brain it was found to be at 
very low levels (Hedlund et al. 2001). 
It was found that both AhR and ARNT are expressed in the brain (Dolwick et al. 
1993) (Li et al. 1994) (Kainu et al. 1995). 
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TCDD can penetrate poorly into rat brain and the concentrations found are far 
lower than in the liver or adipose tissue (Pohjanvirta et al. 1990).  However, after 
repeated exposure TCDD induces more significant oxidative damage in brain than 
in liver  (Hassoun et al. 2000). 
TCDD may also penetrate into the brain, where a high region concentration was in 
the hypothalamus  (Pohjanvirta et al. 1990).  
The molecular size of AhR shows a variation between species.  It was 95 kDa in 
mouse, 101 kDa in chicken, 103 kDa in guinea pig, 104 kDa in rabbit, 106 kDa in 
rat, 106 kDa in human, 113 kDa in monkey and 124 kDa in hamster (Poland and 
Glover 1987). 
It has also been reported that variation was found within rat strains where 106 kDa 
of inbred strain and 101 kDa and/or 106 kDa allelic form of outbred Long-Evans 
rats (Poland and Glover 1987). 
In liver cytosol, two AhR molecular weight, 95 kDa and 70 kDa, were produced 
indicating the 70 kDa was due to proteolytic product of the bigger peptide          
(90 kDa) (Poland and Glover 1987). 
It has also been reported that mouse variation of an AhR molecular size found 
within allele forms.  The Ah b¹ allele has 95000 kDa, Ahb² has 104 kDa and Ahb³ 
has 105 kDa (Poland and Glover 1990).  
In the brain, it was found that TCDD neurotoxicity was mediated by the AhR in 
the mouse cortical endothelial cells and astrocytes (main cellular components of 
the BBB) (Filbrandt et al. 2004). 
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1.6 Aims of the thesis 
Our laboratory has cloned two novel human cytochrome P450, known as CYP4X1 
and CYP4Z1.  However, nothing is known of the function of these two P450s.  In 
order to address this problem, this project will aim to delineate the site of 
expression of these proteins.  As a first step to addressing this, specific antisera 
against these cytochrome P450s will be prepared, prior to western and 
immunohistochemical approaches. 
Specific objectives include: 
1) Characterising the antisera for sensitivity and selectivity of CYP4X1 and 
CYP4Z1. 
2) Characterising the recombinant antigen of CYP4X1 
3) Expression and Tissue-specific localization of CYP4X1 
 
Whilst characterising the antisera against CYP4Z1, high sensitivity antisera 
against recombinant antigens of AhR and C. elegans latrophilin were obtained, 
and subsequently used to characterise the full-length, native proteins.  
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Chapter 2                   Materials and Methods 
 
 
2.1 Materials 
 
2.1.1 General Materials 
All general chemicals used for experiments were obtained at the highest grade. 
The radioactivity [Į-32P]-CTP (800 Ci/mmol) was obtained from ICN Flow 
Company. DNase-free RNase 1U/µl was obtained from Promega. 
Oligonucleotides were synthesised by J.Keyte of the Polymer Synthesis and 
Analysis Unit, Department of Biochemistry, University of Nottingham. UHP 
grade water >13Mȍ/cm³ was produced by using Purite Select Bio system. 
ProSTAR UltraHF RT-PCR for RT-PCR Kit of 1
st
 strand cDNA synthesis was 
purchased from Stratagene. Plasmid mini-prep kit, maxi-prep kit and gel 
extraction kit were obtained from QIAGEN Ltd. X-ray film was manufactured 
by Fuji and obtained from Amersham International plc. Developer and Fixer 
were obtained from Ilford. DEPC was obtained from Sigma. DEPC-treated 
water was prepared by adding 1 ml of Diethyl Pyrocarbonate (dissolved in 9 ml 
absolute ethanol) to 1 litre of UHP water and the mixture has incubated in a 
fume hood for 1 hour and then autoclaved for 20 minutes at 120ºC. Sequa gel 
stock acrylamide solution (19:1 acrylamide: bisacrylamide) was obtained from 
National Diagnostics. Triazol reagent was obtained from (Invitrogen), RNA 
quantitation reagent and kit were obtained from Molecular Probes, Restriction 
enzymes were obtained from Biolab, pGEMT-easy vector was obtained from 
Promega, pRSET-a his-tag expression vectors was obtained from Invetrogen, 
yeast tRNA was obtained from Sigma. SP6 polymerase (20,000 U/ml) was 
obtained from Biolab, T7 polymerase (50,000 U/ml) was obtained from Biolab, 
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RNase A (80 ng/µl) + T1  (250 U/µl) Mix was from PharMingen , DNase I was 
obtained from Sigma, DNA was obtained from Sigma, IPTG was obtained 
from  BRL, Acrylamide stock solution (30% acrylamide w/v, 37.5 : 1 bis-
acrylamide) was obtained from Severn Biotech LTD. Transcription Buffer was 
obtained from Boehringer Mannheim, 1 kb marker DNA ladder was obtained 
from Gibco-BRL, Bacterial strains BL21 (DE3) and BL21 (DE3) plysS were 
obtained from Novagen, RNA guard RNase inhibitor was obtained from 
Amersham Pharmacia Biotech Inc, Mouse genomic DNA  was obtained as a 
gift from Dr. David Bell, Nottingham university, Goat anti-rabbit IgG 
conjugated secondary antibody was obtained from BIO-RAD, Bacterial strain 
JM109 was obtained from Promega, His.Bind resin was obtained from 
Novagen, T4 ligase and buffer were obtained from Biolab, pfu Turbo DNA 
polymerase (2.5 U/µl)  was obtained from Stratagene,1.1 x Reddy Mix PCR 
Master Mix (1.5 mM MgCl2) was obtained from ABgene, Ribonuclease 
Protection Assay (RPA) Kit was obtained from PharMingen. 
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2.1.2 pRSET-a-mcyp-4x1 plasmids 
A genomic fragment of mouse CYP4X1-exon 12 was cloned into pGEMT-easy 
(Promega) in our laboratory to generate the plasmid pGEMT-m-CYP4X1-ex12 
(section 2.2.3.12).  This plasmid contains coding and non-coding region of 
amplified PCR fragments of exon12 from the genomic mouse CYP4X1.  The 
PCR generates a product of 329 b.p; 191 b.p are derived from exon 12 and 138 
b.p are intron as shown in Figure 2.1.  A search of the mouse genome using the 
BLAST algorithm (28/07/05) with this sequence detected no other sequences 
with significant sequence identity to this region of the Cyp4x1 clone. 
 
Exon Intron 
329 b.
 
p. 
191 b.p. 138 b.p. 
 
 
 
FiJure 2.1. PCR of partial sequence of a mouse CYP4X1-exon 12 gene.  
The full length of this sequence is 329 b.p including both exon and intron. The PCR was 
predicted to generate a 329 b.p. fragment on genomic mouse DNA.  
 
 
A PCR fragment of full-length m-CYP4X1 cDNA (section 2.2.4.1) was cloned 
into pRSET-a for expression to give the plasmid pRSET-a-m-CYP-4X1.  The 
plasmid pRSET-a-mCYP-4X1 contains the T7 promoter, with a six-histidine 
tag at the N-terminus of the fusion protein.  The sequence of the protein shows 
that there are 49 amino acids from the pRSET-a vector, while the inserted 
DNA was 497 amino acids as shown in the Figure 2.2. 
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Histag              4X1   4Z1
49 497 amino acids
FiJure 2.2 Diagram of protein produced from pRSET-a-mcyp-4x1. 
The shaded region represents the six-histidine tag fusion and the black dots on a white 
background show the full-length of mcyp-4x1 protein region cloned into expression vector 
(pRSET-a). 
 
2.1.3 pRSET-b-hCYP-4z1 plasmids 
A fragment of the human CYP4Z1 (residues 177-493) was inserted as a XHOI-
HindIII fragment into pRSET-b vector (pRSET-b-hCYP-4z1) for expression in 
E.coli.  The oligonucleotides 
5'AACAAATGGGAGGAACACATTGCCCAAAACTCGAGTCTGGAGCTC
TTTCAACATGTCTCC3' and 
3'GTGAGTTCCGGAGGGGTCGGACAAGCAGTTCAACAGGAGTTCACT
TCCGAACCTTAGGTA 5' were used to PCR the sequence encoding amino 
acids (177-493) of the human 4Z1 cDNA.  The amino acid sequence shows 
318 amino acids of 4Z1 protein and 36 amino acids from the vector as shown 
in the Figure 2.3.  The calculated molecular weight is 39,700 Da.  
 
 
4Z1 Histag 
            36                          316       amino acids 
FiJure 2.3.  Diagram of protein produced from pRSET-b-hCYP-4z1. 
The shaded region represents the six-histidine tag fusion and the plain region represents the 
partial cDNA of human CYP-4z1 protein cloned into expression vector (pRSET-b). 
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2.1.4 pRSET-AhR285-416 plasmids  
A fragment of the mouse AhR b-1 allele (residues 285-416) clone '5g´            
(J, Tao. Thesis, 2004) was inserted by BamHI digestion into the pRSET-c 
vector.  The cloned DNA construct pRSETc-AhR285-418 contains 168 amino 
acids of AhR and the calculated molecular weight is 19,267 Da.  The plasmid 
pRSET-AhR285-418 contains the T7 promoter, with a six-histidine tag at the 
N-terminus of the fusion protein. 
The sequence of the protein shows that there are 35 amino acids from the 
pRSET-c vector, while the inserted DNA was 133 amino acids.  Figure 2.4, 
shows a diagram of the mouse AhR domain structure.   
 
 
Q rich  bHLH PAS domain 
 
 
 
 
 
 
FiJure 2.4. Domain structure of mouse AhR. 
(b) represents the basic region, HLH represents the helix-loop-helix. PAS represents the first 
letters of the finding PAS domain membrane in Drosophila Period clock protein, the vertebrate 
Aryl hydrocarbon receptor nuclear translocator and Drosophila Single-minded protein. The 
highlighted numbers (285 and 416) represent the region of the cloned mouse AhR b-1 allele 
fragments inserted in the expression vector (pRSET-c). 
 
  COOH NH2 A B
805 1 
   285                               416  
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2.1.5 pRSET-c-LpH plasmids 
Latrophilin (LpH) is the receptor for toxic proteins produced by Black Widow 
spider.  A partial C.elegans LpH cDNA was cloned into pRSET-c for 
expression as a histidine-tagged fusion containing 373 amino acids of LpH, 
from 168 to the end of amino acid number 542.  This partial clone of LpH 
protein contains the hormone receptor motif (181-240) and the G-protein-
coupled receptor protease cleavage site (493-541) of the extracellular domain 
as shown in Figure 2.5. 
 
 
 
GPS 
 
 
493-541 
7-TM 
secretin 
 
548-799 
4 Cys 
 
 
815-870 
Hormone 
receptor 
motif 
181-240 
Galactose 
binding 
 lectin   
51-133 
                                                                         1014        
 
 
 
168                      542 
peptide 1 
 
FiJure 2.5. Domain structure of the latrophilin. 
GPS represents the G-protein-coupled receptor proteolytic site domain. 7-TM secretin 
represents the seven transmembrane regions that similar to those of the calcitonin/secretin 
receptor family.  The highlighted numbers (168-542) represent the site of the partial sequence 
of LpH protein that amplified to generate the cloned LpH cDNA inserted into pRSET-c 
expression vector.    
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2.2 Methods 
 
2.2.1 Animals 
Adults (male) C57 BL/6N and 129S4/SvJae strains mice were obtained from 
Queen Medical Centre (QMC). Rabbits (Female New Zealand White rabbits ~ 
4 Kg) were obtained from Queens Medical Centre (QMC) of Nottingham 
University.  The animals were allowed to eat ad libitum and had access to 
drinking water at all times.  
 
2.2.1.1 Dosing of 129S4/SvJae strain mice 
The treated control group were given a single dose by gavage of vehicle 
control, 10ml/kg of corn oil containing 2.5% (v/v) p-dioxane.  The TCDD 
group was given a single dose by gavage of 10ml/kg of corn oil containing 
2.5% (v/v) of p-dioxane and 50µg/kg TCDD.  Dosing for the treated control 
and the TCDD mice group were performed once on day 1 and then animals 
were sacrificed in the morning of day 3.  The Phenobarbital group was dosed 
daily by intraperitoneal injection with 80mg/kg PB in saline (0.75ml) for three 
days and sacrificed on the following day. 
The Ciprofibrate group were dosed daily by gavage with 50mg/kg in corn oil 
(0.75ml) for three days and sacrificed on the following day.  The 
Dexamethasone group were dosed daily by gavage with 50mg/kg in corn oil as 
a suspension for three days and sacrificed on the following day. 129S4/SvJae 
wild type (+/+) mice and knock-out (-/-) mice for PPARĮ were used as 
untreated control group (Akiyama T. E, et al; 2001). 
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The untreated control group were allowed to eat ad libitum and had access to 
drinking water for three days and then sacrificed on the following day.  Animal 
work was done by Declan Brady.  The animals were sacrificed by cervical 
dislocation and liver, kidney, brain; heart, spleen, lung and aorta were weighed 
and harvested quickly and then flash frozen in liquid nitrogen.  The frozen 
tissues were then stored at -80°C until use.   
 
2.2.2 Antiserum Production 
The production of the antibodies was carried out by injection of female New 
Zealand White rabbits (~ 4 Kg) subcutaneously with purified recombinant 
proteins.  An initial test bleed (5 ml) was taken as a preimmune bleed sample 
prior to starting the immunization course.  The test bleed was taken from the 
peripheral ear vein of each rabbit.  In order to produce polyclonal antibodies, 
rabbits were injected with approximately 100µg of recombinant protein as a 
50% emulsion in Freunds incomplete adjuvant.  One injection of the antigen 
was done every month for each rabbit.  The antisera were titred after each 
immunization to check the sensitivity of the antisera, and immunization was 
repeated periodically until a good signal was obtained.  A terminal bleed was 
taken after obtaining a high potency antiserum. 
The terminal bleed was then incubated in a fridge at 4ºC for overnight.  The 
blood was then centrifuged at 3000 rpm for 15 minute.  The plasma was taken, 
aliquoted in eppendorf tubes and then stored at 20°C.  
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2.2.3 General Molecular Biology Techniques 
 
2.2.3.1 Bacterial growth media  
 
E.coli JM 109 strain was used in all experiments and was obtained from 
Stratagene.  
The following components of the bacterial growth media were used: 
 
Luria-Bertania (LB) per litre: 
10 gm   Tryptone 
5 gm    Yeast extract 
10 gm   NaCl   
 
All the materials above were made up to 1 litre with UHP water and autoclaved 
for 20 minutes at 120°C (15lb/in²).  LB-agar media was made by adding 15gm 
of Bactoagar to 1 litre LB-Broth and autoclaved for 20 minutes at 120°C 
(15lb/in²).  For preparing LB agar plates, the media was allowed to cool and 
then an appropriate antibiotic, e.g. Ampicillin to a final concentration of         
50 µJ/ml was added and the media was poured into 10 cm Petri dishes. 
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2.2.3.2  Transformation 
 
2.2.3.2.1  Preparation of electro competent cells 
A single colony from freshly streaked JM109 cells was grown in 5 ml of LB 
broth overnight on the incubator shaker (220 rpm) at 37°C.  50 ml of LB broth 
was added to the overnight culture of cells and placed on the shaker for 2-3 
hours or until O.D600 of 0.5-0.8 was reached.  The cells were then cooled on ice 
and then centrifuged in a JA20 rotor at 23700xg for 10 minutes at 4°C.  The 
supernatant was removed and the pellets were then washed 4 times with 20 ml 
of ice-cold UHP water and were then centrifuged at 23700xg for 10 minutes at 
4°C.  The washed water was decanted and the pellets were resuspended in1 ml 
of ice-cold water.  The wash water was again decanted and the pellets were 
weighed and resuspended with two volume of ice-cold water.  The cells were 
then placed on ice until use for electrotransformation. 
 
2.2.3.2.2  Plasmid transformation into electro competent cells 
Electroporation cuvettes (0.2 cm Bio-Rad genepulser cuvette) were placed on 
ice.  Aliquots of 40ul competent cells were placed on ice and 1µl of plasmid 
DNA was added and mixed thoroughly.  The mixture of the plasmid DNA and 
cells was then transferred to the prepared cuvette and electroporated at 1.8 kv.  
The cells were then immediately resuspended in 1ml of LB broth and then 
transferred to a new eppendorf tube.  The cells were then incubated in a water 
bath at 37°C for 30 minute.  Selection of the transformed cells was obtained by 
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growing the transformed cells on 1% LB glucose agar plate containing 
Ampicillin (50 µg/ml) antibiotic. 
 
2.2.3.3. Phenol preparation  
500 gm of crystalline phenol was melted at 69°C and then 0.1 % (w/v) 
hydroxyquinoline was added.  The melted phenol was then mixed with an 
equal volume of 500 mM Tris-HCl, pH 8.0 and stirred for 15 minutes at room 
temperature.  The mixture was then allowed to separate into two phases.  The 
aqueous phase was removed and the organic phase was then equilibrated with 
an equal volume of 0.1 M Tris-HCl (pH 8.0) with continuous stirring for 15 
minutes.  The mixture was then allowed to settle into two phases. Again the 
aqueous phase was removed and the organic phase was treated several times 
with 0.1 M Tris-HCl until the phenol reached a pH of 8.0.  The equilibrated 
phenol under the 0.1 M Tris-HCl pH 8 was then stored in the dark at 4°C. 
 
2.2.3.4 Phenol/Chloroform extraction 
In order to remove any protein contaminants, phenol/chloroform extraction 
method was used.  One volume of phenol/chlorophorm mixture was added to 
the nucleic acids.  The mixture was then vortexed thoroughly into an emulsion 
for 1 minute and then centrifuged at 20817xg for 5 minutes in a bench top 
centrifuge at room temperature.  Two separated layers (phenolic and aqueous) 
and an interface were obtained.  The aqueous layer contains the nucleic acids 
whereas the interface layer contains the contaminant protein.  The aqueous 
layer was taken carefully into a fresh eppendorf tube.  
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2.2.3.5 Ethanol precipitation of DNA 
Nucleic acids were precipitated by adding two volumes of ice-cold absolute 
ethanol (100%) and 0.25 volume of 4M ammonium acetate.  The solution was 
mixed vigorously by hand for 15 second and then placed at 20°C for 30 
minutes.  The tube was then centrifuged at 23700xg in a microfuge for 15 
minute at room temperature.  The supernatant was decanted and the pellets 
were then washed with 90% ice-cold ethanol (2 volumes) and centrifuged at 
23700xg for 5 minutes.  The supernatant was decanted and the pellets were 
then air-dried for 5 minutes to remove any remaining ethanol.  The pellets were 
resuspended in DEPC-treated water. 
 
2.2.3.6 Isolation of plasmid DNA (small-scale, crude preparation)  
Alkaline lysis is a method for isolating plasmid DNA.  This method is based on 
Sambrook. et al (1995).  Bacterial colonies were inoculated in 15 ml LB broth 
containing an appropriate antibiotic and incubated with shaking overnight at 
37ºC. One ml of each bacterial culture was centrifuged at 20817xg for 1 minute 
in bench top centrifuge.  The supernatant was decanted and the cell pellets 
were resuspended in 100µl of solution I [50 mM glucose, 25 mM Tris-HCl pH 
8, 10 mM EDTA and RNase A (100µg/ml)].  To this, 200ul of solution II [200 
mM NaOH, 1% SDS], freshly prepared, was added to each eppendorf tube and 
the solution were mixed by inversion.  The samples were then allowed to stand 
for 5 minutes at room temperature. 150 µl of ice-cold solution II [5 M 
potassium acetate, 1.5% glacial acetic acid] was then added to each eppendorf 
and mixed by inversion and then placed on ice for 10 minutes to allow the 
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bacterial lysate to precipitate.  The samples were then centrifuged 20817xg for 
10 minutes.  The supernatant was taken to a new eppendorf tube and extracted 
with one volume of phenol/chloroform and then centrifuged at 20817xg for 5 
minutes.  The aqueous layer was taken to a new eppendorf and the DNA was 
precipitated by addition of ¼ volume of 4M ammonium acetate and 2 volume 
of 100% ethanol (section 2.2.3.5).  The sample was then mixed gently and then 
incubated at -80ºC for 30 minute.  The tube was then centrifuged in                  
a microcentrifuge at 20817xg for 15 minute at 4ºC.  The supernatant was 
decanted and the pellets were then washed with 75% ethanol and centrifuged at 
20817xg in a microcentrifuge for 5 minute at 4ºC.  The supernatant was 
removed and the pellets were then allowed to air-dry for 5 minutes.  The 
plasmid DNA pellets were then resuspended in 50µl of DEPC water and stored 
at -20 ºC. 
 
2.2.3.7 Isolation of plasmid DNA Qiagen miniprep method 
This method is based on QIAGEN Handbook. 1.5 ml of an overnight culture of 
bacteria was centrifuged at 20817xg for 1 minute at 4ºC in a minicentrifuge. 
The supernatant was decanted and the pellets were resuspended in 250µl of 
buffer P1 (resuspension buffer).  To this 250µl of buffer P2 (lysis buffer 
containing NaOH) was added and the tubes mixed gently by inversion for 4-6 
times and then 350µl of neutralization buffer N3 (guanidine HCL, acetic acid) 
was added.  The tubes were then mixed gently by inversion again for 4-6 times 
and then centrifuged at 20817xg for 10 minute in a bench top centrifuge.  The 
supernatant was transferred immediately onto the Qiagen column and then 
centrifuged at 20817xg for 1 minute. 
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The flow-through was decanted and the column was washed with 0.5 ml of PB 
(phosphate buffer) and then centrifuged at 20817xg for 1 minute.  The column 
was then washed with 0.75 ml of elution buffer PE and centrifuged at 20817xg 
for 1 minute.  To elute all the PE buffer, the column was centrifuged again at 
20817xg for another 1 minute.  The plasmid DNA was eluted from the column 
using 50µl of UHP distilled water and incubated at room temperature for 1 
minute prior centrifuged at 20817xg for 1 minute and eluted in a clean 
eppendorf tube.  The plasmid DNA was then stored at -20ºC until use. 
 
2.2.3.8 Isolation of plasmid DNA Qiagen maxi prep method 
This method is based on QIAGEN Handbook 10 ml of the overnight cell 
culture was prepared as mentioned in section (2.2.3.7).  The overnight culture 
of bacteria was diluted with 100 ml LB broth containing antibiotic and then 
grown overnight at 37ºC on the shaker (220 rpm).  The culture of cells was 
then centrifuged at 6000xg on a JA10 rotor for 20 minutes at 4ºC.  The 
supernatant was decanted and the pellets were resuspended in 10 ml of buffer 
P1 (50mM Tris-HCl, pH 8).  To this, 10ml of lysis buffer P2 (200 mM NaOH, 
1% SDS w/v) were added and mixed thoroughly 6 times by inversion and then 
incubated at room temperature for 5 minutes.  After incubation, 10 ml of 
neutralisation buffer P3 (3 M potassium acetate, pH 5.5) was added and mixed 
by inversion 6 times and then incubated on ice for 20 minute.  The cells were 
then centrifuged at 20000xg on a JA20 rotary for 30 minute at 4ºC. 
The supernatant was taken to a clean tube and placed on ice. A Qiagen-tip 500 
was equilibrated with 10 ml of buffer QBT (750 mM NaCl, 50 mM MOPS, pH 
7.0, 15% isopropanol v/v, 0.15% Triton® X-100 v/v).  The supernatant was 
transferred to the Qiagen-tip column and allowed to pass through using the 
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gravity force to pull the supernatant through.  The column was then washed 
twice with 30 ml of wash buffer QC (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% 
isopropanol v/v).  To elute the DNA, 15 ml of elution buffer QF (1.25 M NaCl, 
50 mM Tris-HCl, pH 8.5, 15% isopropanol v/v) was added to the column and 
the DNA was collected in a clean tube.  The DNA was then precipitated by 
adding 10.5 ml of isopropanol and then mixed and centrifuged at 15000xg in a 
JA20 rotor at 4ºC for 30 minute.  The supernatant was decanted and the pellets 
were washed with 5 ml of 70% ethanol and then centrifuged at 15000xg in a 
JA20 rotor at 4ºC for 10 minutes.  The ethanol was decanted and the pellets 
were resuspended in 1 ml of DEPC water.  The DNA sample was then stored at 
-20ºC until use.  The DNA concentration was determined as mentioned in 
section (2.2.3.16). 
 
2.2.3.9 RNA extraction from mouse tissues 
Total RNA was extracted with TRIAZOL reagent kit (Invitrogen).  TRIAZOL 
commercial reagent kit contains a solution of phenol and guanidine 
isothiocyanate. 
The extraction was carried out as described in the manufacturers instructions 
and all the glassware and the tubes were cleaned and autoclaved.  Typically, 
approximately 0.1 gm of mouse tissue was homogenised in a Potter-Elvehjem 
glass homogenizer with a Teflon pestle with 1 ml TRIAZOL reagent in a glass 
tube.  The mixture was centrifuged at 12000xg for 10 minutes at 4ºC in a 
microfuge.  This is an optional centrifugation step to remove cell debris.  The 
cleared homogenate was then transferred to a clean eppendorf and incubated 
for 5 minutes at room temperature to allow complete dissociation of 
nucleoprotein complex. 0.2 ml of chloroform was added to the solution and 
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shaken vigorously by hand for 15 second. The solution was then incubated at 
room temperature for 3 minutes.  The solution was then centrifuged at 12000xg 
for 15 minutes at 4ºC.  Three layers were obtained and only the aqueous layer 
was taken.  This aqueous layer was taken into a fresh eppendorf and 0.5 ml of 
isopropanol / 1 ml Triazol reagent was added to precipitate the RNA.  The 
samples were then incubated at 4ºC for 10 minutes.  The samples were then 
centrifuged at 12000xg for 10 minutes at 4ºC.  The supernatant was decanted 
and the samples were then washed by 1 ml ethanol.  The samples were mixed 
and centrifuged at 7500xg for 5 minutes at 4ºC.  The samples were then dried 
for 5 minutes and then resuspended with 100 µl DEPC-treated water.  The 
samples were stored at 80ºC until use. 
 
2.2.3.10 Purification of DNA from an agarose gel  
Amplified PCR products were purified by using the QIAquick gel extraction 
kit (QIAGEN), as described in the manufacturers instructions.  The PCR 
fragments were visualised under visible Light using a Dark Reader (Clare 
Chemical Research) and the PCR fragment was then excised with a sharp 
scalpel.  The gel slice was then weighed and transferred to a clean eppendorf 
tube.  Three volumes of solubilization buffer QG (guanidine thiocyanate) was 
added to the gel slice and then incubated at 50ºC for 10 minutes with inverting 
every 2-3 minutes.  The melted gel slice was then applied into the QIAquick 
column and centrifuged at 20817xg for 1 minute at 4ºC. 
The flow-through was decanted and the column placed to the same collection 
tube.  The column was then washed with 0.75 ml of buffer PE and centrifuged 
at 20817xg for 1 minute at 4ºC.  The flow-through was discarded and the 
column was then centrifuged again at 20817xg for another 1 minute at 4ºC.  
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For eluting the DNA, the column was placed on a clean 1.5 eppendorf tube and 
then 50 µl of distilled water were added to the centre of the QIAquick 
membrane.  The column was then incubated at room temperature for 1 minute.  
The column was then centrifuged at 20817xg for 1 minute at 4ºC.  The eluted 
DNA was then stored at  20ºC until use. 
 
2.2.3.11 Restriction digestion of DNA 
Restriction digestion was carried out according to the standard protocol of 
Sambrook et al, 1989, but using digest buffers provided by the manufacturer.  
The final volume of the reaction takes place in 100µl in an eppendorf tube (1.5 
ml) at 37ºC for 2 hours.  The digested reaction contains of the plasmid DNA 
mixed with 4µl of a restriction enzyme and an appropriate 10X restriction 
enzyme buffer to a final volume of 100µl distilled water.  The mixture was 
then mixed by vortex and then quick centrifuged for 10 second on the bench 
top at room temperature.  The reaction was then incubated at 37ºC for 2 hrs.  
Ethanol precipitation was carried out to stop the reaction as described in 
section 2.2.3.6.  
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2.2.3.12 Ligation of PCR products pGEMT-easy vector. 
Ligation is the process of the formation of phosphodiester bonds in the 
presence of ATP between double-strand DNAs with 3-hydroxyl and 5-
phosphate termini.  The insert DNA was gel purified as described in the section 
(2.2.3.10).  The ligation reaction was carried out for both the experimental and 
the control samples by adding the following components: 
 
Component                                                  Experimental               Control  
 
2X Rapid ligation reaction                                         5µl                             5µl 
pGEMT-easy vector (50ng/µl)                                   1µl                             1µl 
PCR product                                                               2ul                               ---- 
T4 DNA ligase ( 3 U/µl)                                            1µl                             1µl 
Distilled water                                                            1µl                             3µl 
 
Rapid ligation buffer components: 
 
60 mM Tris-HCl, pH 7.8   
20 mM MgCl2  
20 mM DTT 
2 mM ATP 10% PEG 
The Ligation reaction was placed in a clean 1.5ml eppendorf tube and vortexed 
gently prior to brief centrifugation for a few seconds.  The ligation reaction was 
then incubated at room temperature for 2 hours. 
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2.2.3.13 Agarose gel electrophoresis of DNA (non-denaturing) 
 
The buffers were used in agarose gel as follow: 
 
1% agarose gel components: 
0.5 J agarose  
50 ml of 1xTBE 
1 µl of ethidium bromide (10 mJ/ml) 
 
10xloading buffer: [0.25% Bromophenol, 30%glycerol, 0.25% Xylene Cyanol FF]  
 
10xTBE buffer in 1 litre 
10 gm Tris-HCl 
55 gm Boric acid 
40 ml of 0.5M EDTA 
 
 
DNA agarose gel electrophoresis was carried out using a horizontal Pharmacia 
GNA-100 gel electrophoresis kit.  Prior to preparing the agarose gel, the 
apparatus was washed with 30% hydrogen peroxide to remove any DNA, dirt 
and grease contaminants.  A 1% agarose gel was prepared by adding 0.5 gm 
agarose to 50 ml of 1xTBE buffer.  The mixture was then incubated in a 
microwave for several minutes until all the agarose crystal are dissolved in the 
solution.  The solution was then allowed to cool gradually at room temperature.  
Once the agarose solution had cooled to 55ºC, 1 µl of ethidium bromide (10 
mg/ml) was added.  The mixture was then poured into the gel tray containing 
the well-forming comb and allowed to gel at room temperature.  The gel was 
then transferred and placed on the horizontal Pharmacia GNA-100 gel 
electrophoresis kit.  The gel was completely covered with 1xTBE buffer.  Prior 
to loading the samples, wells were flushed with 1XTBE buffer.  The samples 
were then prepared in 1x loading buffer and run at 90 v/cm for 45 minute.  The 
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gels were then illuminated with UV light and fluorescence photographed using 
a Gel-Doc (BIO RAD). 
 
2.2.3.14 denaturing agarose gel electrophoresis of RNA 
RNA denaturing agarose electrophoresis was performed on a Pharmacia GNA-
100 electrophoresis apparatus. RNA can form complex secondary structure; 
hence it needs to use a denaturing condition such as 0.1% SDS to ensure that 
its separation was not due to secondary structure.  The denaturing agarose gel 
is the same agarose gel preparation with addition of SDS to 0.1% (w/v) into the 
gel preparation prior to pouring it to the gel tray.  The gel was then analysed as 
mentioned in section (2.2.3.13). 
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2.2.3.15 RNA quantification  
The concentration of the isolated total RNA was determined by the 
Fluorescence spectrophotometer (Varian).  The special reagents were the 
Ribogreen RNA Quantitation reagent Kit (Molecular probes). The components 
of this assay are as follows: 
 
Ribogreen RNA quantitation reagent (component A)  
1 ml solution in DMSO (Dimethylsulfoxide)  
20xTE (component B) 
25 ml of 200 mM Tris-HCl 
20 mM EDTA, pH 7.5 (20xTE) in DEPC-treated water 
 
Ribosomal RNA standard (16S and 23S rRNA from E.coli (component C) 
Five vials, each containing 200 µl of a 100 µg/ml solution in TE  
 
The concentration of the RNA samples was analysed as described in the 
manufacturing protocol.  Typically, high range assay was chosen and the 
standard curve was carried out and prepared by diluting the concentrated buffer 
(component B) 20-fold with DEPC-treated water.  RiboGreen reagent was 
prepared by diluting an aliquot of the concentrated DMSO stock solution into 
1xTE.  To minimize the photobleaching effects, all the samples of the standard 
curve and sample analysis were diluted in 1 ml of the RiboGreen reagent at the 
same time.  The spectrophotometer was zeroed using DEPC-treated water as a 
blank.  The RNA standard curve was then carried out by preparing 2µJ/ml 
solution of RNA in 1xTE and 1 ml of the RiboGreen solution was added to 
each cuvette.  The fluorescence samples of the standard curve were then 
measured at excitation ~ 480 nm and emission ~ 520 nm. 
The concentration of the RNA was determined on the basis of absorbance at 
260 nm (A260) in a cuvette with a 1 cm path length; an A260 of 0.05 
corresponds to 2 µJ/ml RNA. 
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Table 2.1. The protocol for preparing high-range standard curve. 
 
Volume (µl) 
of TE 
Volume (µl) of  
2 µg/ml RNA stock 
Volume (µl) of 200-
fold diluted 
RiboGreen reagent 
Final RNA concentration in 
RiboGreen assay 
0 
500 
900 
980 
1000 
1000 
500 
100 
20 
0 
1000 
1000 
1000 
1000 
1000 
 
1 µg/ml 
500 ng/ml 
100 ng/ml 
20 ng/ml 
blank 
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2.2.3.16 DNA quantification  
DNA quantification was carried out by the Fluorescence spectrophotometer. 
In determining DNA concentration, a dye called Hoechst 33258 was used. 
The solutions for this assay were first prepared as follow: 
x 1 ml of Hoechst 33258 dye (10 mg/ml) was diluted with 9 ml of 
distilled water to a final concentration 1mg/ml. The dilution was then 
filtered with 0.45 um filter paper and stored at 4ºC in a protected tube 
until use. 
x 10x TNE buffer stock solution were prepared by dissolving the 
following ingredients in 800 ml of distilled water: 
 
         12.11 gm Tris base [Tris (hydroxymethyl) aminomethane] 
         116.89 gm Sodium chloride 
         3.72 gm EDTA 
 
The buffer was then adjusted pH to 7.4 with concentrated HCl and completed 
with distilled water up to 1000 ml.  The buffer was then filtered with a 0.45 µm 
filter and stored at 4ºC until use. 
x DNA stock solution (100µg/ml) 
DNA stock solution was prepared by diluting 10 µl of stock DNA 
preparation 
(10 mg/ml) with 990 µl of 1xTNE solution to a final concentration 100 
µg/ml. 
 
After preparation of all the solutions above, low range assay (5-500 nJ final 
DNA concentration) was chosen for the standard curve at excitation 350 nm 
and emission 450 nm.  For running the standard curve, Quartz cuvette was used 
and the spectrophotometer was zeroed at these conditions using distilled water 
as a blank. 
 79
Al-Anizy M                                                                       Materials and Methods 
Briefly, 1 ml of the Hoechst reagent (1 mJ/ml) was added to each standard 
curve samples containing DNA stock solution (10 mJ/ml) and the unknown 
sample concentrate.  The samples were protected from the light in a dark place 
for 5 minutes and the reading was then taken. 
 
2.2.3.17 1st strand cDNA preparation from the total RNA 
Total RNA of mouse brain was used as a template.  The ProSTAR UltraHF 
RT-PCR Kit was used to generate the first strand cDNA and the reaction was 
carried out as the manufacturers instructions.  All the components were mixed 
in a 0.5 ml tube and quickly centrifuged before using.  The control and the 
experimental reactions were carried out as follow: 
Control Reaction 
33.5µl of RNase-free water (Not DEPC-treated water) 
5ul of 10x StrataScript RT buffer 
3µl of oligo (dT) primer (100 ng/µl) 
5µl of dNTP mix (40mM) 
1µl of control mRNA 
 
Experimental reaction  
33.5µl of RNase-free water (Not DEPC-treated water) 
33.5µl of RNase-free water (Not DEPC-treated water) 
3µl of oligo (dT) primer (100 ng/µl) 
5µl of dNTP mix (40mM) 
1µl of (1:10) mouse brain RNA 
 
The samples were incubated at 65ºC for 5 minutes and then allowed to cool at 
room temperature to allow the primers to anneal to the RNA.  In order to 
prevent heat inactivation, 2.5ul of StrataScript RT (20 U/µl) was added to each 
reaction.  The samples were then incubated at 42ºC for 90 minutes.  The 
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samples were then placed on ice until using for PCR amplification.  The cDNA 
now synthesised and ready for PCR amplification. 
 
2.2.3.18 Polymerase chain reaction (PCR) 
The polymerase chain reaction is a molecular biological method widely used 
for amplifying DNA.  This procedure provides a very large amount of the DNA 
from a small amount of molecules.  Two oligonucleotides are used as primers 
in the presence of a DNA polymerase for amplifying a known sequence in the 
target DNA region.  PCR products were amplified by using 1.1 ReddyMix 
PCR Master Mix (1.5 mM MgCL2) solutions.  The composition of this solution 
was: 
 
125 units of Taq DNA polymerase 
75 mM           Tris-HCL (PH 8.8 at 25 ºC) 
20 mM           (NH4)2SO4 
1.5 mM           MgCL2 
0.01% (v/v)     Tween 20 
0.2 mM each of dATP,dCTP,dGTP and dTTP 
 
The PCR reaction was prepared for both negative and positive control to a final 
PCR reaction volume of 50ul as follow: 
 
Component Positive control Negative control 
5'-Primer 1 (~ 70ng) 1µl 1µl 
3'-Primer 2 (~ 70ng) 1µl 1µl 
DNA template 1µl - 
Reddy Mix 47µl 47µl 
UHP water - 1µl 
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The components were mixed thoroughly and quick centrifuged to collect all the 
mixture in the 0.5 ml tube and then one drop of mineral oil was added to 
prevent evaporation of the components.  The PCR reaction was then carried out 
on a Perkin Elmer DNA Thermal Cycler 480 as follow:  
 
94ºC   for 2 minutes 
60ºC   for 1 minute 
72ºC   for 45 second x 35 cycles 
94ºC   for 0.45 second 
60ºC   for 10 minutes 
4ºC      end 
 
PCR reaction was then analyzed on1% agarose gel electrophoresis and stored 
at -20ºC. 
 
2.2.3.19 Primers for PCR amplification 
Primers were used in all experiments as shown in the Figure 2.6.  The primers 
4x1-12-pF and 4x1-12-pR were annealed into pGEMT-easy to produce 329 
b.p., whereas the primers 4x1-f-pF and 4x1-f-pR were annealed into pRSET-a 
to produce 507 amino acid of mouse cyp4X1. 
Primer Name Sequence (5'-3') 
4x1-12-pF CATGGACATAAGTCCTTTTCCCTTCCTCCT 
4x1-12-pR AAACATAAATTTCGCCATTTCTCCTAGTAT 
4x1-f-pF ATGGAGGCCTCCTGGCTGGAGACTCGTTGG 
4x1-f-pR AAACATAAATTTCGCCATTTCTCCTAGTAT 
 
FiJure 2.6. List of primers for generation mcyp-4x1 PCR. 
All the primers were synthesized by J. Keyete, Dept. of Biochemistry, University of 
Nottingham. 4x1-12-pF represents forward primer and 4x1-12-pR represents reverse primer 
were used for PCR amplification of genomic mouse cyp-4x1 exon 12. 4x1-f-pF represents 
forward primer and 4x1-f-pR represents reverse primer were used for PCR amplification of 
cDNA mouse cyp-4x1. 
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 2.2.3.20 Microsome preparations 
Composition of reagents: 
 
Buffer A (20% glycerol (w/v), 0.1 M KH2PO4, pH 7.4) 
 
Buffer B (0.15 M NaCl, 10 mM KH2PO4, pH 7.4) 
 
Mice Sv/129 strain were sacrificed by cervical dislocation.  The liver was 
perfused with ice-cold buffer B and the inflated gall bladder then was removed.  
The liver was then washed and minced by 10 ml of ice-cold buffer B and 
transferred to a universal tube (30 ml) containing 20 ml of ice-cold buffer B.  
After rinsing the liver, the solution was decanted into a glass homogenisation 
tube and homogenised with 3 ml of buffer B by a motordriven loose-fitting 
pestle on ice.  The homogenised liver was divided into four eppendorf tubes so 
that each one contained 1 ml.  The eppendorf tubes were then centrifuged at 
43,300 x g for 10 minutes at 4°C.  The supernatant was removed and 
centrifuged at 444,000 x g in MLA80 rotor for 30 minutes at 4°C. 
Finally, the pellet was resuspended in 1 ml of buffer A, and the microsomes 
stored at 80°C.  
 
2.2.3.21 Mouse cytosol preparation for AhR assays 
This method was carried out as described in Molecular Pharmacology protocol, 
(34: 229-237) and the composition of reagents as follow: 
 
(MEN) 
25 mM MOPS 
0.02% Sodium Azide 
1 mM EDTA, pH 7.5 
 
(MDENG) 
1 mM Dithiothreitol 
10% (w/v) glycerol 
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One mouse was killed by cervical dislocation. 5 ml of MDENG was injected 
into the portal vein of the liver.  The liver was excised and placed in a tube 
containing MDENG, and then cut into small pieces.  The MDENG solution 
was then decanted.  The liver pieces were transferred into a glass homogeniser 
with 9 ml of MDENG solution and were homogenised.  The solution was 
mixed and transferred into a two test tubes in equal amount.  The solution was 
centrifuged in an MLA-80 rotor for 20 minutes at 444,000 x g at 4ºC.  The 
supernatant was transferred and divided into two test tubes and centrifuged 
again at 444,000 x g for 40 minutes.  The supernatant was then aliquoted and 
stored at 80°C until use. 
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2.2.4 Protein methodologies 
 
2.2.4.1 Bradford assay 
The protein concentration was carried out as described by Bradford (1967) 
assay method (Bradford, 1976).  Typically, 5x Bradford dye concentrates were 
prepared by dissolving100 mg of coomassie brilliant blue G-250 in 50 ml 95% 
ethanol, and 100 ml of concentrated phosphoric acid.  The solution was 
completed by addition of 200 ml of deionised water.  The protein standards 
were from 0 to 40 µg of bovine serum albumin (BSA) freshly prepared from a 
1µg/µl stock solution of BSA.  For each sample duplicate aliquots were diluted 
to a volume 50 µl. 1x Bradford dye reagent was prepared by diluting 11 ml of 
5x Bradford stock dye with 44 ml distilled water.  The solution was then 
filtered through 3MM paper (Whatman).  One ml of 1x Bradford reagent was 
added to each sample, and the samples were then mixed and incubated at room 
temperature for five minutes.  The absorbance of the samples was measured at 
595 nm.  A standard curve of bovine serum albumin (BSA) was used to 
determine the protein concentration, which covers the range of 0-40 µg protein. 
Non-linear regression analysis in Prism v 3.0 was used to calculate the 
unknown sample concentrations.  
 
2.2.4.2 Coomassie staining of SDS-PAGE gels  
Coomassie blue R 250 was used to stain the gels after electrophoresis to 
visualise the resolved protein bands.  Before use, it is filtered through 
Whatman 3MM paper to remove any undissolved particles.  The gel was 
immersed in coomassie blue staining solution (0.25 g coomassie R 250, 90 ml 
methanol: water (1:1 v/v), 10 ml glacial acetic acid) for 1 hr with agitation.  
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The staining solution was decanted and can be reused again.  It can be used 
several times without any change in the quality of staining and can be stored at 
room temperature.  The gel was washed with destain solution, which consists 
of 30% methanol and 10% glacial acetic acid.  The destain solution was 
changed until bands visualise clearly.  After the gel has been completely 
destained it is placed onto Whatman 3MM paper and dried under vacuum at 
80ºC for 2 hrs using a Bio-Rad 583 gel dryer. 
 
2.2.4.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
This technique was described by Laemmli (1970), which depends on the 
separation of protein according to their molecular weight under denaturing 
conditions.  A negative charge produced by binding of sodium dodecyl 
sulphate (SDS) with amino acid chain of the protein and consequently, the 
proteins are separated according to their length 
(i.e. molecular weight). 
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2.2.4.4 Gel preparation 
Protein gel was prepared and run by using a Bio-Rad Mini-Protein II 
electrophoresis cell (Bio-Rad).  Table 2.2, shows different gel concentration for 
separation of different molecular size proteins.  All the glass plates were 
washed with ethanol and distilled water to remove any contaminant prior to 
fitting on the apparatus.  The resolving gel (5 ml) was mixed gently with 50 µl 
of fresh 10% ammonium persulphate (APS) to initiate polymerisation, Table 
2.3.  The solution was then poured immediately between the glass plates. 
To complete the polymerisation of the gel, the solution was covered with 100 
µl of 0.1% SDS solution for 30 minutes at room temperature until the 
polymerisation occurred. 
 
Table 2.2. Acrylamide Gel Percentages for Resolving of Proteins 
 
% Acrylamide Protein size /Range 
8% 
10% 
12% 
40-200 kDa 
21-100 kDa 
10-40 kDa 
  
 
Table 2.3. Resolving Gel for Tris-glycine SDS-Polyacrylamide Gel Electrophoresis                   
(For preparing 100 ml). 
 
Component Resolving gel Stacking gel 
 8% 10% 12% 5% 
 (ml) (ml) (ml) (ml) 
Water 
30% Acrylamide mix 
1,5 M Tris (pH 8.8) 
10% SDS 
10% APS 
TEMED 
46.4 
26.6 
25 
1 
50 µl 
      0.06 
39.6 
33.4 
25 
1 
50 µl 
0.04 
33 
40 
25 
1 
50 µl 
0.04 
68 
17 
12.5 
1 
40µl 
0.10 
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Once resolving gel had completely polymerised, 2 ml of a stacking gel (5% 
stacking gel) were prepared and mixed with 20 µl of APS and poured on the 
top of the resolving gel (Table 2.3).  The comb was then inserted into the 
stacking gel and left > 1 hour at room temperature.  The gel can be used 
immediately or covered by saran wrap and stored at 4ºC until use next day.  
The tank was filled to the top of the gel with electrophoresis buffer, which 
consists of (25 mM Tris, 250 mM glycine). 
The protein samples were prepared by mixing with 5x loading buffer and water 
to a total volume of 15 µl.  The samples were then denatured in water bath at 
90ºC for 10 minutes.  The samples were quickly centrifuged for 5 seconds and 
then loaded and run at 110 v for 90 minutes. 
 
2.2.4.5 Loading buffer preparation 
 
The component of the loading buffer as follow: 
 
5x Load dye (5x loading buffer): 
6 mls of 0.5 M Tris pH 6.8 
2 mls glycerol 
2 mls 10% SDS 
5 mg Bromophenol blue 
This buffer can be stored at room temperature.  Before use, 77 mg DTT per ml 
was added to an aliquot of loading buffer and can be stored at 20ºC.  
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2.2.4.6 Western blotting 
Western blotting is a method, which transfers the proteins from the gel to the 
membrane by using an electric field to bind the protein onto a membrane, and 
then antibodies can detect the immobilised proteins.  It is used to detect 
specifically trace proteins on an immobilizing membrane and therefore enables 
further characterization.  
 
2.2.4.6.1 Electrophoretic transfer of proteins onto PVDF membrane 
Composition of reagents: 
5XTris-glycine electrophoresis buffer: 15 gm Tris, 94 gm Glycine, 5 gm SDS per 1 
litre (Running buffer) 
1XTris-glycine electrophoresis buffer: 200 ml of 5XTris-glycine electrophoresis 
buffer + 800 ml distilled water 
Blocking solution: 10% Marvel dried milk powder made with 1xTBS solution. 
5x TBS: 12.1 gm Tris-HCl (pH 7.6), 40 gm NaCl per litre. 
1xTBS: 200 ml of 5xTBS + 800 ml distilled water 
1x TTBS: 1XTBS containing 0.5 ml Tween20 (v/v) in 1 litter.   
Primary antibody: Rabbits 91, 92, A, B, C, D, E, F, 189 and 190 
Secondary antibody: Goat anti-rabbit IgG (H+L) conjugated to horseradish peroxidase 
(Bio-Rad). 
ECL Western blotting detection kit (Amersham Life Science) 
1x developer solution: (Ilford) 1:9 
1 fixing solution (Ilford) 1:4 and leave it 2 minutes before use  
Methanol (Fisher Scientific corp.) 
PVDF membrane (Millipore Immobilon-P, 0.45 µM pore size) 
Whatman paper 3MM 
UHP water  
 
Protein samples (20 µJ) were resolved by SDS-PAGE on a 12% gel and then 
transferred onto the Polyvinylidene Difluoride (PVDF) membrane for 
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immunoblotting.  Whatman paper (3MM) and 7x10 cm Polyvinylidene 
Difluoride (PVDF) membranes were prepared and immersed in 100% 
methanol for 5 minutes.  The methanol was decanted and the membrane was 
wetted with transfer buffer (25 mM Tris-HCl, 192 mM glycine, 20% methanol 
(v/v), 0.1% SDS w/v) for 10 minutes.  The gel was then placed carefully on the 
Whatman paper.  The PVDF membrane was placed on top of the gel.  Any air 
bubbles were removed between the PVDF membranes and the gel.  Another 
two Whatman papers were placed on the membrane to sandwich the gel and 
the membrane.  The gel sandwich was placed in a blotting cassette where the 
protein transfers to the PVDF membrane in transferring buffer (25 mM Tris-
HCl, 192 mM glycine, 20% methanol v/v, 0,1% SDS w/v) for 1 hr at 90 v. 
 
2.2.4.6.2 Incubation of transferred protein with antibody 
After transfer of protein, the membrane was placed in blocking solution (10% 
marvel solution (w/v) in 1 x TBS) and incubated at room temperature 
overnight.  The blot was then incubated with 40 ml of 1x TTBS containing the 
selected primary antibody at a dilution 1:500 for one hour with agitation.  The 
blot was washed 5 times for 5 minutes with 1x TTBS solutions.  The blot was 
then incubated in 50 ml of 1x TTBS solutions containing 5 µl of secondary 
anti-body 1:10000 (GAR Ig G-HRP) for one hour with agitation.  The blot was 
then washed 5 times for 5 minutes with 1x TTBS solutions and developed with 
ECL kit as mentioned in the manufacturers instructions (Amersham 
Biosciences).  The membrane was then exposed to ECL film (Amersham Life 
Science) for different intervals of time and then each film developed by 1x 
developer solution (Ilford) until bands appear.  The film was washed in water 
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for 2-3 minutes and fixed in 1X fixing solution (Ilford 1:4) until the film 
becomes clear.  The film was then dried at room temperature. 
 
2.2.4.7 Expression of proteins in BL21 (DE3) 
A fresh colony was picked from a plate of BL21 (DE3) bacteria and inoculated 
in 10 ml of 1% glucose LB broth containing Ampicillin (100µg/ml).  The 
culture was incubated at 37ºC on the shaker (220 rpm) overnight. 200 ml of 1% 
glucose LB broth containing Ampicillin were inoculated with the overnight 
culture of bacteria and incubated on the shaker (220 rpm) for 3 hrs at 37ºC or 
until an OD600 of 0.4-0.8 was reached.  5 ml of this culture were taken onto a 
clean universal tube as un-induced bacteria. 200µl of 1M IPTG was added.  
The cultured cells were then incubated at 37°C on the shaker (220 rpm) for 3 
hrs. After induction, 5 ml of the induced cells were taken onto a clean universal 
tube as induced cells.  The remainder of the cells were then centrifuged at 
4360xg for 20 minutes at 4°C.  The cells were then resuspended in 1/10 of the 
original volume of 50 mM sodium phosphate pH8.  The suspension was then 
sonicated for five bursts of 30 seconds and placed immediately on ice for 30 
second.  The sonicated pellets were then centrifuged at 4360xg for 20 minutes 
at 4°C on a JA10 rotor.  The supernatant was decanted into a fresh tube and 
stored at -20°C as induced total cell supernatant.  The pellets were resuspended 
in 6 M urea, 100 mM Tris-HCl (pH 8).  The suspension was incubated for 10 
minutes at room temperature, and then centrifuged at 4360xg for 20 minutes at 
4°C.  The supernatant was decanted into a fresh tube and labelled as 
supernatant of soluble pellets.  This supernatant, which contains the soluble 
protein, was centrifuged twice at 4360xg for 20 minutes on a JA2-21 rotor to 
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remove any particles material.  The supernatant was then poured into a fresh 
tube and stored at -20°C until use.  The protein concentration was then 
determined as described in section (2.2.4.1).  Proteins were then analysed on 
denaturing Polyacrylamide gel electrophoresis. 
 
2.2.4.8 Protein diafiltration  
Protein samples from 2.2.4.7 were diafiltered prior to affinity chromatography. 
An aliquot of protein samples (200µl) were stored as a control sample before 
dilution and dialysis.  One ml of LpH protein was diluted into 10 mls of 0.5 M 
NaH2PO4, 0.1% SDS solution.  For mouse cyp4x1 protein, 90 ml of mcyp4x1 
protein were diluted into 200 ml of 6 M urea, 0.1% SDS solution.  The diluted 
solution was then dialysed in a stirred ultra filtration cells from Millipore 
company (model 8200) at 5 LB/in² using nitrogen gas using YM10 exclusion 
membrane.  If the solution during dialysis fell below half the original dilution 
solution, the diafiltration chamber was then filled again with a dilution 
solution.  The dialysis was continued until the solution becomes clear.  The 
dialyzed solution was stored at 4ºC until use. 
Bradford assay was used to determine the protein concentration before and 
after dialysis.  
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2.2.4.9 Nickel column affinity purification   
The purification of the m-4x1 protein was carried out on the nickel affinity 
chromatography column according to the manufacturers instructions 
(Novagen).  All the following buffers were used and diluted to 1x prior to use 
in the affinity column: 
 
Component Binding 
buffer [8x] 
Elute 
buffer [4x]
Wash 
buffer [8x]
Strip 
buffer [4x] 
Charge 
buffer [8x] 
Imidazole      40 mm 4 M 480 mM - - 
NaCl 4 M 2 M 4 M 2 M - 
Tris-HCl 
(pH 7.9) 
160 mM 80 mM 160 mM 80 mM - 
EDTA - - - 400 mM - 
NiSO4 - - - - 400 mM 
 
 
The column was prepared by insertion of a glass wool and His.Bind chelating 
resin (Novagen).  2.5 ml of His.Bind resin (Novagen) was loaded into 20 ml 
syringe tube. 7.5 ml of distilled water was used to wash the column to remove 
the ethanol in the resin.  The resin was then charged with 12.5 ml of 1x charge 
buffer (50 mM NiSO4).  The column was then equilibrated in 7.5 ml of          
1x binding buffer containing 8 M urea.  The sample was loaded in the column 
and poured gently into the column.  To remove unbound protein,  25 ml of     
1x binding buffer containing 8 M urea were loaded and followed by 15 ml of   
a mixture solution of 11 ml of 1x binding buffer (8 M urea) and 4 ml of          
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1x washing buffer (8 M urea).  The 2-3 ml of un-bound protein were collected 
in a fresh tube and stored at -20ºC.  The bound protein was eluted from the 
column with 15 ml of 1x elution buffer (8 M urea).  The eluted protein was 
collected in clean eppendorf tubes at each 1 ml elution.  All un-bound and 
eluant fractions were analysed by SDS-PAGE.  After all the eluant fractions 
had been collected, the column was washed with 15 ml of 1x strip buffer 
followed by 10 ml of deionised water. 
Finally, the column was then washed with 10 ml of 20% ethanol and then 
stored at 4ºC. 
 
2.2.4.10 Manipulation of Latrophilin protein 
 
2.2.4.10.1 C.elegans preparations 
This method is based on Ian A. Hope (1995).  All the preparations solution 
were made up to 1 litre of UHP water and sterilized by autoclaving. 
Component of the reagents: 
S basal 
5.85 g NaCl 
1 g K2HPO4 
6 g KH2PO4 
1 ml Cholesterol (5mg/ml in ethanol) 
 
1M potassium citrate (pH6): 
20 gm citric acid monohydrate 
293.5 gm tri-potassium citrate monohydrate 
 
 94
Al-Anizy M                                                                       Materials and Methods 
Trace metals solution: 
1.86 g Disodium EDTA (5mM) 
0.69 g FeSO4.7H2O (2.5mM) 
0.2 g MnCl2.4H2O (1mM) 
0.29 g ZnSO4.7H2O (1mM) 
0.025 g CuSO4.5H2O (0.1mM) 
 
1M CaCl2: 
55.5 g CaCl2   
 
1M MgSO4: 
120.4 g MgSO4 (anhydrous)   
 
S medium: 
1 litre S basal 
10 ml 1M potassium citrate, pH 6 
10 ml trace metals solution 
3 ml 1M CaCl2 
3 ml MgSO4 
The S medium components were not autoclaved. 
 
E.coli cells (OP50) was grown in 1 litre LB broth media at 37 ºC overnight. 
The bacteria cells were centrifuged at 2830xg for 15 minute.  The supernatant 
was decanted and the pellets were resuspended in S-basal medium. C.elegans 
worms were grown at 25ºC overnight.  4 ml of the M9 buffer were used to 
transfer the growing worms to the S-basal medium containing E.coli cells.  The 
mixture was incubated at 25ºC on the shaker (3000 rpm) for 2 days. 2 mls of 
the worms culture was taken and viewed under the microscope.  The worm 
culture was centrifuged at 145xg for 2 minutes and then resuspended in 4 ml of 
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M9 buffer.  The worm culture was centrifuged again at 145xg for 2 minutes.  
The supernatant was decanted and the pellets were then transferred to a clean 
measuring cylinder.  25 ml of ice-cold sucrose (60% w/v sucrose) were added 
and mixed immediately.  The worms were then centrifuged at 484xg for 5 
minutes.  The worms which floated on the top of the solution were then 
pipetted and transferred to a new tube, mixed with M9 solution and centrifuged 
at 145xg for 5 minutes.  The supernatant was decanted and the pellets were 
transferred to a clean eppendorf tube.  The pellets were then briefly centrifuged 
and the supernatant was removed.  The pellets were then resuspended in 2 
volumes of M9 buffer and stored at 80ºC until use.  
 
2.2.4.10.2 Preparation of C.elegans fractions 
Frozen C.elegans worm pellets were thawed on ice for a few minutes.  Protease 
inhibitor (50µl) was added to the pellets, along with 20 µl of 0.1 M phenyl 
methyl sulfonyl fluoride (PMSF) per ml worms.  The samples were aliquoted 
and frozen at - 80°C until thoroughly frozen.  Samples were then thawed 
rapidly on ice and sonicated for 6 bursts of 30 seconds, with one minute 
periods on ice in between each sonicated burst.  Total homogenate sample (T) 
was taken after sonication and the samples were then centrifuged at 5000xg for 
5 minutes at 4°C.  The supernatant was transferred to a clean eppendorf tube 
(5K super) and the pellets (5K pellet) were resuspended in 0.5 ml of the buffer 
(20mM Tris-HCl pH 8, 10% glycerol, 150mM NaCl) and stored at -80°C.  The 
supernatant (5K super) was then centrifuged at 15000xg for 30 minute at 4°C.  
The supernatant was taken to a clean eppendorf tube (15K super) and the 
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pellets were then resuspended in 0.5 ml of the buffer (20mM Tris-HCl pH 8, 
10% glycerol, 150mM NaCl) and stored at -80°C.  
 
2.2.4.10.3 Dilution of C-elegans LpH protein in 10% emulgen 913 (0.6%, 
0.8%, 1%, 2%) 
 
Composition of reagents: 
Buffer solution (20 mM Tris pH8, 10% (w/v) glycerol, 150 mM NaCl) 
10% emulgen 913 
2% emulgen 913 
 
C.elegans membrane protein (15 k pellets) (14mg/ml) were prepared and 
stored at -80ºC.  The samples were thawed on ice and one ml was stored at  
-80ºC as a control sample.  1ml was diluted into 7 ml of buffer (20 mM Tris 
pH8, 10% (w/v) glycerol, 150 mM NaCl) to get a final concentration of 2 
mg/ml.  Several percentages of 10% emulgen detergent (0.6% (w/v). 0.8% 
(w/v), 1% (w/v)) were made to dissolve the LpH protein in the solution.  Each 
solution was stirred on ice for one hour.  The samples were centrifuged at 
20,817 x g for 20 minutes at 4ºC.  The supernatant of the samples was taken 
and stored at -80ºC.  The pellets were resuspended in the same amount and the 
concentration of the detergent solution (0.6% (w/v), 0.8% (w/v), and 1% 
(w/v)).  The pellet suspension of each sample was then stored at - 80ºC until 
use.  Two percent emulgen was prepared and the pellet samples were stirred 
with 2% emulgen solution for 1 hr at 4ºC.  The solution was centrifuged at 
793,000 x g for 20 min.  The supernatant was then taken and stored at 4ºC.  
The pellets were resuspended in 1 ml of the buffer (20 mM Tris pH8, 10% 
(w/v) glycerol, 150 mM NaCl) and stored at 4ºC.  
 97
Al-Anizy M                                                                       Materials and Methods 
 
2.2.4.10.4  Dilution of C-elegans LpH protein in dodecylmaltoside 
detergent (0.8%, 1%, 1.2%) 
 
The dodecylmaltoside detergent was added to the membrane pellets to a final 
concentration of 0.8% (w/v), 1% (w/v) and 1.2% (w/v) respectively.  The 
samples were then mixed gently at 4ºC for 1 hour.  The samples were then 
centrifuged at 20,817 x g for 10 minutes at 4ºC.  The supernatant was taken to 
a clean tube and stored at 4ºC.  The pellets were then resuspended in an equal 
amount of original buffer (20 mM Tris pH8, 10% (w/v) glycerol, 150 mM 
NaCL2).  
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2.2.4.10.5 Ammonium sulphate precipitation  
In order to extract and prepare LpH antisera for purification on an affinity 
column, ammonium persulphate was used for precipitation. 
An aliquot (300 µl) of LpH antisera was taken as a control sample and stored at 
4 ºC.  Six ml of LpH antisera were centrifuged at 20,817 x g at 4ºC for 5 min.  
The supernatant was taken and placed in a universal tube and stirred gently on 
ice.  Saturated ammonium sulphate solution (2.85 ml) was pipetted into the 
antibody solution dropwise.  The antibody solutions were incubated at 4ºC for 
6 hr.  The antibody solutions were then centrifuged at 20,817 x g for 5 min to 
give a 25% ammonium sulphate pellet, and supernatant.  The supernatant of the 
antibody solution was transferred into a clean universal tube and stirred with a 
magnetic stirrer at room temperature.  Ammonium sulphate (2.85 ml) was 
poured slowly into the antibody solution.  The solution was incubated at 4ºC 
for at least 6 hr or overnight.  The antibody solution was centrifuged at 10,621 
x g for 10 min.  The supernatant was decanted in a fresh tube (50% NH4SO4 
supernatant).  The pellets were then resuspended by 1 ml of PBS and shaken 
gently to avoid any air bubble (50% NH4SO4 pellets).  The 50% NH4SO4 pellet 
was dialysed in stirred ultra filtration cell from Millipore Company at 5 LB 
/in².  The 50% NH4SO4 pellets was then stored at 4°C until use.  The 50% 
NH4SO4 supernatant was dialysed in stirred ultra filtration cell from Millipore 
Company at 5 LB /in² and then stored at 4°C until use. 
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2.2.4.10.6 Dot blot assay 
Dot blot assay is a clear guide to show how much antibody purification was 
achieved and how much is in each fraction. 
Procedure: 
A sheet of a nitrocellulose (Hybond ECL) was prepared by drawing a circle for 
each sample site on the membrane.  The samples were diluted in the phosphate 
buffer saline (PBS) for each sample 10
 1
, 10
 2
, 10
 3
, 10
 4
, 10
 5
, 10
 6
, 10
 7
, 10
 8 
respectively.  One µl of each sample was spotted onto the membrane and left to 
dry.  The membrane was immersed in a blocking solution 10% (w/v) Marvel 
dried milk for 2 hours at room temperature.  The blocking solution was 
decanted and the membrane then incubated in 50 ml of 1x TTBS solutions 
containing 5 µl of secondary anti-body 1:10000 (GAR Ig G-HRP) for one hour 
with agitation.  The blot was then washed 5 times for 5 minutes with 1x TTBS 
solutions and developed with ECL kit as mentioned in the manufactures 
instructions.  The membrane was then exposed to ECL film (Amersham Life 
Science) for different intervals of time and then each film developed by          
1x developer solution until bands appear.  The film was washed in water for   
2-3 minutes and fixed in 1X fixing solution (Ilford 1:4) until the film becomes 
clear.  The film was then dried.  
 100
Al-Anizy M                                                                       Materials and Methods 
 
2.2.4.10.7 Activated bead preparation  
0.5 ml of N-Hydroxyl succinimide activated agarose (beads) was prepared in a 
fresh eppendorf tube.  The beads were shaken gently and briefly centrifuged 
for a short time.  The alcohol supernatant was decanted and the residue was 
placed on ice.  The beads were washed twice with 1 ml of pure ice-cold water 
and centrifuged at 20,817x g at room temperature.  The water supernatant was 
removed and the residue was placed on ice.solutions and materials: 
 
2.2.4.10.8 Affinity purification with LPH protein 
This method was carried out as described in The Antibodies, a laboratory 
manual (Harlow, E.D; Lane, D. 1988)  
Composition of reagents: 
0.5 M Sodium phosphate pH (7.5) 
1M Sodium chloride, 0.05 M Sodium phosphate pH (7.5) 
4 ml of LpH protein 
50 ml of 100 mM Glycine, pH 2.5 
50 ml of 10 mM of NaH2PO4, pH 6.8 
50 ml of 1 M NaH2PO4, pH 8 
Procedure: 
4 ml of LpH protein (0.6mg/ml) in (20 mM Tris pH8, 10% (w/v) glycerol, 150 
mM NaCl) were centrifuged at 20,817 x g for 2 min at room temperature.  The 
supernatant was decanted in fresh universal tubes.  1ml of LpH protein 
(0.14mg/ml) in (20 mM Tris pH8, 10% (w/v) glycerol, 150 mM NaCl) was 
pipetted onto the beads.  The protein-bead solutions was shaken gently and left 
on the shaker overnight. 
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The protein-bead solution was then left on the bench for 10 min until all the 
beads settled.  The supernatant was decanted and the beads were transferred 
into a fresh eppendorf.  The beads were washed twice with 1 ml of 0.5 M 
NaH2PO4 (pH 7.5) and once with 1 M NaCl, 0.05 M NaH2PO4 (pH 7.5).  The 
beads were then washed with 10 volumes of 100 mM ethanolamine (pH 7.5) 
and incubated at room temperature for 4 hr with gentle mixing.  The beads 
were centrifuged and washed twice with 0.5 M phosphate buffer saline (PBS), 
2 ml of 100 mM glycine, 1 M NaH2PO4 (pH 8) and 1 ml x 4 of PBS.  This 
process yields beads containing covalently bound LPH protein. 
0.6 ml of the 50% NH4SO4 pellets was mixed with protein-beads solution and 
left overnight on the rocker at 4°C.  The Ab-beads solution were loaded into 
the column and washed with 20 ml of PBS.  The beads were then washed with 
10 ml of 10 mM NaH2PO4.  Before the protein elution, eppendorfs were 
prepared which each one contains 20 µl of 1M NaH2PO4 (pH 8) and then 
eluted by 10 x 200 µl of 100 mM glycine (pH 2.5).  The column was then 
washed with 20 ml of PBS and then 2 ml of 0.1 % sodium azide. 
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2.2. 5 Gene expression analysis 
 
2.2.5.1 Denaturing Poly acrylamide gel electrophoresis (6%) 
Composition of reagents 
Sequa gel concentrates: 
237.5g/litre acrylamide 
12.5g/litre methylene bis-acrylamide 
500g/litre 8.3M urea 
 
Sequa gel diluents: 
500g/litre 8.3M urea 
10xTBE buffer 
0.89M Tris base 
0.89M boric acid pH 8.0 
20mM EDTA 
 
RNA can form secondary structure and consequently fails to show linear 
separation with increasing mass.  To address this, denaturing conditions such 
as urea was used in RNA gel electrophoresis using BioRad protein II vertical 
electrophoresis apparatus. 
The glass plates and the spacer (0.4mm) were firstly washed with absolute 
ethanol and then cleaned with water to remove any dirt or acrylamide 
contaminants.  
The poly acrylamide gel preparation was prepared based on the following 
formula:
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1/10 X total gel volume = volume of 10XTBE 
% acrylamide gel required X volume of gel / 25 = volume of Sequa gel concentrate 
volume of gel  (1/10th volume of gel + volume of concentrate) = volume of diluents 
 
 
Based on the formula above, to prepare 6% poly acrylamide gel of 10ml total 
volume gel 2.4ml of Sequa gel concentrate, 1ml of 10xTBE and 6.6ml of 
Sequa gel diluents were mixed in a universal tube.  To this mixture, 6ul of 
TEMED and 100ul of APS were added and mixed gently by hand.  The 
mixture was then pipetted immediately between the glass plates until the glass 
plates fully filling by the mixture.  The comb was then inserted in between the 
glass plates and the gel allowed polymerising for 1 hour.  The polymerised gel 
was placed in the gel tank and 1xTBE was used to fully cover the anode and 
cathode compartment.  The wells were then flushing by 1xTBE running buffer 
to remove any precipitant of unpolymerised acrylamide and Urea 
crystallization form.  The samples were loaded and the gel was run at 120 v/cm 
for 90 minute.  The gel was fixed in 10% methanol and 1% acetic acid and 
placed on the shaker for 1 hour.  The solution was decanted and the gel then 
washed by water and placed on the shaker for 1 hour.  The washed water was 
decanted and the gel again washed by water for 15 minute on the shaker.  The 
gel was then removed and placed on 2x3MM paper and then dried under the 
vacuum.  The dried gel was transferred to an intensifying apparatus and 
exposed to Kodak BioMax MS film for overnight at  80ºC.  The intensifying 
apparatus was removed from the  80ºC and allowed to warm in a dark room at 
room temperature.  The film was then treated by the fixer and the developer 
solutions as described in section (2.2.9.2). 
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2.2.5.2 RNase protection assay 
Ribonuclease protection assay (RPA) is a high sensitive and specific method to 
detect and quantitative RNase.  This method is based on a method described by 
Melton et al (1984).  The RNase protection assay used was obtained from 
PharMingen Ltd, commercially available as Riboquant®.  The assay was 
performed as manufacturers instructions. 
 
2.2.5.3 Generation of the DNA template 
Before starting the RNase protection assay, the plasmid DNA (pGEMT-easy) 
containing the inserted mouse 4X1 cDNA was used as a template for the 
RNase protection assay.  The plasmid DNA was linearised by a restriction 
digest (NcoI) and analysed on 1% agarose gel.  The DNA was then precipitated 
by two volume of absolute ice-cold ethanol and 0.25 volume of 7MM 
ammonium acetate for 30 minute at  20ºC.  The sample was centrifuged at 
20817xg for 15 minute at 4ºC.  The supernatant was decanted and the 
precipitant pellets were then washed with 70% ice-cold ethanol.  The sample 
was centrifuged again at 20817xg for 5 minutes at 4ºC.  The pellets were 
resuspended in 30ul of DEPC-treated water. 
 
2.2.5.4 Synthesis of 170 b.p labelled [P32] Marker 
The marker was generated from a synthesized plasmid DNA (pGEMT-easy) 
containing a known sequence of an inserted PCR fragments.  The inserted 
fragments were 124 b.p.  The marker was synthesised as described in section 
2.2.13.2.4.1. 
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2.2.5.5 Incorporation test 
This is a method for estimating the amount of radioactivity that incorporates 
into the probe.  Whatman DE81 filter paper was used for this test.  The 
DE81has positive charge which strongly bind to nucleic acids. In brief two 
DE81 (Whatman) filter paper were labelled unwashed and washed, with a 
pencil.  One microlitre of probe was pipetted onto each paper and allowed to 
dry.  One DE81 filter paper was then washed five times for five minutes with 
10 ml of 0.5M NaHPO4, five times for five minutes with 10 ml of distilled 
water and five times for five minutes with 10 ml ethanol.  The filter was then 
allowed to air-dry at room temperature.  Unincorporated nucleotides are easily 
removed by the washing process with 10 ml of 0.5M NaHPO4. 
The measuring of the radioactivity for both filter papers (the washed and 
unwashed filters) was carried out by a Geiger counter.  The incorporated 
radioactivity nucleotides rate into the probe was then calculated by the 
difference between the two readings using the formula: 
 
 
 
 CPS of washed filter 
CPS of unwashed filter 
= Incorporation rate (%) 
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2.2.5.6 RNA probe synthesis 
The RNase protection assay was carried out using Riboquant probe kit from 
PharMingen Ltd.  . The Riboquant probe kit contains the following reagents: 
1xHybridization buffer 
1xRNase buffer 
RNase A+T1 (80ng/ml, 250U/µl) 
1xProteinase K buffer 
Proteinase K (10mg/ml) 
Yeast tRNA (2mg/ml) 
4M ammonium acetate 
1xLoading buffer 
 
In order to prepare the RNA probe for the RNase protection assay, the 
transcription of this probe was performed by adding 1ul of RNA guard, 4µl of 
5xTCB, 2µl of DTT, 2µl of A,G,UTP (3 mM), 10µl of [Į-³²P] CTP (specific 
activity 800Ci/mmol), 1µl of distilled water, 1µl of linearised DNA, and 1µl of 
Sp6 or T7 polymerase enzyme. 
The reaction above was added in order and mixed by gentle pipetting or 
flicking and then quick centrifuged on the bench top centrifuge.  The reaction 
was then incubated at 42ºC for Sp6 or 37ºC for T7 polymerase for 1 hour.  The 
reaction sample was tested to DE81 assay to measure the incorporated labelled 
nucleotide into the synthesised RNA as described in section (2.2.13.2.3).  The 
incorporation test to be accepted it should be at least 10% other wise rejected.  
The assay was then terminated by adding 3ul of DNase and then mixed gently 
prior to quick centrifuged into a bench top centrifuge.  The assay sample was 
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then incubated at 37ºC for 30 minute and then 26µl of EDTA (20mM), 25µl of 
Tris-saturated phenol, 25µl of Chloroform:Isoamyl alcohol (50:1), and 2µl of 
yeast tRNA (2µg/µl) were added in order.  The reaction was mixed by vortex 
into an emulsion and then centrifuged for 5 minutes at room temperature on 
bench top centrifuge.  The upper aqueous layer was taken to a new eppendorf 
tube and 50µl of Chloroform/Isoamyl alcohol (50:1) were added and mixed by 
vortex and then centrifuged for 2 minute at room temperature on a bench top 
centrifuge.  The aqueous layer was then transferred to anew eppendorf tube and 
50µl of 4M ammonium acetate and 250µl of ice-cold 100% ethanol were added 
mixed by inversion and then incubated for 30 minute at -80ºC to precipitate the 
RNA probe.  The reaction was centrifuged at 20817xg for 15 minute at 4ºC.  
The supernatant was decanted and the pellets were washed with 100µl of 90% 
of ice-cold ethanol and then centrifuged for at 20817xg for 5 minutes at 4ºC.  
The supernatant was removed and the pellets were air-dried for 5-10 minutes.  
The pellets were resuspended in 50µl of hybridisation buffer by gentle vortex 
for 20 second and then quick centrifuged to collect the components in the tube.  
The probe was then ready to use or stored at - 20ºC until use within 2 days after 
preparing. 
 
2.2.5.7 RNA samples preparation and hybridisation 
30µg of each RNA sample were precipitated as described in section (2.2.3.5) 
and then resuspended with 8µl of hybridisation buffer.  The samples were 
solubilized by gentle vortex and then briefly centrifuged in a bench top 
centrifuge.  To this, 1ul of the synthesised probe (0.3µl probe) was hybridised 
with 30µg of each RNA sample and then mixed by pipetting.  One drop of oil 
was added to each sample to prevent component evaporation.  The samples 
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were placed on a water bath at 90ºC for 3 minutes and then immediately the 
temperature was turned down to 56ºC and incubated overnight.  The 
temperature was then turned down to 37ºC for 15 minute prior to the RNase 
treatments.  The samples were treated with 100ul of RNase cocktail pipetted 
under the oil layer except the positive control (-ve tRNA) where treated with 
100ul of RNase buffer.  The samples were centrifuged and incubated for 45 
minute at 42ºC.  Meanwhile this incubation, 18µl of Proteinase K cocktail were 
added to each a new eppendorf tube.  The RNase digestion was taken and 
transferred to the new eppendorf tubes containing the Proteinase k cocktail.  
The samples were mixed by vortex and then incubated for 15 minute at 42ºC. 
A 65µl of Tris-saturated phenol and 65µl of Chloroform: Isoamyl alcohol 
(50:1) were added and mixed by vortex to each sample and then centrifuged at 
room temperature for 15 minute. 
The aqueous layer was transferred to a new eppendorf tube and then 120µl of 
4M ammonium acetate and 650µl of 100% of ice-cold ethanol were added and 
mixed by inversion 6-12 times.  The samples were then incubated at -80ºC for 
30 minute and then centrifuged at 20817xg for 15 minute at 4ºC.  The 
supernatant was removed and the pellets were resuspended in 100µl of 90% 
ice-cold ethanol.  The supernatant was decanted and the pellets were air-dried 
for 5 minutes.  The pellets were then resuspended in 5µl of 1x loading buffer 
and then brief centrifuged on a bench top centrifuge.  The samples were heated 
at 95ºC for 3 minutes on a water bath and then placed immediately on ice.  The 
samples were loaded on 6% Polyacrylamide gel and electrophoreted at 120 
v/cm until the loading buffer dye reach the bottom of the gel. 
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The gel was then treated with destaining solution (10% of glacial acetic acid 
and 10% of methanol) for 1 hour.  The gel was dried under the vacuum drier 
for 2 hours and then exposed to Kodak BioMax MS film at -80ºC for 
overnight.  The film was then treated by the fixer and the developer solutions 
as described in section (2.2.4.6.2). 
 
2.2.6 Immunohistochemistry 
Solutions: 
0.2M phosphate buffer (buffer A and buffer B) 
Buffer A (0.2M KH2PO4) 
13.61 g of potassium dihydrogen orthophosphate 
Buffer B (0.2M Na2HPO4.12H2O) 
35.81 g of disodium hydrogen orthophosphate  
Buffer A and B were each made up to 500 ml with UHP water and then mixed 
together and the mixture was adjusted to pH 7.2 at 20ºC.  
 
0.01M sodium citrate buffer (pH 6.0): 
2.9 g sodium citrate 
3.4 ml HCl 
 
The buffer was made up to 500 ml with UHP water and adjusted to pH 6.0 at 
20ºC.  
Tris-HCl, pH 7.6 (TBS): 
8.1 g sodium citrate 
0.6 g Tris-HCl hydroxymethylamine 
3.8 ml HCl 
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The buffer was made up to 500 ml with UHP water and adjusted to pH 7.6 at 
20ºC.  
 
2.2.6.1 Immunohistochemistry fixative 
Immunohistochemistry fixative solution was made by mixing one part of 8% 
paraformaldehyde with one part 0.2 M phosphate buffer. 
 
2.2.6.2 Mouse perfusion 
Adult male S129 mice were anesthetized using halothane and then perfused 
using perfusion solution (50:50 paraformaldehyde and 0.2M phosphate buffer) 
for 20 minutes.  The brain tissue was kept in fixative solution overnight at        
4|C.  
 
2.2.6.3 Paraffin-embedded sections 
Brain tissue was embedded in paraffin because it provides excellent 
morphological detail and resolution. Paraffin is a mixture of paraffin wax and 
resin.  Paraffin-embedded sections was prepared by Leica TP1020 automatic 
tissue processor as follow: 
 
70% alcohol for 90 minute 
80% alcohol for 90 minute 
96% alcohol for 90 minute 
100% alcohol for 60 minute 
100% alcohol for 60 minute 
Xyleene         for 90 minute 
Xyleene         for 90 minute 
Paraffin          for 2 hours 
Paraffin          for 2 hours 
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Brain tissue was then blocked (10x10x3 mm) in paraffin and placed on a cool 
plate prior to store at 4|C until use.  The block was cut with a cryotome (Leica 
CM1900) at 10 µm thickness.  The paraffin sections were then placed on    
poly-L-lysine coated slides and stored at 4ºC.  
 
2.2.6.4 Immunohistochemistry for NFT and GFAP on paraffin sections   
Brain paraffin slides were placed in a black plastic slide rack and 
deparaffinzed, and then hydrated as follows: 
 
Xylene                            2x5 minutes 
100% Ethanol                 2x5 minutes 
90% Ethanol                   2x5 minutes 
70% Ethanol                   2x5 minutes 
50% Ethanol                   2x5 minutes 
Running tap water          5 minutes 
 
The slides were transferred to a plastic container containing approximately 300 
ml of fresh 0.01M citrate buffer (pH 6.0) and heated by microwave for 10 
minutes.  The slides were allowed to cool for 20 minutes and then immediately 
placed in cold running water.  The sections were wiped with tissues and 
outlines of them were drawn using a hydrophobic pen.  The slides were placed 
in hydrogen peroxide solution (59 ml hydrogen peroxide and 1 ml of ethanol) 
for 10 minutes to quench, endogenous peroxidases.  The slides were washed in 
TBS and placed into a hydrophobic chamber prior to adding protein blocker.  
The slides were incubated with protein blocker for 30 minutes at room 
temperature.  The slides were then drained and incubated with diluted primary 
antibodies (1:1000) for two hours at 4ºC.  The slides were washed using TBS 
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and incubated with link No.3 from the LSAB2 kit for 20 minutes at room 
temperature.  The slides were washed again and incubated with link No.4 from 
the LSAB2 kit for 20 minutes at room temperature.  The slides were washed in 
TBS and then 300 µl of DAB solution (one ml of peroxidase substrate solution 
and one drop of chromogen) were added to the sections for approximately 10 
minutes at room temperature.  To stop the DAB reaction, the slides were 
washed using water.  The slides were dried around the sections, mounted in 
aqueous mounting media and then sealed around the edges with nail varnish. 
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Chapter 3                        Results 
 
 
3.1 Sensitivity of antisera against CYP4Z1   
Native human CYP4Z1 in tissue samples cannot be specifically detected and, 
hence characterisation relies on Western blot analysis.  Therefore, it was 
necessary to develop a sensitive human CYP4Z1-specific antibody.  
A partial cDNA of human CYP4Z1 was cloned into pRSET-b for expression as  
 a histidine-tagged fusion protein, containing 319 amino acids (residues 177-
493) of 4Z1.  The purified protein was approximately 39 700 Da. The integrity 
of the protein was confirmed by SDS-PAGE (not shown), and the protein 
concentration was 0.3 mg/ml as determined by Bradford assay (not shown).  
Polyclonal antibodies were produced by injection of female New Zealand 
White rabbits (~ 4 kg) with purified CYP4Z1 recombinant protein. Rabbits 
were initially injected with the CYP4Z1 antigen (100 µg) as a 50% emulsion in 
Freunds incomplete adjuvant and bleeds were taken approximately two weeks 
later (all animal work done by D. Brady).  Subsequent immunisations were at 
approximately monthly intervals.  Antisera were obtained from four rabbits; 
91, 92, C, D. Antisera were titred for reactivity against 4Z1 by western blotting 
using various amount of protein (e.g. 10, 3, 1, 0.3 ng).  The protein was blotted 
and detected with primary antiserum at a dilution of 1:500, Figure 3.1.  The 
antigen CYP4Z1 is easily visualised in the left hand panel of Figure 3.1, in 
lanes 10, 3, 1 and 0.3 ng.  Three bands were detected by the antisera from each 
rabbit.  The size of the CYP4Z1 antigen was determined by Prism v 3.0 
program and it was 39 700 Da, and this is shown by an arrow; higher molecular 
 114
Al-Anizy M                                                                                               Results 
weight bands were visible in a coomassie-stained gel of this antigen; these may 
be artefacts, possibly arising from protein aggregation. 
The terminal antiserum from rabbit D detected 0.3 nJ of antigen, whereas the 
terminal antiserum from rabbit C detected 1 nJ of antigen.  Therefore, the 
antiserum from rabbit D was more sensitive than that from rabbit C. 
 
 
              D                                                                  C 
                                                            
    
  
 
 
         
 
 
 
 
 
 
 
 
 
      
40 kDa 
40 kDa 
   10        3         1       0.3   ng                                                       10        3         1       0.3  ng   
 
FiJure 3.1. Sensitivity of antisera against CYP4Z1.   
The indicated amount (0.3, 1, 3 or 10 ng) of CYP4Z1 protein was run on 12% SDS-PAGE then 
blotted to PVDF membrane as described in the methods.  The membranes were incubated with 
antiserum (from rabbit C or D) at a concentration of 1:500, and the blots were developed with 
ECL as described in the methods.  Film was exposed for thirty minutes.  The arrow shows the 
protein at ~ 40 kDa. 
 
 
Thus the western blotting technique provides a characterisation of the 
sensitivity of the antiserum for antigen.  The terminal antisera from rabbits 91 
and 92 were less sensitive, and detected 10 ng of antigen (data not shown).  
The development of antisera over time was followed by western blotting of 
sequential bleeds.  Time course injections were given at four week intervals 
and once a sufficient antibody titre was obtained a terminal bleed sample were 
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collected.  Figure 3.2, shows the sensitivity of antiserum for antigen over the 
course of several immunizations. 
The sensitivity of antiserum increased with each immunisation of the rabbit, 
achieving sensitivity at the 0.3 ng level after 6 boosters, at which point the 
terminal bleed was taken. 
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Figure 3.2. Development of antisera against CYP4Z1.  
 Rabbits were immunised six times for western blotting at monthly intervals. Both antisera 
detected 1 ng of antigen was diluted 1:500.  The diamond represent the antisera of rabbit C and 
the square represent the antisera of rabbit D, which had been collected at the indicated date, 
characterised as shown in FiJure 3.1.  The data points represent the minimum amount of 
antigen detected. 
 
 
The sensitivity of the antisera against hCYP4Z1 was shown to be sufficient for 
subsequent characterization of CYP4Z1.  The detection limit was 0.3 ng but a 
lengthy course of immunisations was required to achieve this level of 
sensitivity. 
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3.2 Characterisation of antisera against the Aryl hydrocarbon-Receptor 
(AhR) 
Native AhR in tissue samples and after recombinant expression was too low to 
detect by coomassie blue staining on SDS-PAGE and hence characterisation 
relies on Western blot analysis or functional analysis (ligand-binding assay).  
Therefore, it was necessary to produce antisera specific for the mouse AhR.  
A fragment of the mouse AhR b-1 allele (residues 285-416) (J.Fenlon, M. Q. 
Fan, and DR. Bell) was inserted by BamHI digestion into the pRSET-c vector 
(clone '5g´). 
The cloned DNA construct pRSETc-AhR285-416 encodes 131 amino acids of 
AhR and the calculated molecular weight of the protein is 19,267 Da.  
Recombinant protein was provided by John Fenlon.  The protein was shown to 
be intact by SDS-PAGE and the concentration was determined to be 0.76 
mg/ml by Bradford assay (not shown). 
Two rabbits were injected with the recombinant AhR fragment to generate 
antisera against the AhR recombinant protein.  Time course injections were 
given at four week intervals and once sufficient antibody titres were obtained, 
terminal bleed samples were collected. 
Bleeds from rabbits A and B were collected after each immunisation, and gave 
strong and clear bands against the antigen (AhR), Figure 3.3.  The minimum 
amount of antigen detected was 0.3 ng at a primary antibody dilution of 1:500; 
this gave a strong band in both rabbit bleeds.  Figure 3.4, shows a graph of the 
sensitivity of antisera over time.  In the initial titration, the sensitivity of the 
antisera was 3 ng, whereas the sensitivity of the terminal bleeds for both rabbits 
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was less than 1 ng.  This indicates an improvement in the sensitivity of the 
antisera from these rabbits against the antigen over the course of several 
immunizations and shows that the antisera can be used to sensitively detect the 
AhR LBD protein of mouse. 
 
            A                                                                                B 
 
                                             
20 kDa 20 kDa
     3       1      0.3   ng                                                       3        1       0.3   ng  
 
Figure 3.3.  Sensitivity of antisera against AhR.  
The indicated amount (3, 1, 0.3 ng) of AhR protein was run on an 18% SDS-PAGE gel, then 
blotted to PVDF membrane as described in the methods. The membranes were incubated with 
the indicated antiserum (A or B) at a concentration of 1:500, and the blot developed with ECL 
as described in methods.  Films were exposed for thirty minutes.  
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Figure 3.4.  Development of antisera against AhR protein. 
Rabbits were immunized at monthly intervals for six months.  Antisera from rabbits A and B 
were collected at the indicated time, diluted 1:500, and incubated with antigen for 1 hr.  
Diamond points represent rabbit B and the square points represent rabbit A, these show the 
minimum amount of AhR antigen detected at the indicated time. 
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The detection limit of the antisera for AhR LBD was 0.3 ng.  This was 
sufficient for further characterization of the AhR protein in mouse and rat 
cytosol.  
The antisera were tested for cross-reactivity and specificity against native liver 
proteins.  The AhR is known to be expressed in rodent liver, and so cytosol 
was prepared from the livers of C57BL/6 mice (male) and Wistar rats (male) as 
described in the methods.  Cytosolic proteins from the livers of mice and rats 
were western blotted and incubated with antiserum, Figure 3.5.  Several minor 
bands of reactivity were seen in both mouse and rat cytosol possibly due to 
proteolysis because it is also known that the AhR is sensitive to proteolytic 
degradation (Poland et al, 1990).  However, there was a strong band of AhR 
protein at a size of ~111kDa in mouse cytosol and ~110 kDa in the rat cytosol.  
This corresponds approximately to the expected migration of the AhR protein 
on SDS-PAGE, 104 kDa in C57BL/6 mice and 106 kDa in rats (Poland et al, 
1987, 1990).  The lower molecular weight bands were found to be strong in the 
mouse cytosol, whereas these bands in the rat cytosol were faint.  Furthermore, 
the intensity of the higher molecular weight bands was greater in the rat cytosol 
than in the mouse. 
The antisera against mouse LBD detected the rat AhR due to high sequence 
identity. 
The percentage amino acid identity of mouse AhR and rat AhR LBD is 93% 
and only five residues are different. 
 119
Al-Anizy M                                                                                               Results 
 
 
 
  Mouse                                                                       Rat   
                                                                
~111 kDa ~110 kDa
 
10     20 µg                                                               10    20 µg 
 
Figure 3.5  Western blotting of mouse and rat cytosol.  
The indicated amount (20, 10 µg) of C57BL/6 and wistar cytosol protein was run on 8% SDS-
PAGE gel, then blotted to PVDF membrane as described in the methods.  The membranes 
were incubated with antiserum A at a concentration of 1:500, and the blot developed with ECL 
as described in methods.  Films were exposed for 30 minutes. The arrows show the AhR 
protein at a size of ~ 111 kDa in mouse cytosol and ~110 kDa in rat cytosol. 
 
 
Characterisation of the antisera against native liver proteins of mouse and rat 
showed that it was sufficient to detect the AhR in 10 µg of cytosol protein.  
The signals produced in rat cytosol were stronger than in mouse cytosol.   
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3.3 Characterisation of antisera against Latrophilin (LpH)  
Latrophilin (LpH) is the receptor for toxic proteins produced by Black Widow 
spiders.  A partial C.elegans LpH cDNA was cloned into pRSET for 
expression as a histidine-tagged fusion protein containing 374 amino acids of 
LpH (residues 168 -542), with a predicted mass of 46 447 Da.  The integrity of 
the protein was confirmed by SDS-PAGE (not shown), and its concentration 
was determined to be 3.3 mg/ml by Bradford assay (not shown).  
In order to characterise the purified and native LpH protein, antibody specific 
to LpH was required.  Two New Zealand white female rabbits (E and F) (~ 4 
kg) were injected with ~ 100 µg of LpH antigen.  Booster injections were given 
at four week intervals and once sufficient antibody titre was obtained, terminal 
bleed samples were collected.   
An example of a Western blot to detect LpH protein is shown in Figure 3.6. 
This Figure shows a good titre with antiserum, which was collected from 
rabbits E and F.  Different amounts of protein were blotted and visualised using 
antiserum E and F to determine the sensitivity of the antiserum.  Both antisera 
show a high sensitivity to the LpH (0.3 ng) at a dilution of 1:500.  There are no 
differences in the intensity of protein bands detected using antisera from rabbit 
E or rabbit F. 
The rabbits were injected with the antigen once a month and bleed samples 
were tested for antibody titre, shown in Figure 3.7.  The minimum amount after 
the first injection of the antigen was 3 ng and the sensitivity of antisera 
increased to detect 0.3 ng after six months. 
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Figure 3.6.  Sensitivity of antisera against LpH.   
The indicated amount (10, 3, 1, 0.3 ng) of LpH protein was run on a 12% SDS-PAGE gel, and 
then blotted to PVDF membrane as described in the methods.  The membranes were incubated 
with the indicated antiserum (E or F) at a concentration of 1:500, and the blot developed with 
ECL as described in methods.  Films were exposed for thirty-minutes. 
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Figure 3.7.  Development of antisera against LpH.   
Rabbits were immunized at monthly intervals for six months.  Antisera of rabbits E and F were 
collected at the indicated times diluted 1:500, and incubated with antigen for 1 hr.  Diamond 
points represent the amount of antisera rabbit F was detected at the indicated time.  The square 
points represent the amount of antisera rabbit E was detected at the indicated time. 
 
Antiserum against latrophilin was sensitive enough to detect 0.3 ng of antigen, 
sufficient for use in further studies. 
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3.3.1 Characterisation of latrophilin (LpH) protein 
The LpH protein is 1014 amino acids in length and is predicted to be a G-
protein coupled receptor (Poland et al; 1991), with seven membrane-spanning 
domains, on the basis of its primary structure.  This protein would therefore be 
predicted to be localised in a membrane compartment.  In order to test this 
hypothesis, different sub-cellular fractions of C.elegans were isolated.  
C.elegans were purified by sucrose density gradient purification to remove 
contaminating bacterial debris, which otherwise gave immunoreactive bands 
(data not shown).  The C.elegans was lysed by extensive sonication, and initial 
separation was a 5,000rpm (3,020 x g) spin for five minutes to remove worm 
carcasses and nuclei (the 5k pellet).  The 5,000rpm (3,020 x g) supernatant (5k 
super) was fractionated by centrifugation at 15,000rpm (27,200 x g) for thirty 
minutes to yield a 15k pellet and 15k supernatant (15k super). 
The15k pellet and supernatant were blotted and probed with antiserum F.  
Figure 3.8, shows that several bands were found in these fractions.  The 15k 
pellet fraction has a band at approximately ~ 113 kDa which represents the 
expected size of the LpH protein, whereas no band of this size was found in the 
15k supernatant.  Therefore, LpH protein is found in the cell membrane 
compartment.  Furthermore, several bands of reactivity were seen in both 
fractions (15k pellet and 15k supernatant), these are possibly due to protein 
cleavage at the GPS site, but it is also possible that they are non-specific cross-
reactivity.   
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Figure 3.8. Western blotting of sub-cellular fractions of C.elegans (15k pellet and 
supernatant).  
20 µg of each fraction was run on a 12% SDS-PAGE gel, and then blotted to PVDF membrane 
as described in the methods.  The membrane was incubated with 1:500 antiserums F for 1 hr, 
and the blot was then developed with ECL as described in the methods. A film was exposed for 
thirty minutes.  The arrow shows a protein at ~113 kDa.  
 
 
 
3.3.2 Wild type and latrophilin knockout C.elegans 
As a further control for the specificity of the LpH antiserum, we used the 
antiserum to probe protein extracts from wild-type and LpH null worms.  The 
LpH null worms are derived from strain VC965, which are heterozygous for 
the ok1465 allele (http://aceserver.biotech.ubc.ca/cgi-
bin/generic/allele?class=Allele;name=ok1465), and were used to generate 
homozygous ok1465 null worms (DRB, unpublished data). 
The ok1465 allele has an extensive deletion of the LpH gene, including the 
entirety of the region covered by the LpH antigen (Figure 3.9).  These worms 
should therefore be a negative control for the LpH antiserum. 
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Figure 3.9. Cartoon of the ok1465 deletion. The top figure shows the exons (numbered) of 
the LpH gene, and the alternatively spliced exons 3a and 3b are shown in red and blue, 
respectively. The region of the deletion is marked by a red box. The bottom figure shows the 
domain organisation of the C. elegans LpH protein. The secretion signal (secretion), Lectin 
binding domain (lectin), Hormone binding domain, GPS proteolysis motif and cleavage site, 
transmembrane regions 1-7 (TM1-7), and the 4 cystein motif (4Cys), are indicated, together 
with the putative extracellular, transmembrane and intracellular domains. The deletion is 
marked as a red box, and this position of the antigen used for immunisation by a black box 
(Antigen). 
 
 
 
 
The two strains of C.elegans were sonicated and pelleted as described in 
section 2.2.4.10.2, the purity of the culture was checked by PCR analysis on 
the worms to demonstrate the presence and absence of the respective alleles 
(DRB, unpublished). Figure 3.10 shows that several low molecular weight 
bands are present in both worm samples, and these are therefore non-specific 
binding of the antibody.  However, the latrophilin knockout C.elegans did not 
contain a specific band of ~113 kDa in the 12k pellet, whereas the wild type 
did contain this band, which is the expected size of the LpH protein.  The band 
at 113kDa is smeared, and covers a size range.  This is typical for the 
mammalian LpH proteins, where the smearing is a result of glycosylation of 
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the protein.  This shows that the LpH antiserum was able to specifically detect 
native LpH protein, and suggests that the C. elegans LpH is glycosylated. 
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Figure 3.10. Western blotting of wild type and LpH knockout C.elegans. 
20 µg of each LpH knockout fraction and (12,20, 20,6.5 µg) of wild type C.elegans 
fractions(total pellet, 5k pellet, 12k pellet, and 12K supernatant respectively) were run on a 8% 
SDS-PAGE gel, and then blotted to PVDF membrane as described in the methods.  The 
membrane was incubated with 1:500 antiserums F for 1 hr, and the blot was then developed 
with ECL as described in the methods. A film was exposed for twenty minutes.  The arrow 
shows a protein at ~113 kDa.  
 
 
LpH was found in the cell membrane compartment. In order to liberate this 
protein from the cell membrane into solution, solubilization by detergents was 
performed using Emulgen 913 and 2% Dodecylmaltoside.   
 
3.3.3 Solubilisation of latrophilin (LpH)  
LpH protein was solubilized from the 15k pellet fraction with Emulgen 913 
detergent at 0.6%, 0.8%, or 1% concentrations.  A Western blot of the resulting 
fractions shows that little protein was detected in the resulting solutions.  
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However, an intense immunoreactive band was detected in the pooled, 
detergent-insoluble fractions of the 15k pellet, Figure 3.11.  A strong band of 
113 kDa was seen in the lane containing the pooled detergent insoluble protein, 
Figure 3.11.  Therefore, LpH protein was not solubilized in 0.6%, 0.8% or 1% 
Emulgen 913.   
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Figure 3.11. Solubilization of LpH.   
The 15k pellet (15k) was treated with 0.6, 0.8, or 1% Emulgen 913 to yield soluble fractions, 
and a pooled pellet (pellet); fractions were run on a 10% SDS-PAGE gel, then western blotted 
with antiserum F as described in the methods.  Film was exposed for thirty minutes.  The arrow 
shows a protein at ~113 kDa.  
 
The 15k pellet was also treated with 2% dodecylmaltoside.  In order to 
optimise protein solubility, the sub-cellular fractions were incubated in 2% 
dodecylmaltoside for varying lengths of time as shown in Figures 3.12 and 
3.13.    
A fresh 15k supernatant, treated with 2% dodecylmaltoside detergent, showed  
a strong immunoreactive band at ~113 kDa, Figure 3.12.  However, after 
storage of these samples at  80ºC, an intense band at 66 kDa was detected in 
addition to faint lower molecular bands, Figure 3.13.  
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Figure 3.12. Solubilization of a fresh sub-cellular fraction of C.elegans (15K pellet and 
supernatant) in 2% dodecylmaltoside detergent.  
The fractions were incubated in 2% dodecylmaltoside for different length of time (10, 20, 60 
min).  20 µg of each fraction was run on a 10% SDS-PAGE gel, and blotted to PVDF 
membrane as described in the methods.  The membrane was incubated with 1:500 antiserums F 
for 1 hr, and the blot was then developed with ECL as described in the methods. (P) represents 
the pellet fraction and (S) represents the supernatant fraction.  Film was exposed for thirty 
minutes.  The arrow shows the protein at  ~ 113kDa.  
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Figure 3.13. Solubilization of sub-cellular fractions of C.elegans (pellet and supernatant) 
in 2% dodecylmaltoside detergent.   
The fractions were incubated in 2% dodecylmaltoside and left on a shaker at 4ºC overnight.  20 
µg of each fraction was run on a 10% SDS-PAGE gel, and blotted to PVDF membrane as 
described in the methods.  The membrane was incubated with 1:500 antiserum F for 1 hr, and 
the blot was then developed with ECL as described in the methods.  (T) represents total 
homogenised LpH protein. (P) represents the pellet fraction and (S) represents the supernatant 
fraction. Film was exposed for thirty minutes.  The arrow shows a part of this protein at 66 
kDa. 
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The intense band at ~ 66 kDa may be due to the presence of a G protein 
coupled receptor proteolysis site (GPS) between positions C497 and M536 of 
LpH, which is a characteristic feature in the LpH protein family as shown in 
FiJure 3.14.  After cleavage at the GPS site between L529 and T 530, the 
predicted N-terminal fragment would be a 529 amino acid protein of 58 513 
Da.  
 
497 CVWWNHHELKWKPSGCKLSYHNKTMTSCDCTHL THFAVLM 536 
FiJure 3.14. The amino acid sequence of the G protein coupled receptor site of LpH.  
All amino acids under line are conserved and the cleavage site is between L529 and T530 as 
indicated by the arrow. 
 
 
C.elegans Latrophilin GPS sequence was compared with the rat latrophilin 
GPS (accession No. 2239297) to determine if there was sequence identity.  
This comparison showed an amino acid sequence (Figure 3.14) that is 
conserved (41%) between rat and C.elegans Latrophilin GPS sequence.  The 
conserved residues are also known to be conserved in other GPS proteins 
(Krasnoperov et al, 1997).  The cleavage site of LpH between L529 and T 530 
is present in both rat and C.elegans Latrophilin GPS sequence.  Therefore, the 
GPS domain represents important key for proteolytic process and functionally 
significant of GPS superfamily.    
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Fractionation of antiserum was performed to improve the specificity of 
antiserum for LpH.  Ammonium sulphate precipitation of the antiserum was 
performed using 25% or 50% saturated solutions of ammonium sulphate.  The 
resulting samples were analysed by SDS-PAGE and dot blotting to determine 
how much of the antibody was present in each fraction.  Figure 3.15, compares 
serial dilutions of the serum and fractions from the ammonium sulphate steps 
and shows that most of the antibodies were successfully precipitated in the 
25% and 50% pellet fractions.  Furthermore, no antibodies were seen in the 
50% supernatant (fraction), Figure 3.15, track 4, and the amount of precipitated 
antibodies in both pellet fractions (25% and 50%) was equal.  
Antiserum treated with 50% saturated ammonium sulphate contained low 
amounts of other proteins and hence was selected for sensitivity and selectivity 
testing.  
The coomassie stained gel in Figure 3.16, shows that several bands were 
present in the 25% and 50% pellets.  A strong band of ~ 66 kDa, which is 
probably albumin, was mostly removed from the 25% and 50% pellet fractions. 
Therefore, the data show that albumin concentration was reduced in the 
fraction containing the antibodies.    
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Figure 3.15. Ammonium sulphate precipitation of antibodies. 
Antiserum was treated with several dilutions of saturated ammonium sulphate, yielding 25% 
and 50% pellets, and the 50% soluble fraction.  Fractions were analysed by dot blotting onto a 
nitrocellulose membrane, the membrane was incubated with antirabbit antibody and developed 
with ECL as described in methods. Track (1) represents untreated of the total antiserum of 
rabbit F. Track (2) represents the pellet of the treated antiserum of rabbit F with 25% saturated 
ammonium sulphate. Track (3) represents the pellet of the treated antiserum of rabbit F with 
50% saturated ammonium sulphate. Track (4) represents the supernatant of the treated 
antiserum of rabbit F with 50% saturated ammonium sulphate. Dilutions are indicated the right 
of the FiJure. 
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Figure 3.16. A coomassie stained gel of ammonium sulphate precipitation of antibodies. 
The fractions of solubilized antibodies were loaded and run on a 10% SDS-PAGE gel.  Track 
(1) represents the protein marker (sigma SDS 6H). Track (2) represents the pellet of the treated 
antiserum of rabbit F with 25% saturated ammonium sulphate. Track (3) represents the 
supernatant of the treated antiserum of rabbit F with 50% saturated ammonium sulphate. Track 
(4) represents the pellet of the treated antiserum of rabbit F with 50% saturated ammonium 
sulphate. Track (5) represents untreated of total antiserum of rabbit F. 
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The antibodies were further purified using an affinity column, to which the 
LpH protein was attached.  LpH protein was coupled to agarose (beads), and 
then antibodies binding LpH were purified on the beads.  In order to confirm 
that the prepared column was working properly, LpH protein concentration 
was determined by Bradford assay before and after binding of the antigen to 
the LpH protein.  The concentration of LpH protein before binding was 0.6 
mg/ml, whereas the concentration of the protein after binding was 0.01 mg/ml.  
Therefore, most of the LpH protein binds to the column.  Figure 3.17, 
compares serial dilutions of the purified antibodies from the affinity column.  
The purified antibodies from the column represented > 50% of the original 
antibodies in the antiserum.  The purified antibodies had a lesser sensitivity for 
LpH protein (10 ng), Figure 3.18. 
When the protein extracts from Figure 3.8 were probed with antiserum F, 
several bands appeared.  However, the purified antiserum gave selective 
principal bands at 113 kDa and 66 kDa, Figure 3.19. 
Clarification of antiserum was carried out by 25% and 50% saturated 
ammonium sulphate precipitation.  Pellet (50%) fraction was further purified 
using an affinity column and the antiserum selectivity was improved.  
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FiJure 3.17. Antibodies purified by affinity column. 
Antibodies were purified from antiserum using affinity column containing immobilized LpH 
binding protein.  Fractions were analysed by dot blotting onto a nitrocellulose membrane. The 
membrane was incubated with antirabbit antibody and developed with ECL as described in 
Methods. Track (1) represents the 50% saturated ammonium sulphate antiserum pellet. of 
rabbit F. Tracks (2-10) represent the eluted fractions of purified antibodies. Dilutions are 
indicated to the right of the figure. 
 
 
 
 
          Dilution               Dilution  
    1:100     1:300      1:600     1:1000  
  
46 kDa
  10     1   10   1     10     1    10     1  ng 
 
Figure 3.18.  Sensitivity of purified antisera against LpH.   
1 ng or 10 ng of LpH protein was run as indicated amount on a 12% SDS-PAGE gel, then 
blotted to PVDF membrane as described in the methods.  The membrane was incubated with 
purified antiserum F diluted as shown, and the blot was developed with ECL as described in 
methods.  Film was exposed for thirty minutes. 
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Figure 3.19. Western blot showing sub-cellular fractions of C.elegans, probed with 
purified antiserum F.  
The fractions of C.elegans were run on a 12% SDS-PAGE gel, and then blotted to PVDF 
membrane as described in the methods.  The membrane was incubated with purified antiserum 
F for 1 hr, and the blot was developed with ECL as described in the methods. Film was 
exposed for thirty minutes. Track (1) represents 15K of the total homogenate C.elegans lysate.  
Track (2) represents 15k pellet of the sub-cellular fraction of 15k C.elegans lysate. Track (3) 
represents 15k supernatant of the sub-cellular fraction of 15k C.elegans lysate.    
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3.4 Gene expression studies 
 
3.4.1 Extraction of total mouse RNA 
Total RNA was isolated from mouse brain and liver using the Triazol Method 
(Invitrogen) as described in the Methods, section 2.2.3.9.  The yield of total 
RNA from mouse brain and liver tissues were 1.8 mg/g and 4.3 mg/g 
respectively.  RNA concentration was determined using the RiboGreen 
quantitation kit as described in the Methods, section 2.2.3.15 and the integrity 
of the RNA samples was analysed by agarose gel electrophoresis.  Figure 3.20, 
shows that RNA integrity was maintained as shown by intact 18S and 28S 
ribosomal RNA bands. 
 
 
  1            2            3   M 
 
28 S
18 S
FiJure 3.20. Agarose gel electrophoresis of mouse brain RNA. RNA was extracted using 
TRIAZOL reagent.  
Brain samples were run on a 1% agarose gel (containing 0.2% SDS and 0.2 µg/ml ethidium 
bromide)  at 125 v for 1 hr with 1XTBE. Lanes (1-3) represent 5 µg; 10 µg and 15 µg of RNA 
were loaded respectively. M represents marker 1kb DNA. The gel was photographed under UV 
transillumination. The arrows show the position of intact 28S and 18S rRNA bands. 
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3.4.2 Specificity of m4x1 probes 
Determination of the probe specificity is an essential step prior to using the 
RNase protection assay.  The specificity of the probe was determined by the 
inclusion of two control yeast tRNA samples, positive and negative controls, 
which were hybridised to the probe.  The positive control was carried out by 
hybridisation of the probe with yeast tRNA in the presence of RNase A/T1 
(+ve control). The negative control was carried out by hybridisation of the 
probe with yeast tRNA and no RNase was added (-ve control).  Figure 3.21, 
shows the specificity of the assay. It demonstrates that the probe in the negative 
control was full-length and intact.  In the positive control that included RNase 
A/T1, the probe was degraded and no bands can be seen. 
Therefore, the probe specificity on the control samples confirms that signals 
that were obtained from mouse RNA samples were due to specific protection 
of the probe. 
For optimisation of the riboprobe, several probes were prepared and diluted 4-
fold and 10-fold as shown in Figure 3.21.  Figure 3.21, shows that the intensity 
of these probes decreased according to the dilution range as expected. 10-fold 
dilution probe was subsequently prepared for all samples because intensity was 
sufficient at this dilution and low level of background noise.   
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                                    -ve RNase                   +ve RNase 
 
 
                              
424 b.p 
 
                                           2          0.5       0.2          2       0.5     0.2 µl    probe 
 
              
FiJure 3.21. RNase protection assay specificity and optimisation. 
The specificity of the assay was shown by hybridisation of the riboprobe to yeast tRNA with 
and without RNase A/T1 treatment. To demonstrate probe integrity, control yeast tRNA (20 
µg) samples were hybridised to the probe, with or without RNase A/T1 (+ve or -ve). No 
detectable signal of the riboprobe (+ve control) was observed after yeast tRNA hybridisation 
with the probe and RNase treatment indicating that the radioactivity signal obtained in test 
samples was due to specific hybridisation of probe to RNA. The full-length of the riboprobe is 
424 b.p. Numbers (2, 0.5 and 0.2) represent the volume of probe used.  
 
 
 
3.4.3 PCR amplification of m-4x1 (exon 12) 
The mouse CYP4X1 gene has 12 exons and putatively encodes a protein.  In 
order to prepare a probe for use in RNase protection assay for cyp4X1, PCR 
amplification of m-cyp4x1 (exon 12) fragments was performed. PCR of 
genomic DNA (C57 Bl/6) generated a 330 b.p. product which contained 177 
b.p. of exon and 153 b.p. of intron.  Amplified PCR fragments were then 
subcloned into pGEMT-easy as described in section 2.2.3.12.  Genomic DNA 
from adult (male) C57 Bl/6 mice was obtained as a gift from Dr. D.Bell 
(Biology School, Nottingham University).  Thirty mer primers were designed 
to amplify a region of the m-cyp4X1 gene within the sequence in accession 
number AL731651 of XX-PAC129 on chromosome 4. 
 137
Al-Anizy M                                                                                               Results 
A region (121000-121330 b.p) of exon 12 of the mouse cyp4X1 gene was 
amplified from the genomic DNA.  A PCR fragment (330 b.p) was generated 
from genomic DNA.  Figure 3.22, shows the position of the primers designed 
to amplify mcy4X1-12 genomic DNA. 
The PCR was tested with annealing temperature of 55ºC, 60ºC, 63ºC and also 
with different concentrations of magnesium (1.5mM Mg²+, 2.5mM Mg²+and 
3.5mMg²+).  The negative control of the PCR sample was also carried out at 
the same conditions. 
 
 
CATGGACATAAGTCCTTTTCCCTTCCTCCTGAAAAGAATGTTTCAATCA
GAGGAAACTGCTAAGCAGCTGTGGACTCCAGACTTATTCTAGAAACTTAC
CCCTCTCTCTCCCTTGGTGTCTACAGGAACTGCATCGGGCAGCAGTTTGCC
ATGCTGGAGCTAAAGGTGGCCATTGCCTTGATTCTGCTCCACTTTCAAGTA
GCTCCAGACCTCACCAGGCCTCCTGCCTTCTCCAGCCACACTGTCCTCAGA
CCCAAGCATGGAATCTATTTGCACCTGAAGAAACTCCTTGAGTGTTAGATA
CTAGGAGAAATGGCGAAATTTATGTTT 
 
 
FiJure 3.22. Mouse cyp-4x1 (exon 12) clone for RNase protection assay. 
PCR of genomic DNA (C57BL/6) generated a 330 b.p. fragment. a genomic. Amplified PCR 
fragments were then sub-cloned into pGEMT-easy vector. Bold nucleotides represent the 
forward primer and the reverse primer. The shaded region represents exon fragments (177 
b.p.), whereas the unshaded region represents intron fragments (153 b.p.). 
 
 
 
The PCR amplified a 330 b.p. fragment.  The amplified PCR fragments were 
analyzed on 1% agarose gel electrophoresis as shown in Figure 3.23 and were 
successful at all annealing temperatures and magnesium concentrations, track 
2-5, whereas no band was observed in the negative control, track 1.  The 
optimum amounts of PCR product were obtained at a temperature of 60ºC with 
2.5mM magnesium.  Gel electrophoresis showed that the primers amplified a 
330 b.p product, which is the size expected from the sequence.  The fragment 
was then excised from the gel, purified using the QIAquick gel extraction kit 
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(QIAGEN).  The amplified PCR fragment of cyp4X1 (exon 12) was then sub-
cloned into pGEMT-easy and the gel shows that the plasmid DNA was inserted 
correctly as shown in Figure 3.24.  
 
  
  1  2   3  4  5 M 
 
 
FiJure 3.23.  PCR of cyp4x1 (exon 12) genomic DNA.  
The DNA was amplified using cyp4x1 primers of exon 12 for 35 cycles. The samples (10 µl) 
were run on 1% agarose gel at 125 V for 1 hr. Lane 1 shows the ve control. Lanes (2-4) show 
the PCR products obtained in 2.5mM MgCl and a different annealing temperature (55ºC, 65ºC 
and 60ºC respectively). Lane 5 shows the PCR product obtained in 1.5mM MgCl at 60ºC 
annealing temperature. M shows 1 Kb DNA ladder. The gel was photographed under U.V. 
transillumination.  
 
 
 
    1    2     3          
   
330 b.p. 
330 b.p. 
FiJure 3.24. Restriction digest of cyp4x1 (exon 12) inserted into pGEM-T easy. 
 DNA was restriction digested with EcoRI and run on 1% agarose gel at 120 V for 1 hr. The 
DNA was visualized by Ethidium bromide staining. Lane 1 shows 1 Kb ladder. Lane 2 shows 
uncut plasmid DNA and lane 3 shows digested pGEM-T easy containing inserted 4x1 genes 
(exon 12). 
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Six clones of the transformed pGEM-T easy containing the inserted DNA were 
obtained and analyzed on agarose gel electrophoresis.  One sample was 
purified using Qiagen mini prep column and sent for sequencing.  Figure 3.22, 
shows the sequence result of the PCR m-cyp4x1 fragments. The sequencing 
PCR fragments data shows complete identity when comparing with the 
sequence of exon 12 of mouse genomic DNA (accession number AL731651).   
Therefore, the sequencing confirmed that the plasmid DNA of the mcyp-4x1 
(exon 12) was cloned successfully from the genomic mouse DNA and was in 
the correct antisense orientation necessary for the generation of a riboprobe. 
The exon 12 clone was then used for RNase protection assay. 
 
3.4.4 PCR amplification of the full-length mouse 1st strand cDNA 
Although the genomic sequence of cyp-4X1 is known (AJ297131), the cDNA 
sequence is not known and there are possible ambiguities as to where the 
intron/exon junctions are.  Therefore, cyp4X1 was cloned from mouse brain as 
a full-length open reading frame from the PCR product. While the native 
sequence has putative 5 and 3 untranslated sequences, these were not 
examined in this study. In order to synthesise the full-length mcyp4X1, 1st 
strand cDNA was prepared using ProSTAR UltraHF RT-PCR kit (Stratagene) 
from mouse (S129) brain RNA.  Primers were designed from the beginning 
and end of the known human CYP4X1 cDNA sequence, and from the sequence 
of mouse genomic DNA.  Figure 3.26, shows the amino acid alignment of the 
regions of the mcyp-4X1 used to design the PCR primers.  The sense primer 
(4x1-f-pF) was                                                                    5'-
ATGGAGGCCTCCTGGCTGGAGACTCGTTGG-3' and the antisense primer 
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(4x1-f-pR) was 5'-AAACATAAATTTCGCCATTTCTCCTAGTAT-3'. PCR 
was   carried out as described in section 2.2.3.18.  Figure 3.25, shows a cartoon 
of the strategy used to produce the amplified 1.6 kb mcyp-4X1 cDNA. 
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FiJure 3.25. Cartoon of the full-length mouse cyp4x1 cDNA.  
The mouse cyp4x1 fragment (The solid black line) was obtained by NcoI and SalI and then 
subcloned into plasmid pRSET-a.  
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The resultant PCR fragments were analyzed on a 1% agarose gel as shown in 
lane (S) in Figure 3.27.  The Figure shows that small amounts of a 1620 b.p. 
fragment of the full-length mouse 4x1 were produced and it was of the 
predicted molecular size.  This means that the cDNA was generated 
successfully from the total mouse brain RNA. Because the cDNA was faint, the 
PCR product of lane (S) was reamplified using the same primers and a Reddy 
Mix kit as shown in lanes (1-3) of Figure 3.28. 
The reamplification of the PCR resulted in an increase in the PCR fragments 
intensity when analyzed on 1% agarose gel.  The reamplified PCR product was 
excised and purified as described on section 2.2.3.10. The excised and purified 
cDNA was then sub-cloned into pGEMT-easy cloning vector as described in 
section 2.2.3.12 and designated pGEMT-f-mcyp-4x1.  
 
 
 
 
                                                        A 
      human CYP4X1     (1) MEFSWLETRW 
      mouse Cyp4x1     (1) MEASWLETRW 
  
 
                               B  
      human CYP4X1   (500) YLHLKKLSEC 
      mouse Cyp4x1   (498) YLHLKKLLEC 
        
 
FiJure 3.26. Amino acid alignment for PCR primer design. 
 Primers were designed from the beginning of exon 1 and the ending of exon 12 of human 
CYP4x1 sequence. (A) shows amino acids alignment for region of forward primer. (B) shows 
amino acids alignment for region of reverse primer. 
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1.6 kb 
  S     C    M 
 
FiJure 3.27. PCR amplified fragments of mcyp4x1 cDNA. 
The mcyp4x1 cDNA was generated by reverse transcription of the total RNA brain sample 
using UltraHF RT-PCR kit. The sample was then run on 1% agarose gel at 120v for 1 hour. 
The amplified fragments were visualised under dark reader U.V light. M shows marker (1 kb 
ladder). C shows control sample and S shows mcyp4x1 cDNA amplified sample.      
 
 
 
  1       2       3    C   M 
   
                                        
FiJure 3.28.  Agarose gel showing reamplified PCR of cDNA. 
The mcyp4x1 cDNA fragments were reamplified using full-length mcyp4x1 PCR primers for 
35 cycles with Reddy Mix kit. The mcyp4x1 cDNA was amplified using different 
concentrations of MgCl and run on 1% agarose gel electrophoresis at 90v for 1 hour. M shows 
the marker (1kb ladder). (C) Shows the control sample of amplifying cDNA kit reaction. Lanes 
(1-3) show amplified mcyp4x1 cDNA at several MgCl concentrations (1.5mM, 2.5mM, 
3.5mM MgCl respectively).  
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To confirm the presence of the insert cDNA in the vector, several colonies 
were obtained and double restriction digests were carried out with NcoI and 
SalI and then analyzed on a 1% agarose gel.  The cloned cDNA was then 
purified by Qiagen mini prep and two samples were sent for double stranded 
sequencing and both clones had an identical sequence as shown in Figure 3.29.  
The deduced mouse cyp4x1 cDNA was submitted to Genbank under accession 
number AJ786769.  The DNA sequence and deduced amino acid sequence of 
the cDNA are shown in Figure 3.29 and Figure 3.30 respectively.  Translation 
of the full-length mouse cyp4x1 1524 b.p. gives an open reading frame of 507 
amino acids.  
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1 ATGGAGGCCT CCTGGCTGGA GACTCGTTGG GCGCGGCCCT TGCACCTGGC 
TTTGGTGTTC TGCCTGGCGC TGGTGCTGAT GCAGGCCATG  AAGCTCTACC 
 
101 TGCGGAGACA GCGACTGCTG CGCGACCTGA GCCCCTTCCC GGGGCCTCCC 
GCCCACTGGC TCCTGGGACA CCAGAAGTTT CTTCAGGAGG  ATAATATGGA 
 
201 GACGCTTGAT GAGATTGTCA AAAAGCACCC TTGTGCCTTC CCCTGCTGGG 
TAGGGCCCTT CCAGGCATTT TTCTACATCT ATGACCCAGA  CTATGCGAAG 
 
301 ATATTTCTGA GCAGAACAGA CCCAAAGATG CAGTATCTGC ACCAGCTCCT 
GACTCCATGC ATTGGACGAG GACTCCTGAA TTTAGATGGG  CCCAGGTGGT 
 
401 TCCAACACCG CTGCCTCCTA ACTCCTGCAT TCCATCAGGA CATCCTAAAA 
CCATGTGTGG ACACGATGGC CCACTCTGTG AAAGTGATGC  TGGATAAATG 
 
501 GGAGAAGATG TGGACCACTC AGGAAACAAC CATCGAGGTT TTTGAACACA 
TCAACTTGAT GACCCTGGAC ATAATAATGA AATGTGCTTT  TGGCCAGGAG 
 
601 ACCAACTGCC AGATAAACGG CACCTATGAG TCTTACGTGA AGGCAACATT 
TGAACTTGGT GAAATCATAT CTTCTCGCTT GTACAATTTC  TGGCATCATC 
 
701 ATGACATAAT TTTCAAACTC AGTCCTAAGG GCCACTGCTT CCAGGAGTTA 
GGCAAAGTGA TACATCAATA CACAGAAAAG ATAATCCAGG  ACAGAAAGAA 
 
801 AATCCTCAAG AATCAAGTAA AGCAGGATGA CACTCAGACG TCTCAAATTT 
TTCTGGATAT TGTTCTTTCT GCACAGGCTG AAGATGAACG  AGCCTTCTCA 
 
901 GATGCTGACC TTCGGGCTGA GGTGAACACC TTCATGTGGG CAGGACATGA 
TGCCTCTGCA GCTAGCATCT CCTGGCTCCT TTACTGCCTG  GCTCTAAATC 
 
1001 CCGAGCATCA GGACAGATGC CGGACAGAGA TCAGGAGCAT CCTGGGAGAT 
GGGTCTTCCA TCACCTGGGA ACAGCTGGAT GAGATGTCAT  ACACCACAAT 
 
1101 GTGCATCAAG GAGACACTCC GCTTGATTCC TCCTGTCCCA TCCATCTCCA 
GGGAGCTCAG CAAACCCCTT ACCCTCCCAG ATGGACACTC  ACTGCCTGCA 
 
1201 GGTATGACTG TGGTTCTTAG TATTTGGGGT CTCCACCACA ACCCTGCTGT 
CTGGAACGAC CCAAAGGTCT TTGACCCCTT GAGATTCACT  AAGGAGAATT 
 
1301 CTGATCAGAG ACACCCCTGT GCCTTCCTAC CATTCTCCAG TGGTCCAAGG 
AACTGCATCG GGCAGCAGTT TGCCATGCTG GAGCTAAAGG  TGGCCATTGC 
 
1401 CTTGATTCTG CTCCACTTTC AAGTAGCTCC AGACCTCACC AGGCCTCCTG 
CCTTCTCCAG CCACACTGTC CTCAGACCCA AGCATGGAAT  CTATTTGCAC 
 
1501   CTGAAGAAAC TCCTTGAGTG TTAG 
 
FiJure 3.29.  Nucleotide sequence of the mcyp-4x1 cDNA. 
The deduced mcyp-4x1 cDNA shows that the full-length of the cyp4X1 open reading frame 
(1524 b.p. long). Sequence analysis was carried out by J. Keyte, Biochemistry Dept., 
Nottingham University (Acc. No. AJ786769). 
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    1 MEASWLETRW ARPLHLALVF CLALVLMQAM KLYLRRQRLL RDLSPFPGPP 
   51 AHWLLGHQKF LQEDNMETLD EIVKKHPCAF PCWVGPFQAF FYIYDPDYAK 
  101 IFLSRTDPKM QYLHQLLTPC IGRGLLNLDG PRWFQHRCLL TPAFHQDILK 
  151 PCVDTMAHSV KVMLDKWEKM WTTQETTIEV FEHINLMTLD IIMKCAFGQE 
  201 TNCQINGTYE SYVKATFELG EIISSRLYNF WHHHDIIFKL SPKGHCFQEL 
  251 GKVIHQYTEK IIQDRKKILK NQVKQDDTQT SQIFLDIVLS AQAEDERAFS 
  301 DADLRAEVNT FMWAGHDASA ASISWLLYCL ALNPEHQDRC RTEIRSILGD 
  351 GSSITWEQLD EMSYTTMCIK ETLRLIPPVP SISRELSKPL TLPDGHSLPA 
  401 GMTVVLSIWG LHHNPAVWND PKVFDPLRFT KENSDQRHPC AFLPFSSGPR 
  451 NCIGQQFAML ELKVAIALIL LHFQVAPDLT RPPAFSSHTV LRPKHGIYLH 
  501 LKKLLEC 
 
FiJure 3.30. The amino acid sequence of mcyp4x1 cDNA. 
The deduced amino acid sequence shows that the cDNA encodes a protein of 507 amino acids.  
 
 
After this sequence was deposited in Genbank, two other mouse sequences of 
4x1 were found. NM_001003947 is identical, and is a cDNA prediction based 
on genomic sequence, and my sequence, AJ786769.  It was also found that this 
sequence has high identity (94%) with the published rat CYP4x1 (AF439343) 
cDNA sequence. 
The deduced mcyp4x1 protein sequence shows a high level of similarity but 
not complete identity when compared with rat and human sequences as shown 
in Figure 3.31.  This Figure shows that identity is 94 % and 79.2 % between 
the full-length mouse 4x1 sequence and rat (AF439343), and human (Q8N118) 
respectively.  Therefore, the alignments of the mouse CYP4X1 amino acid 
sequence with the rat and human CYP4X1, showed a high level of homology 
between them. 
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                          1                                               50 
      mouse Cyp4x1    (1) MEASWLETRWARPLHLALVFCLALVLMQAMKLYLRRQRLLRDLSPFPGPP 
      human CYP4X1    (1) MEFSWLETRWARPFYLAFVFCLALGLLQAIKLYLRRQRLLRDLRPFPAPP 
      RatCYP4x1       (1) MEASWLENRWARPLHLALVFCLALVLMQAVKLYLRRQRLLRDLRPFPGPT 
 
                          51                                             100 
      mouse Cyp4x1   (51) AHWLLGHQKFLQEDNMETLDEIVKKHPCAFPCWVGPFQAFFYIYDPDYAK 
      human CYP4X1   (51) THWFLGHQKFIQDDNMEKLEEIIEKYPRAFPFWIGPFQAFFCIYDPDYAK 
      RatCYP4x1      (51) AHWLLGHQKFLQEDNMEKLDEIVKEYPCAFPCWVGPFQAFFYIYDPDYAK 
 
                          101                                            150 
      mouse Cyp4x1  (101) IFLSRTDPKMQYLHQLLTPCIGRGLLNLDGPRWFQHRCLLTPAFHQDILK 
      human CYP4X1  (101) TLLSRTDPKSQYLQKFSPPLLGKGLAALDGPKWFQHRRLLTPGFHFNILK 
      RatCYP4x1     (101) IFLSRTDPKTQYLHQLMTPFLGRGLLNLDGPRWFQHRCLLTPAFHQDILK 
 
   151                                            200  
      mouse Cyp4x1  (151) PCVDTMAHSVKVMLDKWEKMWTTQETTIEVFEHINLMTLDIIMKCAFGQE 
      human CYP4X1  (151) AYIEVMAHSVKMMLDKWEKICSTQDTSVEVYEHINSMSLDIIMKCAFSKE 
      RatCYP4x1     (151) PCVDMMAHSVNMMLDKWEKTWTTQETTIEVFEHINLMTLDIIMKCAFGQE 
     
                          201                                            250 
      mouse Cyp4x1  (201) TNCQINGTYESYVKATFELGEIISSRLYNFWHHHDIIFKLSPKGHCFQEL 
      human CYP4X1  (201) TNCQTNSTHDPYAKAIFELSKIIFHRLYSLLYHSDIIFKLSPQGYRFQKL 
      RatCYP4x1     (201) TNCQINGTYESYVKATFELGEIISSRLYNFWHHHDIIFKLSPKGHCFQEL 
 
 251                                            300   
      mouse Cyp4x1  (251) GKVIHQYTEKIIQDRKKILKNQVKQDDTQTSQIFLDIVLSAQAEDERA 
      human CYP4X1  (251) SRVLNQYTDTIIQERKKSLQAGVKQDNTPKRKYQDFLDIVLSAKDESGSS 
      RatCYP4x1     (251) GKVIHQCTEKIIQDRKKTLKDQVNQDDTQTS--QNFLDIVLSAQAGDEKA 
 
         301                                            350 
      mouse Cyp4x1  (299) FSDADLRAEVNTFMWAGHDASAASISWLLYCLALNPEHQDRCRTEIRSIL 
      human CYP4X1  (301) FSDIDVHSEVSTFLLAGHDTLAASISWILYCLALNPEHQERCREEVRGIL 
      RatCYP4x1     (299) FSDADLRSEVNTFMWAGHDASAASISWLLYCLALNPEHQDRCRTEIRSIL 
 
         351                                            400  
      mouse Cyp4x1  (349) GDGSSITWEQLDEMSYTTMCIKETLRLIPPVPSISRELSKPLTLPDGHSL 
      human CYP4X1  (351) GDGSSITWDQLGEMSYTTMCIKETCRLIPAVPSISRDLSKPLTFPDGCTL 
      RatCYP4x1     (349) GDGSSITWEQLDEIPYTTMCIKETLRLIPPIPSISRELSKPLTLPDGHSL 
 
         401                                            450  
      mouse Cyp4x1  (399) PAGMTVVLSIWGLHHNPAVWNDPKVFDPLRFTKENSDQRHPCAFLPFSSG 
      human CYP4X1  (401) PAGITVVLSIWGLHHNPAVWKNPKVFDPLRFSQENSDQRHPYAYLPFSAG 
      RatCYP4x1     (399) PAGMTVVLSIWGLHHNPAVWKDPKVFDPLRFTKENSEQRHPCAFLPFSSG 
      
          451                                            500  
      mouse Cyp4x1  (449) PRNCIGQQFAMLELKVAIALILLHFQVAPDLTRPPAFSSHTVLRPKHGIY 
      human CYP4X1  (451) SRNCIGQEFAMIELKVTIALILLHFRVTPDPTRPLTFPNHFILKPKNGMY 
      RatCYP4x1     (449) PRNCIGQQFAMLELKVAIALTLLRFRVAADLTRPPAFSSHTVLRPKHGIY 
 
                          501 
      mouse Cyp4x1  (499) LHLKKLLEC 
      human CYP4X1  (501) LHLKKLSEC 
      RatCYP4x1     (499) LHLKKLPEC 
 
 
FiJure 3.31. Alignment of the deduced amino acid sequence of mcyp-4x1 cDNA with that 
of rat and human 4x1 sequences. 
The alignment shows high similarity of 94% and 79.2% between mouse cyp-4x1 (AJ786769) 
and rat (AF439343), human 4x1 (Q8N118) respectively.  
 148
Al-Anizy M                                                                                               Results 
Alignment of the deduced amino acid sequence of the mouse cyp4x1 cDNA 
with that of rat (AF439343) and human (Q8N118) CYP4x1, show high 
similarity of 94% and 79% respectively.  The length of the primary sequence of 
mouse cyp4x1 cDNA was equal to that of rat and human CYP4x1 respectively.  
Furthermore, Exon 11 and exon 12 were found to code a highly conserved 
amino acid, PFSGG(A/S)RNCIG, which comprises the haem-binding domain 
which is essential for all cytochrome P450 proteins (Gonzalez, 1989).  
Therefore, comparison of the deduced amino acid sequences of the cloned 
mouse cDNA with known 4x1(rat and human) demonstrate that the cDNA 
encodes a 4x1 protein. 
 
3.4.5 Comparison of the mouse cDNA with genomic DNA and intron/exon 
boundaries 
 
The intron and exon junction site was determined by direct comparison of the 
4X1 cDNA against the genomic sequence of XX-Pac129 on chromosome 4 
(see Figure 3.32).  The intron and exon junction of exon 1 to 12 of the genomic 
mouse cyp4x1 cDNA are summarised in Table 4. 
 
 Exon-
Intron No. 
Intron Exon Exon 
 
Intron 
1   AAG GTA 
2 TAG TTT CAG GTA 
3 CAG ACC TTG GTA 
4 AAG GAC CTG GTA 
5 CAG GAT CGG GTC 
6 CAG CAC CAG GTA 
7 CAG AAA CAG GTA 
8 TAG GCT CTG GTA 
9 CAG GGA CAG GTC 
10 CAG GTA AAG GTA 
11 CAG GTC AAG GTG 
12 CAG GAA   
 
Table 3.1. The intron-exon junction’s boundaries of exon 1 to exon 12 of mouse cyp4x1.  
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Determination of the intron/exon junctions is listed in Table 5, a comparison of 
the consensus sequence of intron/ exon junctions in mouse cyp4x1 gene with 
the published intron/exon consensus (Introduction to Genetic Analysis, Ed. 
Griffiths et al). The data in Table 5, demonstrate that the intron/exon junction 
is CAG/GNN, whereas in the published is CAG/GN and the exon/intron 
junction is CAG/GTA, whereas in the published is (A/C)AG/GT(A/G).  
 
Nucleotide Intron    % Exon   % Exon   % Intron   % 
A 9  100 0 18 45 36 27 64  0 0   0 73 
C 73  0  0  9 18 36 64  0  0 0   0 18 
G 0  0 100 64  9  0  0  9 100 100 0  9 
T 18  0  0 9  27 27 9  27  0 0  100  0 
  C  A  G G   N   N  C  A   G G   T   A 
 
Table 3.2. Consensus sequence of intron/ exon junctions in mouse cyp4x1 gene. 
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96129 
GCTCAGAGTGATGGAGGCCTCCTGGCTGGAGACTCGTTGGGCGCGGCCCTTGCACCTGGCTTT
GGTGTTCTGCCTGGCGCTGGTGCTGATGCAGGCCATGAAGCTCTACCTGCGGAGACAGCGACT
GCTGCGCGACCTGAGCCCCTTCCCGGGGCCTCCCGCCCACTGGCTCCTGGGACACCAGAAGGT
AGATGGAG  96305 
 
102524 
TTTACTATAGTTTCTTCAGGAGGATAATATGGAGACGCTTGATGAGATTGTCAAAAAGCACCC
TTGTGCCTTCCCCTGCTGGGTAGGGCCCTTCCAGGCATTTTTCTACATCTATGACCCAGACTA
TGCGAAGATATTTCTGAGCAGAACAGGTAAGGAATG 105764  
 
103501 
GGTTCTGCAGACCCAAAGATGCAGTATCTGCACCAGCTCCTGACTCCATGCATTGGTATGTAT
GTG 103546 
 
105637 
TTCCTCAAGGACGAGGACTCCTGAATTTAGATGGGCCCAGGTGGTTCCAACACCGCTGCCTCC
TAACTCCTGCATTCCATCAGGACATCCTAAAACCATGTGTGGACACGATGGCCCACTCTGTGA
AAGTGATGCTGGTAAGTGAAAC  105764 
 
108127 
CTCTGGCAGGATAAATGGGAGAAGATGTGGACCACTCAGGAAACAACCATCGAGGTTTTTGAA
CACATCAACTTGATGACCCTGGACATAATAATGAAATGTGCTTTTGGCCAGGAGACCAACTGC
CAGATAAACGGGTCAGTGATG  108253 
 
108331 
CTTCTTGCAGCACCTATGAGTCTTACGTGAAGGCAACATTTGAACTTGGTGAAATCATATCTT
CTCGCTTGTACAATTTCTGGCATCATCATGACATAATTTTCAAACTCAGTCCTAAGGGCCACT
GCTTCCAGGAGTTAGGCAAAGTGATACATCAATACACAGGTAAAAACAC 108485 
 
109854 
TTCTGTGCAGAAAAGATAATCCAGGACAGAAAGAAAATCCTCAAGAATCAAGTAAAGCAGGAT
GACACTCAGACGTCTCAAATTTTTCTGGATATTGTTCTTTCTGCACAGGTAAGTGCACC 
109955 
 
110485 
GTGTTGTAGGCTGAAGATGAACGAGCCTTCTCAGATGCTGACCTTCGGGCTGAGGTGAACACC
TTCATGTGGGCAGGACATGATGCCTCTGCAGCTAGCATCTCCTGGCTCCTTTACTGCCTGGCT
CTAAATCCCGAGCATCAGGACAGATGCCGGACAGAGATCAGGAGCATCCTGGGAGATGGGTCT
TCCATCACCTGGTAAGATCCAC 110675  
 
117040 
TCCTTACAGGGAACAGCTGGATGAGATGTCATACACCACAATGTGCATCAAGGAGACACTCCG
CTTGATTCCTCCTGTCCCATCCATCTCCAGGGAGCTCAGCAAACCCCTTACCCTCCCAGATGG
ACACTCACTGCCTGCAGGTCTTCACATTC 117174  
 
118298 
TGTCTCAGGTATGACTGTGGTTCTTAGTATTTGGGGTCTCCACCACAACCCTGCTGTCTGGAA
CGACCCAAAGGTAAGATTGTCT 118362 
 
119869 
CGTTTCAGGTCTTTGACCCCTTGAGATTCACTAAGGAGAATTCTGATCAGAGACACCCCTGTG
CCTTCCTACCATTCTCCAGTGGTCCAAGGTGAGATGAAC 119950  
 
121127 
TGTCTACAGGAACTGCATCGGGCAGCAGTTTGCCATGCTGGAGCTAAAGGTGGCCATTGCCTT
GATTCTGCTCCACTTTCAAGTAGCTCCAGACCTCACCAGGCCTCCTGCCTTCTCCAGCCACAC
TGTCCTCAGACCCAAGCATGGAATCTATTTGCACCTGAAGAAACTCCTTGAGTGTTAGATACT
AGGAG 121300 
 
FiJure 3.32. Intron/exon junctions of the mouse cyp4x1 gene.  
Bold nucleotides represent exons, whereas faint nucleotides represent introns. 
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3.4.6 Analysis of amino acid sequence of mouse cyp4X1 
The sequence of exon 1 contains an ATG codon which is the translation start 
codon.  The translation stop codon is at the end of exon 12.  The presence of 
the stop codon at the end of exon 12 suggests that exon 12 is the final exon of 
the mcyp4X1.  The open reading frame of mcyp4X1 codes a protein of 507 
amino acids.  
The deduced amino acids sequences encoded by each exon were compared 
with the corresponding published amino acid sequences of the rat (AF439343) 
and human (Q8N118) as shown in table 6.  By comparing amino acid sequence 
of mouse cyp4x1 with other rat and human CYP4X1 genes, it showed that 
mouse cyp4X1 is highly similar to rat (94%) and human (71%) CYP4X1.  
From the comparison, it was found that amino acid sequences corresponding to 
exon 2, 5, 8 and 11 are highly similar between mouse cyp4X1 and rat and 
human CYP4x1 genes among other exons.  Furthermore, exon 1 and exon 3 are 
highly similar between mouse cyp4X1 and human CYP4X1, whereas exons 3, 
6 and 7 of the human amino acid sequences are very dissimilar.    
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Exon No. Rat (% identity) Human (% identity) 
1 (1-58) 96.4 84.2 
2 (59-106) 97.9 73.4 
3 (107-121) 80 46.6 
4 (122-164) 93 67.4 
5 (165-207) 97.6 72 
6 (208-258) 98 56.8 
7 (259-292) 91.6 58.3 
8 (293-356) 96.8 70.3 
9 (357-401) 93.3 82.2 
10 (402-423) 95.4 90.9 
11 (424-449) 96.1 76.9 
12 (450-507) 91.3 72.4 
 
Table 3.3. Percent identity of amino acid sequences by exons between mouse cyp4x1 and 
that of rat and human CYP4x1.  
Exons were deduced from mouse cyp4x1 cDNA amino acid sequences and compared with the 
corresponding published amino acid sequences of the rat and human CYP4x1.  
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Alignment of intron/exon junction sites between mouse cyp4x1 cDNA 
(Acc.No AJ786769) and published mouse cyp4b1 (Acc.No. BC008996) and rat 
CYP4a1 (Acc. No. M57718M33937) was determined (see Figure 3.33).  The 
comparison show that very close intron/exon junction site between mouse 
cyp4X1 and mouse cyp4b1, whereas, more diversion between mouse cyp4X1 
and rat CYP4a1.    
 
Mouse cyp4x1   MEASWLET-----RWARPLHLALVFCLALVLMQAMKLYLRRQRLLRDLSPFPGPPAHWLL 55 
Mouse cyp4b1   MALSFLSP-----SLSRLGLWASVVILMVTVLKLLSLLFRRQKLARALDSFPGPPKHWLF 55 
Rat   CYP4a1   MSVSALSSTRFTGSISGFLQVASVLGLLLLLVKAVQFYLQRQWLLKAFQQFPSPPFHWFF 60 
      
 
Mouse cyp4x1   GHQKFLQEDN-METLDEIVKKHPCAFPCWVGPFQAFFYIYDPDYAKIFLSRTDPKMQYLH 114 
Mouse cyp4b1   GHALEIQKTGGLDKVVTWTEQFPYAHPLWLGQFIVFLNIYEPDYAKAVYSRGDPKAAYVY 115 
Rat   CYP4a1   GHK-QFQGDKELQQIMTCVENFPSAFPRWFWGSKAYLIVYDPDYMKVILGRSDPKANGVY 119 
                  
 
Mouse cyp4x1   QLLTPCIGRGLLNLDGPRWFQHRCLLTPAFHQDILKPCVDTMAHSVKVMLDKWEKMWTTQ 174 
Mouse cyp4b1   DFFLQWIGKGLLVLEGPKWFQHRKLLTPGFHYDVLKPYVAIFAESTRVMLDKWEKKAS-E 174 
Rat   CYP4a1   RLLAPWIGYGLLLLNGQPWFQHRRMLTPAFHYDILKPYVKNMADSIRLMLDKWEQLAG-Q 178 
                   
 
Mouse cyp4x1   ETTIEVFEHINLMTLDIIMKCAFGQETNCQINGTYESYVKATFELGEIISSRLYNFWHHH 234 
Mouse cyp4b1   NKSFDIFCDVGHMALDTLMKCTFGK-GDSGLSHSDNSYYLAVSDLTLLMQQRIDSFQYHN 233 
Rat   CYP4a1   DSSIEIFQHISLMTLDTVMKCAFSHNGSVQVDGNYKSYIQAIGNLNDLFHSRVRNIFHQN 238 
                  
 
Mouse cyp4x1   DIIFKLSPKGHCFQELGKVIHQYTEKIIQDRKKILKNQVKQDDTQTS--QIFLDIVLSAQ 292 
Mouse cyp4b1   DFIYWLTPHGRRFLRACQIAHDHTDHVIRQRKAALQDEKEQKKLQERRHLDFLDILLGAR 293 
Rat   CYP4a1   DTIYNFSSNGHLFNRACQLAHDHTDGVIKLRKDQLQNAGELEKVKKKRRLDFLDILLLAR 298 
                  
 
Mouse cyp4x1   AEDERAFSDADLRAEVNTFMWAGHDASAASISWLLYCLALNPEHQDRCRTEIRSILGDGS 352 
Mouse cyp4b1   DESGIKLSDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPMHQQRCREEVREILGDRD 353 
Rat   CYP4a1   MENGDSLSDKDLRAEVDTFMFEGHDTTASGVSWIFYALATHPEHQQRCREEVQSVLGDGS 358 
                   
 
Mouse cyp4x1   SITWEQLDEMSYTTMCIKETLRLIPPVPSISRELSKPLTLPDGHSLPAGMTVVLSIWGLH 412 
Mouse cyp4b1   SFQWDDLAQMTYLTMCMKECFRLYPPVPQVYRQLSKPVTFVDGRSLPAGSLISLHIYALH 413 
Rat   CYP4a1   SITWDHLDQIPYTTMCIKEALRLYPPVPGIVRELSTSVTFPDGRSLPKGIQVTLSIYGLH 418 
                  
 
Mouse cyp4x1   HNPAVWNDPKVFDPLRFTKENSDQRHPCAFLPFSSGPRNCIGQQFAMLELKVAIALILLH 472 
Mouse cyp4b1   RNSAVWPDPEVFDPLRFSPENMTGRHPFAFMPFSAGPRNCIGQQFAMNEMKVVTALCLLR 473 
Rat CYP4a1     HNPKVWPNPEVFDPSRFAPD--SPRHSHSFLPFSGGARNCIGKQFAMSEMKVIVALTLLR 476 
                  
 
Mouse cyp4x1   FQVAPDLTRPPAFSSHTVLRPKHGIYLHLKKLLEC--- 507 
Mouse cyp4b1   FEFSPDPSKIPIKVPQLILRSKNGIHLYLKPLGPGSGK 511 
Rat   CYP4a1   FELLPDPTKVPIPLPRLVLKSKNGIYLYLKKLH----- 509 
 
FiJure 3.33. Alignment of mouse cyp4X1 protein with mouse cyp4b1 and rat CYP4a1. 
Colors represent each exon in legend.  
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In order to study protein expression, a sub-cloning strategy for putting the 
mcyp-4X1cDNA into an expression vector was formulated as shown in FiJure 
3.25.  The first step was excision of the inserted mcyp-4X1cDNA with NcoI 
and SalI restriction enzymes (1620.bp.) and then sub-cloned into pRSET-a cut 
by NcoI and XhoI restriction enzymes, an expression vector for bacterial 
expression, as described in section 2.2.3.11. 
Several clones were isolated and the positive clones were identified by double 
digestion with NcoI and NdeI (Data not shown).  The insertion of 
mcyp4X1cDNA into pRSET-a was confirmed by DNA sequencing using 
forward primer (4X1-f-pF) 
5`ATGGAGGCCTCCTGGCTGGAGACTCGTTGG 3` and reverse primer  
(4X1-f-pR) 3` TATGATCCTCTTTACCGCTTTAAATACAAA 5 `as shown 
in FiJure 3.29.  The sequencing data confirmed that the full-length m4X1 
cDNA had been produced successfully and cloned correctly.  
 
 
3.4.7 Expression and localisation of mcyp-4X1 mRNA   
It has been shown in this lab that human 4x1 is expressed in aorta (Bell D.R, et 
al 2005), and that the cyp4X1 gene is expressed in rat brain (Bylund et al, 
2001), but nothing is known about its expression in mouse.  Hence, mouse 
tissues were investigated. 
In order to analyse the expression of this gene, RNase protection assays were 
performed on total RNA (30µg) from mouse brain using a riboprobe for 
mcyp4X1, Figure 3.34, and total RNA from liver was used as a control.  The 
probe was synthesised as described in section section 3.5.3.  The probe was 
generated from the Sp6 promoter of Nco1 digested template and a full-length 
mcyp4X-12 probe of 424 b.p was produced.  
The integrity of the isolated RNA was analysed by 1% agarose gel 
electrophoresis.  The protected RNA fragments were run on 6% poly 
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acrylamide gels and then film exposed overnight.  The principle of this 
experiment is that the hybridisation of riboprobe to the m4X1 mRNA forms a 
double-stranded RNA structure, which is resistant to degradation by RNase.  In 
Figure 3.34, the specificity of the probe was determined by the inclusion of two 
control yeast tRNA samples, positive and negative control, hybridised to the 
probe (see lane 1 and 5 of Figure 3.34).  This is an essential step to confirm 
that the probe is selective and works properly.  The CYP4X1 (exon 12) probe 
was shown the   full-length (RNase ve track) and gave 424 b.p. as shown in 
lane 5 of Figure 3.34.  The RNase positive track shows an absence of signal 
when hybridised to yeast tRNA, which shows that, in the absence of 
complementary RNA, the probe RNA is fully degraded.  Therefore, the 
protected fragments in the samples must be due to protection of the probe by 
complimentary RNA sequences. 
In this study expression of cyp4X1 was investigated in the brain and liver of 
mice. RNase protection assay was carried out on total RNA using a riboprobe 
for cyp4X1 (Figure 3.34).  The riboprobe generated is 330 b.p. long as 
described in section 3.5.3.  The probe will give a 177 b.p. fragment for RNA, 
but a much longer fragment (327 b.p.) for genomic DNA. 
The protection assay in Figure 3.34, lane 3, shows that a strong signal was 
produced at 177 b.p.  Furthermore, two high molecular weight bands were also 
produced.  However, since these are the same length as the full length probe, 
they do not correspond to the fragment size of protected RNA, and were not 
considered to reflect specific protection of the probe.  The size of the protected 
fragment in mouse brain sample was shorter than the full-length probe, which 
shows that RNase treatment has removed 247 b.p. of unprotected probe.  
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Figure 3.34, shows that the brain samples have a specific protected fragment of 
177 b.p, which corresponds to the expected size of the cyp4X1-12 RNA, 
whereas no signal was produced in the liver RNA sampleas shown in Figure 
3.34, lane 4.  Therefore, the murine CYP4X1 is not expressed in control liver, 
but is expressed in the brain (Figure 3.34) and the signal was protected due to 
hybridization of the mcyp4X1 probe to endogenous 4X1 transcripts in brain.  
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  1    2       3   4        5 
  
424 b.p. 
124 b.p. 
177 b.p 
       
FiJure 3.34. RNase protection assay of CYP4X1.  
The protection assay was performed against 30 µg of total RNA extracted from mouse brain 
and liver tissues. The full-length probe (b.p.) was generated by in vitro transcription of NcoI 
cut mcyp4x1-12 plasmid with Sp6 RNA polymerase and then hybridised to the samples. Lane 
1 shows a +ve control, lane 2 shows a marker probe (124 b.p). Lane 3 and 4 show a protection 
assay on brain and liver RNA samples respectively.  The arrows indicate a protected fragment 
(177 b.p.) of CYP4X1 (exon 12) and the marker size (124 b.p.).    
 
 
 
3.4.8 mcyp4X1 RNA expression in wild type (+/+), knock-out (-/-) and 
control  
It is known that cyp4a genes are regulated by PPARĮ (Bell et al, 1993) and the 
availability of PPARĮ knock-out mice which do not contain a functional 
PPARĮ gene offers an ideal system to study any role of PPARĮ in the 
expression of mcyp4X1.  Hence, the expression of cyp4X1 expression in wild 
type and knock-out mice was investigated.  Figure 3.35, shows expression of 
mcyp4X1 in total brain RNA extracted from wild type and knock-out mice. 
The wild type mice and the knock-out mice all showed strong mcyp4X1 gene 
signals as shown in Figure 3.35.  The signals produced by wild type and knock-
out mice show no intensity differences between them as shown in Figure 3.35.  
Therefore, brain cyp4X1 expression was similar in both wild type and knock-
out and PPARĮ has no effect on expression of this gene in brain. 
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-ve  +ve  1  2  3   1  2  3 
                   +/+      -/- 
 
FiJure 3.35. Expression of cyp4x1 in wild-type and knock-out mice brain tissues.  
RNase protection assays were performed on mouse total RNA samples using [Į-³²P] labelled 
antisense riboprobe to mcyp4x1. The control mice were dosed using corn oil (vehicle) as 
described in section 2.2.1.1.  The wild type (+/+) and knock-out (-/-) mice were given a normal 
diet (untreated mice). Antisense riboprobe was generated by transcribing NcoI cut mcyp4x1-12 
plasmid with Sp6 RNA polymerase. Full-length probe was 424 b.p and the protected fragment 
of the samples was 177 b.p long. Total RNA was isolated as described in section 2.2.3.9 and 30 
µg of each RNA sample was hybridized with [Į-³²P] CTP labelled probe. Two yeast tRNA 
control samples were hybridized to the probe, one sample treated with the RNase A/T1 (+ve 
control) and the other sample without RNase A/T1 (-ve control) (10 µg/ml). The numbers (1, 2, 
and 3) indicate the number of each mouse.  M shows the marker (124 b.p).  RNase protection 
assay was run on 6% denaturing poly acrylamide gel in 1xTBE at 120v for 1hour. Gels were 
then fixed, dried and exposed to Hyperfilm at -80ºC overnight.  
 
 
 
 
RNA expression in other mice tissues (lung, heart, and kidney) was also 
investigated as shown in FiJure 3.36. FiJure 3.36, shows that protected bands 
was produced after probe hybridisation for these tissues.  The protected signals 
were detected only after prolonged exposure of autoradiography (four days).  
Therefore, cyp-4X1 gene is expressed in these tissues but at very low levels.  
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124 b.p. 
177 b.p. 
424 b.p. 
 -ve       +ve     Lu    H      K        M 
 
 
 
FiJure 3.36.  .Expression and induction of cyp4x1 in mouse lung, heart, and kidney 
tissues. RNase protection assays were performed on mouse total RNA samples using [Į-³²P] 
labelled antisense riboprobe to mcyp4x1. Antisense riboprobe was generated by transcribing 
NcoI cut mcyp4x1-12 plasmid with Sp6 RNA polymerase. Full-length probe generated was 
424 b.p long. Total RNA was isolated as described in section 2.2.3.9 and 30 µg of each RNA 
sample was hybridized with [Į-³²P] CTP labelled probe. Two yeast tRNA control samples were 
hybridized to the probe, one sample treated with the RNase A/T1 (+ve control) (10 µg/ml) and 
the other sample without RNase A/T1 (-ve control).  Lu shows lung, H shows heart, K shows 
kidney. M shows the marker (124 b.p).  RNase protection assay was run on 6% denaturing poly 
acrylamide gel in 1xTBE at 120v for 1 hour. Gels were then fixed, dried and exposed to 
Hyperfilm at -80ºC for four days.  
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3.4.9 Expression of mcyp4X1 in Aorta tissues 
It is known that CYP4X1 is predominantly expressed in human aorta and 
induced by the PPARĮ agonist Wy14643 in HepG2 cells (Savas U et al, 2005).  
However, nothing is known in mouse aorta.  In order to address this issue, 
aorta tissues were pooled from 13 mice and aorta RNA was extracted as 
described in section 2.2.3.9.   RNase protection assay was performed as 
described in section 2.2.5.2. 
Ciprofibrate was used to induce cyp4X1 gene.  FiJure 3.37 shows expression 
and induction of this gene in both treated and untreated mice.  The RNase 
protection assay shows that a specific protected band was produced in the total 
aorta tissue and no protected band was present in the positive control.  Two 
protected bands were observed, of which the lower protected band was 
possibly due to probe degradation.  The protected bands produced in both 
treated and untreated mice were at a similar level.  Therefore, cyp4X1 gene is 
expressed in Aorta tissue, but at low level. Furthermore, there was zero or little 
induction of cyp4X1 produced in aorta in response to dosing with the inducing 
agent (ciprofibrate). 
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 (-ve) tRNA  (+) tRNA      AU          AT                   M 
 
FiJure 3.37. Expression and induction of cyp4x1 in Aorta tissues.  
The protection assay was performed against 30 µg of total RNA extracted from mouse aorta 
tissues. The mice were dosed with ciprofibrate as described in the methods.  The full-length 
probe (424 b.p.) was generated by in vitro transcription of NcoI cut mcyp4x1-12 plasmid with 
Sp6 RNA polymerase and then hybridised to the samples. Two yeast tRNA control samples 
were hybridized to the probe, one sample treated with the RNase A/T1 (+ve control) and the 
other sample without RNase A/T1 (-ve control) (10 µg/ml). Track (AU) represents a protection 
assay on untreated mice (control). Track (AT) represents a protection assay on treated mice. 
The arrows indicate a protected fragment (b.p.) of cyp4x1 and the marker (M) size (124 b.p.). 
RNase protection assay was run on 6% denaturing poly acrylamide gel in 1xTBE at 120v for 1 
hour. Gels were then fixed, dried and exposed to Hyperfilm at -80ºC overnight.   
 
 
 
3.4.10 Induction of mcyp4X1 
A study of tissue-specific expression of mcyp4X1 RNA was performed by 
treating the mice with inducing agents such as peroxisome proliferators (PPs). 
Peroxisome proliferators are known to induce the CYP450s enzymes.  The 
induction was carried out by dosing 129S4/SvJae mice as described in section 
2.2.1.1. 
Each group consisted of three mice and the samples were carried out on 30µJ 
for each sample.  These were seven groups of mice: the control group, TCDD 
group, Dexamethasone group, Phenobarbital group, Ciprofibrate group.  All 
total RNA brain samples from these groups were isolated as described in 
section 2.2.3.9 and probed with m-cyp4X1-12 probe.  The integrity of the total 
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RNA was analysed by 1% agarose gel electrophoresis.  The tissues studied 
were brain, liver, heart, kidney, aorta, lung and spleen.  
 
 
3.4.11 Induction of mcyp-4X1 RNA in brain tissues 
RNase protection assays were performed on 30 µg of total RNA using a 
riboprobe for mcyp4x1, Figure 3.38. Samples from all mice in each group were 
hybridized using the same riboprobe at the same time.  Figures 3.38, show that 
the brain samples had a specific protected fragment of 177 b.p. which 
corresponded to the expected size of the cyp4X1-12 RNA. Induction of 
mcyp4X1 RNA in the brain samples was assessed roughly by comparing the 
signal intensity of the induced samples with that produced from the control 
samples.  In Figure 3.38, the mcyp4X1-12 probe was almost shown to be in 
full-length (RNase ve tract).  The RNase positive lane demonstrated an 
absence of signal when hybridised to yeast tRNA, which indicates the 
specificity of the signal in the samples.  A protected single band was produced 
in all protection reactions.  Figure 3.38, shows the protected bands were 
produced after probe hybridisation for these tissues. 
The size of the protected brain fragment in mouse samples was shorter than the 
full-length probe, which indicates the RNase removal of 247 b.p. of 
unprotected probe.  
Therefore, the murine cyp4X1 is strongly expressed in all brain samples 
protected by the probe as shown in Figure 3.38.  However, there was no 
evidence of any significant differences in the level of m4X1 observed in either 
control or mice treated with TCDD, Dexamethasone, Phenobarbital and 
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Ciprofibrate.  Therefore, there was no induction of mcyp4X1 RNA in any of 
treated mice in response to dosing with inducing agents. 
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177 b.p. 
124 b.p. 
 
FiJure 3.38. Expression and induction of cyp4x1 in brain tissues. 
The protection assay was performed against 30 µg of total RNA extracted from mouse brain 
tissues. Animals were treated with TCDD, PB, Dex and Cipro as described in the methods.  
The full-length probe (424 b.p.) was generated by in vitro transcription of NcoI cut mcyp4x1-
12 plasmid with Sp6 RNA polymerase and then hybridised to the samples. Two yeast tRNA 
control samples were hybridized to the probe, one sample treated with the RNase A/T1 (+ve 
control) and the other sample without RNase A/T1 (-ve control) (10 µg/ml).  Track (1) 
represents a control mouse. Track (2) represents induced mice by TCDD. Track (3) represents 
induced mice by Dexamethasone. Track (4) represents induced mice by PB. Track (5) 
represents induced mice by ciprofibrate.  M shows the marker (124 b.p).  RNase protection 
assay was run on 6% denaturing poly acrylamide gel in 1xTBE at 120v for 1 hour. Gels were 
then fixed, dried and exposed to Hyperfilm at   -80ºC overnight.   
 
 
3.4.12 Induction of mcyp4X1 in liver tissues 
The effect of treatment of the mice with inducing agents was also investigated 
using liver samples.  It is known that cyp4a genes are regulated by PPARĮ in 
liver (Bell et al, 1993).  The mice were treated as described in the methods.  
Liver RNA was extracted and RNase protection assays were carried out as 
described in section 2.2.5.6.  Figure 3.39, shows that only faint expression 
bands were produced from these tissues. 
All the induced samples when compared with the control mice show the same 
level of protected fragment.  This means that no induction of mcyp4X1 RNA 
was produced in liver in response to dosing with the inducing agents.  The 
autoradiography film was exposed for five days, so there are many non-specific 
signals as the 4X1 signal in liver is very low.  
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FiJure 3.39.  Expression and induction of cyp4x1 in mouse liver tissues.  
RNase protection assays were performed on mouse total RNA samples using [Į-³²P] labelled 
antisense riboprobe to mcyp4x1. The control mice were dosed using corn oil (vehicle) as 
described in section 2.2.1.1.  The wild type (+/+) and knock-out (-/-) mice were given a normal 
diet (untreated mice). Antisense riboprobe was generated by transcribing NcoI cut mcyp4x1-12 
plasmid with Sp6 RNA polymerase. Full-length probe was 424 b.p. and protected the fragment 
of the samples were 177 b.p. long. Total RNA was isolated as described in section 2.2.3.9 and 
30 µg of each RNA sample were hybridized with [Į-³²P] CTP labelled probe. Two yeast tRNA 
control samples were hybridized to the probe, one sample treated with the RNase A/T1 (+ve 
control) and the other sample without RNase A/T1 (-ve control) (10 µg/ml). A shows 
expression of cyp4x1 in a control, wild type (+/+) and knock-out mice liver samples. B shows 
induction of cyp4x1 in liver mice samples by ciprofibrate. L shows liver while the numbers 
show the mice number in the treated group. M shows the marker (124 b.p).  RNase protection 
assay was run on 6% denaturing poly acrylamide gel in 1xTBE at 120v for 1 hour. Gels were 
then fixed, dried and exposed to Hyperfilm at -80ºC for 5 days.  
 
 
Ciprofibrate is a known inducing agent in mice liver.  Livers were weighed and 
extracted from control mice and ciprofibrate treated mice.  The effect of 
ciprofibrate treatment on the liver weight was determined by liver: body weight 
ratio as shown in Figure 3.40.  It demonstrated that there was a significant 
difference (p<0.05) between the ciprofibrate induced mice liver and the 
control.  A statistically significant liver weight change was produced after 
ciprofibrate administration to mice, which therefore demonstrates that 
ciprofibrate was having a pharmalogical effect at this dose level.  
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FiJure 3.40. Induction of ciprofibrate in total mice liver.  
The control mice and the ciprofibrate treated mice were dosed as described in the methods. 
Three mice were used per group. All values are given as number of liver weight. Each bar 
shows the STD of the three samples in that group. Error bars shows the standard error of the 
samples in each group. Data shows a significant liver weight increase was observed in 
ciprofibrate treated mice, whereas no liver weight increase in that of control mice (p<0.05). 
 
 
3.4.13 RNase protection assay of Ciprofibrate induction 
Several tissues such as heart, kidney, lung and spleen were isolated and the 
total RNA was extracted as described in section 2.2.3.9.  The effect of 
ciprofibrate treatment on the level of cyp4X1 was determined by RNase 
protection assay of total homogenate of heart, kidney, lung and spleen samples 
as shown in Figure 3.41.  RNA extracts from untreated heart tissue were used 
as a control, tract H (1-3) of Figure 3.41. 
The tissues, which were induced with ciprofibrate, show no evidence of any 
signal induction.  Therefore, mcyp4X1 is not induced in these tissues following 
treatment with ciprofibrate.  The control samples from untreated heart tissue 
also show that no bands were produced.  The autoradiography films were 
exposed for five days, so there are many non-specific signals  
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FiJure 3.41. Expression and induction of cyp4x1 in several mouse tissues. 
RNase protection assays were performed against 30 µJ of total RNA extracted from mouse 
heart, kidney, lung and spleen tissues. Total RNA was isolated as described in section 2.2.3.9. 
The treated mice were dosed with ciprofibrate as described in section 2.2.1.1. Antisense 
riboprobe was generated by transcribing NcoI cut mcyp4x1-12 plasmid with Sp6 RNA 
polymerase and labeled with [Į-³²P] CTP. Full-length probe generated was 424 b.p. long. Two 
yeast tRNA control samples were hybridized to the probe, one sample treated with the RNase 
A/T1 (+ve control) and the other sample without RNase A/T1 (-ve control) (10µg/ml). RNA 
heart samples (H) were used as a control (untreated mice).  H shows heart (control), h shows 
heart (treated mice), K shows kidney, Lu shows lung and S shows spleen, while the numbers 
show the mice number in the group. M shows the marker (124 b.p).  RNase protection assay 
was run on 6% denaturing poly acrylamide gel in 1xTBE at 120v for 1 hour. Gels were then 
fixed, dried and exposed to Hyperfilm at -80ºC for 5 days.  
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3.4.14 Expression of m-4X1 protein 
pRSET-a-m4X1 plasmid DNA was transformed into BL21 (DE3) and 
BL21(DE3)pLysS E.coli strain. Small scale expression was used to optimise 
protein samples for SDS-PAGE analysis. Both types of E.coli transformed cells 
were induced with a final concentration of 1mM IPTG, as described in section 
2.2.3.2.1.  The induced and uninduced cells were then sonicated and 
centrifuged as described in section 2.2.4.7.  The proteins from the induced and 
un-induced cells were analysed by SDS-PAGE as shown in Figure 3.42.  
Figure 3.42, shows that a specific band of ~ 62 kDa was expressed in both 
cells, BL21 (DE3) and BL21 (DE3) pLysS, after IPTG addition, whereas no 
protein expression was seen in the uninduced cells, or cells with pRSET-a 
vector, (BL21) DE3 and BL21 (DE3) pLysS.  Therefore the induction of 
protein production was successful.  Furthermore, the induced protein was 
produced at a higher level in BL21 (DE3) cells than that in the pLysS cells.  
Therefore, BL21 (DE3) cells were used in future experiments.   
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FiJure 3.42. The expression and induction of m-cyp4x1 recombinant protein in BL21 
(DE3) pLysS and BL21 (DE3). The cells were induced using a final concentration of 1mM 
IPTG for three hours. The pellets (P) were lysed by sonication and fractionated by 
centrifugation (S) as described in the methods. The supernatant (S) and the pellets were 
analysed on 10% SDS-PAGE and then visualized by coomassie blue staining. Tracks labelled 
1 have pRSET-a, 2 are pRSET-4x1 in BL21 (DE3) pLysS cells and 3 are pRSET-4x1 in BL21 
(DE3) cells. Track P1 shows pellet of uninduced pRSET-a. Track P2 shows pellet of induced 
BL21 (DE3) pLySs cells. Track P3 shows pellet of induced BL21 (DE3) cells. Track S1 shows 
supernatant of induced pRSET-a. Track S2 shows supernatant of induced BL21 (DE3) pLysS 
cells. Track S3 shows supernatant of induced BL21 (DE3) cells.  M shows protein marker. The 
size of the molecular weight markers are shown in kDa, and position of the induced band is 
shown by the arrow.  
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In Figure 3.42, the majority of induced protein was found in the pellet fraction 
(insoluble), whereas a very low amount, if any, was found in the supernatant 
fraction (soluble).  Therefore, further sonication and solubilization of pellets 
with 8M urea, 0.1% SDS was required to solubilise the protein.  The 
solubilisation of the pellet with 8M urea, 0.1% SDS is illustrated in Figure 
3.43.  Figure 3.43, shows that the recombinant protein existed in both pellet 
and supernatant of the solubilized DL21 (DE3) pellet with 8M urea, 0.1% SDS.  
Some recombinant protein in the pellet was found in the supernatant fraction, 
whereas the majority of the recombinant protein was in the pellet.  Therefore, 
approximately half of the recombinant protein in the pellet was solubilized in 
the solution and a strong band of molecular weight ~ 62 kDa can be seen as 
shown in Figure 3.43, whereas no bands were observed in BL21 (DE3) control 
cells.  The cyp4X1 cDNA contains 507 amino acids.  The N-terminal fusion 
peptide from pRSET-a contains 49 amino acids including a six-histidine tag. 
Therefore, the whole cyp4X1 fusion protein contains 556 amino acids with a 
predicted molecular mass of 62, 808 Da.  The size of the detected band at the 
position of ~ 62 kDa on SDS-PAGE was consistent with the predicted value.  
The size of the protein produced was slightly lower than the predicted 
molecular size of the m-4X1 protein.  The protein was therefore successfully 
expressed in the cells and it was ready for purification using an affinity 
column.  In order to purify large amounts of expressed protein, 1 litre of BL21 
DE3-full-length-m4X1 was prepared under the same conditions as described in 
section 2.2.4.7. 
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FiJure 3.43. The expression and induction of m-cyp4x1 recombinant protein in BL21 
(DE3).  The cells were induced using a final concentration of 1mM IPTG for three hours.  The 
pellet was prepared from induced BL21 (DE3) and treated with 8M urea, 0.1% SDS (PT) and 
fractionated by centrifugation (ST) as described in the methods.  Track C shows the control of 
untransformed pRSET-a.  Track U shows uninduced BL21 (DE3) expression vector.  Tracks P 
and S show pellet and supernatant of solubilized BL21 (DE3) pellet with 8M urea, 0.1% SDS. 
The induced and uninduced BL21 (DE3) were analysed on 10% SDS-PAGE and then 
visualized by coomassie blue staining. M shows protein marker of sigma SDS 6H.  Track E 
shows purified cyp4x1 protein after His.Bind Nickel affinity column.  
 
 
3.4.15 Affinity purification and diafilter of mcyp-4X1 protein   
The induced protein was solubilized in 8M urea, 0.1%SDS.  In order to purify 
this protein, the His.Bind Nickel affinity column was used.  Purification of the 
expressed protein was carried out on the affinity column as described in section 
2.2.4.9 after diafiltration on YM10 exclusion membrane as described in section 
2.2.4.8. 
The solubilized protein fraction was passed through the His.Bind affinity resin. 
The unbound eluted protein and bound protein fractions were collected 
sequentially.  Figure 3.44, shows SDS-PAGE analysis of 1ml eluted fractions 
several protein bands can be seen in the eluted fractions.  Figure 3.44, 
demonstrates that the majority of the solubilized protein passed through the 
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nickel column, whereas a few bands of bound protein were obtained in the 
eluted fractions (2-5).   
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FiJure 3.44. Affinity purification of mcyp-4x1 recombinant protein in Nickel affinity 
column. 
The soluble protein (S) was diafiltered on stirred ultrafiltration cells as described in section 
2.2.4.8.  The purified recombinant mcyp-4x1 protein was analysed on 10% SDS-PAGE and 
then visualized by coomassie staining blue. M shows protein marker.  (A) shows soluble 
protein before Nickel affinity purification. (B) shows protein flow through after passing 
through the column. (W) shows wash buffer. E (1-8) shows the elution protein fractions 
respectively. 
 
 
In the eluted protein fractions, there are more than three bands in each fraction. 
The majority of eluted protein was a recombinant mcyp-4X1 and it was in the 
expected molecular size of m-4X1 (62 kDa), whereas the faint band at ~ 110 
kDa is possibly due to protein aggregation and the smaller protein fragments 
may be due to proteolysis.  These bands were obtained from the early eluted 
fractions.  However, no bands were observed in the late eluted fractions 
(fraction 6-8).  This means that most of the protein was eluted in three mls as 
shown in Figure 3.44, (E2-E4), and the concentration of the first eluted fraction 
was 1.4 mg/ml.  Therefore the purification of the protein was successful and 
the bands were very clear. 
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3.5 Characterisation of antisera against mouse cyp4X1  
Native mouse cyp4X1 in tissue samples cannot be specifically detected and, 
hence characterisation relies on Western blot analysis.  The antibody against 
human CYP4X1 did not cross react with mouse cyp4x1 protein (see Figure 
3.45).  Therefore, it was necessary to develop a sensitive mouse cyp4x1-
specific antibody.  
Antisera against human CYP4X1 were described earlier and were used to 
probe the mouse cyp4X1 recombinant protein, Figure 3.45.  Antisera were 
titred for reactivity against mouse cyp4X1 by Western blotting using various 
amounts of protein (100, 30, and 10 ng).  The protein was blotted and detected 
with primary antiserum at a dilution of 1:500.  Mouse cyp4X1 antigen was 
detected by the human cyp4X1 antiserum at a sensitivity of 100 ng, Figure 
3.45.  A lower molecular weight band was also detected using human antisera, 
but this is non-specific antibody binding. 
Therefore, the mouse cyp4X1 antigen has very low sensitivity or no cross-
reactivity with the human CYP4X1 antiserum.  
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FiJure 3.45. Sensitivity of human CYP4x1antisera against purified recombinant cyp4x1 
protein. 
The indicated amounts (100 and 30 ng) of mouse cyp4x1 protein were run on 10% SDS-PAGE 
then blotted to PVDF membrane as described in the methods.  The membrane was incubated 
with humanCYP4x1 antiserum at a concentration of 1:500, and the blot was developed with 
ECL as described in the methods.  Film was exposed for 2 hours.  The arrow shows the protein 
at ~ 53 kDa. 
  
 
 
A full length cDNA encoding mouse cyp4X1 was cloned into pRSET-a for 
expression as a histidine-tagged fusion protein, containing 507 amino acids of 
cyp4X1. 
The deduced sequence of the fusion protein shows that there are 49 amino 
acids from the pRSET-a vector, while the inserted DNA was 497 amino acids. 
pRSET-a-m4X1 plasmid DNA was transformed into BL21 (DE3) E.coli strain 
and induced to a final concentration of 1mM IPTG (section 2.2.4.7).  The 
induced cells were then sonicated and centrifuged as described in section 
2.2.4.7.  A 62 kDa protein was observed when the cells were exposed to 1 mM 
IPTG.  The protein was solubilized in 8M urea, 0.1 SDS and then purified by 
affinity chromatography on a nickel column. 
The protein contains 546 amino acids with a predicted molecular mass of 
62,808 Da and the purified protein was approximately 62 kDa on SDS-PAGE. 
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Therefore, the detected protein band at the position 62 kDa was consistent with 
the predicted value, and identified as the recombinant mouse cyp4X1.  The 
purified protein concentration was 0.38 mJ/ml as judged by Bradford assay 
(not shown).  
Two New Zealand white female rabbits (189 and 190) (~ 4 kJ) were injected 
with ~ 100µJ of mcyp4X1 antigen.  Booster injections were given at four week 
intervals and once sufficient antibody titre was obtained, terminal bleed 
samples were collected. 
Bleeds from rabbits 189 and 190 were collected after each immunisation and 
titred for reactivity against mouse cyp4X1 by Western blotting using various 
amount of protein (e.g. 10, 3, 1 and 0.3 ng) as shown in Figure 3.46. 
 
 
 
10
3
1
30
10
3
0
5
10
15
20
25
30
35
4 5 6
Number of immunisation
n
g 
o
f a
n
tig
en
 
 
FiJure 3.46. Development of antisera against mouse cyp4x1protein.  
Rabbits were immunized at monthly intervals for six months.  Antisera from rabbits 190 and 
180 were collected at the indicated time, diluted 1:500, and incubated with antigen for 1 hr.  
Diamond points represent rabbit 190 and the square points represent rabbit 180, these show the 
minimum amount of cyp4x1 antigen detected at the indicated time. The data shows an 
improvement in the sensitivity of the antisera from these rabbits against the antigen over the 
course of several immunizations 
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The antigen cyp4X1 is clearly visible in Figure 3.47 (A), in lanes 1, 2 and 3. 
Only one band at 53 kDa in three tracks was detected by the antisera from 
rabbit 190.  The antisera from rabbit 189 detected only one clear band at 53 
kDa in three tracks and the others were less clear as shown in Figure 3.47 (B).  
The streaky bands produced in Figure 3.47 (B) show a clear band at 10ng, but 
indistinct bands at 3, 1, and 0.3 ng.  Although titration of the antiserum from 
rabbit 189 was repeated three times, the streaky banding was consistently 
reproduced.  
The antiserum from rabbit 190 detected 1 ng of antigen at a primary antibody 
dilution of 1:500, whereas the antiserum from rabbit 189 detected 3 ng of 
antigen, but not 1 ng.  
Therefore, the antiserum from rabbit 190 was more sensitive than that from 
rabbit 189 and the antisera can be used to sensitively detect the mouse cyp4X1 
protein.  Therefore, the antiserum from rabbit 190 was used for further 
characterization of native cyp4X1.   
 
                        A                                                                 B 
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FiJure 3.47. Sensitivity of antisera against mouse cyp4x1. 
The indicated amount (0.3, 1, 3 or 10 ng) of mcyp4x1 protein was run on 12% SDS-PAGE then 
blotted to PVDF membrane as described in the methods.  The membranes were incubated with 
antiserum (from rabbit 189 (B) or 190 (A)) at a concentration of 1:500, and the blots were 
developed with ECL as described in the methods.  Film was exposed for 2 hours.  The arrow 
shows the protein at ~ 53 kDa. 
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3.5.1 Specificity of antisera against the native mouse cyp4X1 protein 
The mouse cyp4X1 RNA was found to be expressed in brain, but not in liver, 
and hence specificity tests of antisera against the native cyp4X1 protein relies 
on these tissues.  
In order to test the specificity of the antiserum to mcyp4x1 protein in tissue 
extracts, immune and pre-immune sera were tested against microsomal and 
cytosolic extracts from adult male 129S4/SvJae mouse brain and liver on 
Western blots.  Cyp4X1 antigen was used as a positive control on the blots.  
Figure 3.48, track 1 and 2, shows that a strong band at 53 KDa was detected in 
mouse brain microsomes and cytosol using the cyp4X1 antisera, whereas in 
liver this band was not detected. 
Minor cross-reactivity bands were detected in brain and liver. However, the 
protein bands detected in brain fractions were not observed after probing with 
preimmune serum. Furthermore, several bands were detected in liver 
microsomes and cytosol after probing with preimmune serum and were the 
same bands that were detected by the immune serum in liver.  These confirm 
that the antisera specifically detected cyp4X1 but not other proteins in mouse 
brain microsomes and cytosol.  
The size of the protein detected (~ 53 kDa) by mouse cyp4X1 antibody in brain 
microsomes and cytosol was slightly lower than that of the purified 
recombinant protein, consistent with the 49 amino acid N-terminal fusion.  
Therefore, the protein detected in brain microsomes and cytosol samples has 
the expected size for the mcyp4X1 protein.   
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FiJure 3.48. Western blots showing brain and liver protein extracts probed with 
antiserum from rabbit 190. 
20 µg mouse brain and liver microsomes and cytosol and 10 ng purified recombinant mcyp4x1 
protein were run on 12% SDS-PAGE gel and then blotted to PVDF membrane as described in 
the methods. The membranes were incubated with antiserum from rabbit 190 (A) or pre-
immune serum (B) at a concentration of 1:1000, and the blot was developed with ECL as 
described in the methods. Films were exposed for five seconds. Track (1) in A represents 
antigen protein (+ve control). For both Figures, track (2) represents brain microsomes, track (3) 
represents brain cytosol, track (4) represents liver microsomes and track (5) represents liver 
cytosol. The arrows show the cyp4x1 protein at a size of ~ 53 kDa in mouse brain microsomes 
and cytosol. 
 
 
 
 
Unexpectedly, Figure 3.49 showed that 4X1 was present in both microsomes 
and cytosol.  To confirm that mouse cyp4X1 was located in brain cytosol, 
microsomes and cytosol were extracted from three adult female mice (S129) 
and analyzed on SDS-PAGE.  The microsome preparations and cytosol were 
centrifuged twice at 328000 xg for thirty minutes at 4°C. Liver microsomes 
and cytosol were used as a control. Figure 3.49, shows that cyp4X1 (~ 53 kDa) 
was detected in all mice, but not in the control liver fractions.  After the first 
centrifugation of the microsomes, strong bands and lower molecular weight 
bands were observed in all mice.  However, these bands were less strong after 
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double centrifugation, with no lower molecular weight bands.  Furthermore, 
the microsome preparations and cytosol were also centrifuged once at 568000 
xg for one hour at 4°C (Figure 3.50). 
Although cyp4X1 bands were also detected in all cytosol samples after double 
centrifugation, these are probably due to artifacts. 
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FiJure 3.49. Western blots showing double centrifugation of mice brain microsomes and 
cytosol probed with antiserum 190. 
The brain microsomes and cytosol were double centrifuged at 328000 xg for thirty minutes as 
described in the methods.  10 µg mouse brain and liver microsomes and 10 ng purified 
recombinant mcyp4x1 protein were run on 12% SDS-PAGE gel and then blotted to PVDF 
membrane as described in the methods. The membrane was incubated with antiserum (rabbit 
190) at a concentration of 1:1000, and the blot was developed with ECL as described in the 
methods.  Film was exposed for 2 minutes. +ve control represents antigen.  Numbers (1-3) 
refer to mice 1-3.  Roman Figures (I, II and III) represent cytosol double centrifugation. 
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FiJure 3.50. Western blots showing centrifugation of mouse brain microsomes and 
cytosol probed with antiserum 190. 
The brain microsomes and cytosol were centrifuged at 568000 xg for one hour as described in 
the methods.  20 µg mouse brain and liver microsomes and 30 ng purified recombinant 
mcyp4x1 protein were run on 12% SDS-PAGE gel and then blotted to PVDF membrane as 
described in the methods. The membrane was incubated with antiserum (rabbit 190) at a 
concentration of 1:1000, and the blot was developed with ECL as described in the methods.  
Film was exposed for 20 minutes.  +ve control represents antigen.  Numbers (1-3) refer to mice 
1-3.  Roman Figures (I, II and III) represent cytosol double centrifugation. 
 
 
As a further test of specificity, cyp4X1 antiserum was also blocked by adding a 
large excess of purified recombinant cyp4X1 protein and tested against the 
purified protein. 
In order to confirm that the signals produced in Figure 3.48 were due to the 
specificity of the antiserum to cyp4X1, normal cyp4X1 antiserum and 
antiserum pre-incubated with purified cyp4X1 protein were tested against brain 
and liver microsomes.  
Figure 3.51, shows that specific bands were detected in both the positive 
control, cyp4X1 antigen, and in brain microsomes using the antisera.  
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However, these protein bands were not observed in the samples after probing 
with blocked immune serum, confirming that the antisera specifically detected 
cyp4X1.  Liver microsomes were also probed using immune serum, Figure 
3.51 (A), and preincubated serum, Figure 3.51 (B).  Two bands were detected 
in liver microsomes after probing with cyp4X1 antisera, whereas the same 
bands are detected after probing with preincubated serum.  This indicates that 
the cyp4X1 antiserum is able to differentiate between cyp4X1 and other 
proteins.  
Therefore, the specificity of the antisera for cyp4X1 was confirmed. 
 
                     A                                                                                     B 
 
 
 
m
ic
ro
so
m
es
(1
0 
µ
g)
L
iv
er
 m
ic
ro
so
m
es
 
(5
 µ
g)
B
ra
in
 m
ic
ro
so
m
es
 
(1
0 
µ
g)
B
ra
in
 m
ic
ro
so
m
es
 
(5
 µ
g)
B
ra
in
 m
ic
ro
so
m
es
 (
10
 µ
g)
+v
e 
co
nt
ro
l
B
ra
in
 m
ic
ro
so
m
es
 (
5 
µ
g)
L
iv
er
 m
ic
ro
so
m
es
 (
5 
µ
g)
Li
ve
r
m
ic
ro
so
m
es
(1
0 
µg
)
53 kDa
 
FiJure 3.51.  Selectivity of the mouse cyp4x1 antiserum.  
Microsomal proteins from mouse brain, liver (5 µg and 10 µg of protein respectively) and 30 
ng purified recombinant mcyp4x1 protein were resolved on 12% SDS-PAGE gels and then 
blotted to PVDF membranes as described in the methods.  Pre-incubated antiserum was 
prepared by incubation of the cyp4x1 antisera with purified cyp4x1 protein for 1 hour at room 
temperature.  The membranes were incubated with normal antiserum 190 (A) or pre-incubated 
antiserum 190 (B) at a concentration of 1:1000, and the blot was developed with ECL as 
described in the methods.  Films were exposed for one minute.  The arrows show the cyp4x1 
protein at a size of ~ 53 kDa in mouse brain microsomes. 
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3.5.2 Quantitation of microsomal mouse cyp4X1 
Quantitation of microsomal mouse cyp4X1 was carried out by Western 
blotting.  Figure 3.52, shows that the signal intensity of microsomal cyp4X1 in 
the brain microsomal sample (1µg) was approximately equal to the signal 
intensity from 10 ng of 4X1 antigen.  The total amount of cyp4X1 in brain 
microsomes was calculated to be 0.2 n mol per mg of microsomal protein.   
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FiJure 3.52. Mouse cyp4x1 quantitation. 
Several brain microsomal dilutions (3, 1, 0.5, 0.1, 0.05, and 0.01 µg) and purified cyp4x1 (30 
and 10 ng) were subjected to Western blotting on 12% SDS-PAGE gel and then blotted to 
PVDF membrane as described in the methods.  The membrane was incubated with antiserum 
(rabbit 190) at a concentration of 1:1000, and the blot was developed with ECL as described in 
the methods.  Film was exposed for  10 minutes.  
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3.5.3 Cyp4X1 protein localization 
In order to determine the cyp4X1 protein localization in mouse brain tissues, 
immunohistochemistry was carried out using female mouse brain 
(129S4/SvJae) sections (Figure 3.53).  The negative control of brain tissue 
stained in the absence of primary antiserum (Rabbit 190) (Panel A) showed 
that no cells were immuno-stained, which indicates that the stained cells 
observed in the test samples were due to the presence of cyp4X1 protein.  
Figure 3.53, panel B shows that the cyp4X1 protein was localized in the 
cytoplasm of cells of the cerebellum.  These appear to be neurons based on 
their size and shape.  Definitive neuronal localization as opposed to glial 
staining must await double labelling experiments using GFAP and NF 
antibodies to identify the cell type.  Blood vessels were stained showing that 
the vascular endothelial cells also contained cyp4X1 protein. Interestingly not 
all neurons of the cerebellum were stained; as the Purkinje cells identified by 
their large size and layered distribution did not contain the P450 protein (Panel 
D). 
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FiJure 3.53. Immunohistochemistry of mouse brain tissue 
Brain tissue was perfused and fixed as described in the methods. The sections were incubated 
with primary antiserum (from rabbit 190) at a concentration of 1:1000, and stained with DAB 
solution as described in the methods. (A) shows unstained brain tissue without primary 
antiserum (scale bar 50 µm). (B) shows stained neuron cells (scale bar 30 µm). (C) shows 
stained blood vessels (scale bar 30 µm). (D) Purkinje cells were not stained by the antibody to 
cyp4x1 (scale bar 30 µm). Arrows indicate the cells in each cerebellum section. 
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FiJure 3.53. Immunohistochemistry of mouse brain tissue 
Brain tissue was perfused and fixed as described in the methods. The sections were incubated with primary
antiserum (from rabbit 190) at a concentration of 1:1000, and stained with DAB solution as described in the
methods.
 
(A) shows unstained brain tissue without primary antiserum (scale bar 50 µm). (B) shows stained 
neuron cells (scale bar 30 µm). (C) shows stained blood vessels (scale bar 30 µm). (D) Purkinje cells were
 
 
not stained by the antibody to cyp4x1 (scale bar 30 µm). Arrows indicate the cells in each cerebellum
section. 
                                  
A B
C D
 
 
 
 
 
 
 
 
 
185 
AL-Anizy M                                                                                        Discussion 
Chapter 4                                   Discussion 
 
One of the aims of this present study was to generate antisera against, and 
subsequently characterize, human CYP4Z1, mouse AhR LBD and C. elegans 
latrophilin.  Antisera were successfully produced, as discussed below. 
 
4.1 Characterisation of CYP4Z1 
Antisera against human CYP4Z1 were produced by immunising two rabbits 
(denoted "C" and "D"), both of which responded.  The sensitivity of antisera 
improved with increased numbers of immunizations, and the minimum 
detection limit obtained was 1 ng. 
The antisera detected the protein antigen at 40 kDa on SDS-PAGE, which is 
the predicted molecular size of the CYP4Z1 antigen.  CYP4Z1 antiserum has 
not been used to detect native protein in human tissues yet.  However, it has 
recently been shown that CYP4Z1 RNA is expressed in human tissues (Rieger 
2004), and that the antiserum detects the full-length recombinant protein 
expressed in cells.  In the present study, it was not possible to obtain human 
tissue; thus the CYP4Z1 antiserum was not tested against native human 
protein.  The characterization of CYP4Z1 antisera confirms that the antisera are 
sensitive and are ready to use in detection of the native human CYP4Z1 
protein.  The characterisation of CYP4Z1 protein expression and 
immunohistochemical localisation would be a substantial advance in 
understanding the biology of the CYP4Z1 protein in human. 
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4.2 Characterisation of AhR LBD 
The aim of this experiment is to produce antibodies against the LBD domain of 
the mouse AhR
b-1 
protein and then to test the specificity and selectivity of these 
antibodies.  An antibody specific for the AhR LBD is an important reagent for 
studying the recombinant expression of the mouse AhR
b-1 
AhR LBD (T. Jiang, 
PhD thesis, 2004). 
The antisera produced against the AhR LBD were more sensitive than those 
against CYP4Z1, detecting as little as 0.3 ng of antigen.  The antisera could 
specifically detect native AhR in 10 µg of liver cytosol from both mouse and 
rat.  The AhR is reportedly found at ~100 fmol/mg of cytosolic protein (Poland 
et al, 1987, 1990), or ~10ng of AhR/ mg cytosolic protein, equivalent to 100pg/ 
10 µg of cytosol, confirming that the antisera are highly sensitive.  Thus, these 
results confirm that the antisera are highly sensitive. 
The specificity of these antisera was for AhR tested by immunodetection of 
AhR in rodent liver cytosol preparations.  Clear bands were detected in hepatic 
cytosol from mouse and rat at 110 kDa and 111 kDa respectively, when 
preparation were probed with the antisera.  Previous workers have determined 
the size of the AhR protein to be 104 kDa (C57B1/6 mouse) and 106 kDa (rat) 
(Poland et al, 1987, 1990).  This confirms that the antisera detect native AhR at 
the predicted molecular weight.  It was not surprising that antisera against 
mouse AhR LBD can detect the rat AhR protein, given the high sequence 
identity (5 mismatches in 192 amino acids) in AhR LBD between mouse and 
rat.  Indeed, this antisera detects recombinant human AhR (Ming Qi Fan, 
unpublished data). 
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It has been reported that the variation in AhR molecular weight between mouse 
and rat is due to genetic polymorphism (Poland et al., 1990).  In the current 
study, a slight variation in the apparent molecular weight of AhR between 
mouse and rat cytosol was also seen and this is likely to be for the same reason.  
Poland et al (1990) also reported that the cytosolic AhR can undergo 
proteolytic degradation, so the detection of low molecular weight bands in 
mouse liver cytosol may be due to the presence of AhR fragments following 
proteolysis.  The data presented here confirm that the antisera produced against 
AhR are both sensitive and specific in mouse and rat.  
 
4.3 Characterisation of LpH 
Our laboratory has used C. elegans as a model system for studying the effects 
of BWSV.  The C. elegans latrophilin homologue, B0457.1 (LpH), mediates 
the toxic effects of black widow spider venom, since C.elegans subject to an 
RNAi knock-out of latrophilin was resistant to the toxic effect of BWSV (Mee 
et al., 2004).  For studying the native LpH protein in C.elegans, 
characterisation relies on Western blotting.  Therefore it was necessary to 
develop a sensitive latrophilin-specific antibody.  The antisera raised against 
latrophilin improved in sensitivity over time, detecting as little 0.3 ng of the 46 
kDa LpH antigen.  However, several bands were detected in sub-cellular 
fractions of C.elegans.  
C. elegans were homogenised, then fractionated into a 5k pellet (nuclei and 
carcasses), a 15 k pellet (cell membranes and mitochondria) and 15k 
supernatant (endoplasmic reticulum and cytosol).  Western blots of the 15k 
pellets were probed with both immune and pre-immune sera.  When immune 
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sera were used to probe 15k pellets of C.elegans, a clear band of reactivity with 
the antisera was detected at a size of ~113 kDa, which was absent from other 
fractions.  Several other bands were also detected in the 15k pellet fractions.  
However, none of the bands detected by the immune serum appeared after 
probing with preimmune serum, which argues that all of the bands detected by 
the immune serum are specific.  However, the antigen was purified from E. 
coli, and was contaminated with small amounts of E. coli protein; given that C 
elegans eats E. coli, this does not exclude the possibility that some of the 
proteins detected by the immune serum may be unrelated to latrophilin. 
The detected band at ~ 113 kDa is likely to be LpH, because the primary 
sequence of the LpH cDNA predicts a protein of 113 kDa.  The sub-cellular 
localisation of this protein in the membrane fraction, together with its apparent 
molecular mass being consistent with the predicted molecular mass of LpH, 
suggest that this protein is the C. elegans LpH.  
Previous studies have reported that the mammalian latrophilin has a molecular 
weight of 116 kDa (Lilianova et al., 1997), or 120 kDa (Krasnoperov et al., 
1996) (Daveltov et al., 1996) (Itchenenko et al., 1999).  It has also been 
reported to have two subunits (120 kDa and 80 kDa) (Krasnoperov, V., et al 
2002).  In the same study above, the 120 kDa band represents the intracellular 
latrophilin fragment, whereas the 80 kDa protein was due the glycosylated 
extracellular domain of the LpH protein.  
Several lower molecular weight bands were also detected in the membrane and 
cytosolic fractions (15k pellet and supernatant) and these bands were possibly 
due to protein cleavage at the GPS site or non-specific cross-reactivity.  
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To test these possibilities, the antibodies were further purified using an affinity 
column and subsequently showed improved selectivity for the LpH protein.  
However, there was a loss of sensitivity: purified antibody detected 10 ng of 
the antigen, whereas the antisera before purification could detect 0.3 ng.  The 
band detected using purified antibody was very strong at an antibody dilution 
of 1:1000, which indicates that a large quantity of antibody was purified.  
The purified antibody, consistent with the antisera, detected a strong band at 
113 kDa and a faint lower molecular weight band in total C.elegans lysate, 
whereas a single band was detected at ~ 66 kDa in the 15 k sub-cellular pellet.  
The lower molecular weight bands (~ 66 kDa) may be due to proteolysis.  
The majority of the latrophilin protein was found at ~ 113 kDa in the 15k pellet 
(membrane proteins) with antisera and hence to solubilise the protein, emulgen 
913 and 2% dodecylmaltoside were used.  In these detergents, LpH was more 
soluble in 2% dodecylmaltoside than in 2% emulgen 913.  
A fresh 15k supernatant treated with 2% dodecylmaltoside showed a strong 
band of LpH protein at ~113 kDa. However, this 113kDa band was absent 
following overnight storage of samples at  80ºC.  Figure 3.13 shows that an 
intense band at ~66 kDa was detected in these samples following storage, 
which must therefore be due to degradation of the ~113 kDa LpH protein.  
Improved methods for sample preparation and storage need to be developed for 
further studies, given the apparent instability of LpH. 
It is known that mammalian latrophilin is a member of the secretin family of 
G protein-coupled receptors with two fragments, one of which has a molecular 
size of 116 kDa (Lelianova et al., 1997).  The full-length latrophilin protein is 
subject to proteolytic degradation and cleavage occurs between residues 
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Leu (837) and Thr (838) in the extracellular region of mammalian latrophilin 
close to the first transmembrane segment (Krasnoperov et al., 2002).  In the 
same study, multiple homologous sequences to this cleavage site have been 
demonstrated in other G protein coupled receptors.  
In the data presented here, several faint lower molecular weight bands were 
detected as shown in Figure 3.12 and a strong band was seen at 66 kDa as 
shown in Figure 3.13.  
The presence of these lower molecular weight bands may be attributed to the 
presence of a GPS (G protein-coupled receptor proteolysis site) between 
positions C497 and M536 of LpH.  This GPS is a characteristic feature of the 
LpH protein family.  
Recently, a functional role for the GPS domain in receptor cleavage has been 
proven in CIRL 1 (latrophilin 1), where mutations in the GPS domain render 
the molecule resistant to intracellular cleavage (Krasnoperov et al., 2002). 
After cleavage at the GPS site between L529 and T530, the predicted N-
terminal fragment would be a 529 amino acid protein of 58 513 Da.  This 
fragment would be detected by the antibody, which was raised against  
a recombinant expressed fragment containing amino acids 169-536 of the  
C. elegans LpH protein.  The presence of LpH and LpH fragments in the 15k 
pellet indicates that this protein is localized in the membrane compartment.  
The sub-cellular localisation of this protein in the membrane fraction, together 
with its apparent molecular mass being consistent with the predicted molecular 
mass of LpH, strongly suggest that the detected protein is indeed C. elegans 
LpH.  Furthermore, the presence of a protein at 113 kDa with a proteolytic 
fragment at 66 kDa is in agreement with published studies on latrophilin.  
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In summary, antisera were produced against latrophilin and these detected 
several protein bands in C.elegans.  Purified antibody still detected more than 
one band in the membrane compartment of C.elegans sub-cellular fractions, 
but the molecular weights of the detected proteins were consistent with GPS 
cleavage of LpH.  
 
4.4 Sequence analysis of the cloned mouse cDNA 
Human CYP4X1 and CYP4Z1 have been cloned (Savas et al., 2005; Rieger et 
al., 2004).  However, we do not know where these CYP450s are expressed in 
human and it is difficult to obtain human tissue, so further investigation of 
these proteins in human is difficult.  Therefore, I sought to establish a mouse 
model to study the expression of these CYP450s.  However, nothing is known 
of mouse cyp4X1; the expression and function of this P450 is of interest.  
Hence, the next aim of the study was to generate mouse cyp4X1 probes.  
Mouse cyp4X1 was therefore cloned and characterized as described below. 
For the cloning of mouse cyp4x1, two primers, 4x1-f-pF and 4x1-f-pR, were 
designed from the aligned protein sequences from human CYP4X1 
(Figure3.26).  These primers were designed from the beginning and end of the 
known human CYP4X1 cDNA sequence, and from the sequence of mouse 
genomic DNA (Fig 3.28). 
The primers were used to amplify a cDNA fragment of ~1600 bp, the predicted 
size of the murine cyp4x1 cDNA.  The PCR product is shown in Figure 3.28. 
The cloned cDNA was purified, cloned and multiple independent clones 
sequenced to confirm its identity (Fig 3.29).  The sequence of the cDNA was 
1524 b.p., with an open reading frame of 507 amino acids (Fig 3.30).  
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In the nucleotide sequence of the mcyp4X1 cDNA, the forward primer (4x1-f-
pF) and the reverse primer (4x1-f-pR) have been reproduced, which indicates 
that cDNA amplification and cloning was successful. 
The predicted protein from the cDNA sequence was 507 amino acids, starting 
with a methionine translation start site (Figure3.30).  It has been reported that 
mouse cyp4b1 and rat CYP4a1 each have 12 exons (Acc BC008996, Acc 
M57718M33937).  The presence of the stop codon at the end of exon 12 
indicates that this is also the final exon for the mouse cyp4x1.  This result is 
similar to the exon number of other CYP4 family genes.  
The deduced mcyp4x1 protein sequence shows a high level of similarity but 
not complete identity when compared with rat and human sequences as shown 
in Figure 3.31.  This Figure shows that identity is 94 % and 79.2 % between 
the full-length mouse 4X1 sequence and rat (AF439343), human (Q8N118) 
respectively.  The alingment shows that mouse cyp4x1 is more similar to rat 
CYP4X1 protein than to the human CYP4X1, and the length of the three 
proteins is identical.  This high sequence identity with the rat defines the mouse 
as a new member of the CYP4X cytochrome P450 subfamily.  Moreover, the 
genomic sequence suggests that there is only one mouse cyp4X gene, and 
hence this is the mouse cyp4X1 gene. 
Table 6 shows that amino acid sequences corresponding to exon 2, 5, 8 and 11 
show higher similarity between mouse cyp4X1 and rat and human CYP4X1 
genes than the other exons.  This higher conservation of these exons suggests 
that they might encode functionally important regions of the protein. 
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Exon 4 encodes for a highly conserved motif 
GRGLLNLDGPRWFQHRCILLTPAFHQDILKPCVDTMAHSVKVML, 
located between residue sites 121 and 165 in the cyp4X1 (Figure 3.33).  
When using nucleotide sequence of this motif against blast search, it found that 
only the CYP4 subfamily was matched against this motif.  This indicates that 
this motif is conserved in all the CYP4 family and subsequently it suggests that 
it might play an important role in the enzyme activity of this CYP4 family. 
Exon 8 putatively encodes LRAEVNTFMWAGHDAS, a 16 amino acid motif. 
This motif contains a stretch of 13 amino acids and has been proposed to be a 
signature for the CYP4 family due to its high conservation, even in cockroach 
(Blaberus discoidalis) CYP4C1 (Bradfield et al., 1991). 
Furthermore, Exon 11 and exon 12 were found to encode a highly conserved 
amino acid motif, PFSGG (A/S) RNCIG, which contains the haem-binding 
cysteine which is essential for all cytochrome P450 proteins (Gonzalez, 1989).  
In conclusion, the mouse Cyp4X1 protein contains several motifs, which are 
know to be highly conserved within the CYP4 family, and required for 
function.  It is therefore likely that the mouse Cyp4X1 encodes a functional 
cytochrome P450.  Therefore, comparison of the deduced amino acid 
sequences of the cloned mouse cDNA with known 4X1 (rat and human) 
demonstrate that the cDNA encodes a 4X1 protein.  
The enzyme activity of cyp4X1 has not been characterized, but it is likely that 
it metabolizes fatty acids by Ȧ and Ȧ-1 oxidation due to its high similarity to 
mouse cyp4b1 and rat CYP4A1 proteins of known enzyme activity (Okita and 
Okita., 2001).  
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4.5 Analysis of intron/exon junction boundaries in mouse cyp4X1 
The intron and exon junction sites (1-12) were determined by direct 
comparison of the 4X1 cDNA against the genomic sequence of XX-Pac129 on 
chromosome 4 (see Figure 3.32).  To determine the intron/exon junction, there 
are several rules, and these are  described at 
http://www.cc.ndsu.nodak.edu/instruct/mcclean/plsc731/transcript/transcript4.h
tm. The junctions of the mouse cyp4X1 gene are in agreement with the 
published rules for >90% of this data. 
Mouse cyp4a genes have been localized to chromosome 4 (Bell et al., 1993., 
Henderson et al., 1994), adjacent to the cyp4b subfamily (Heng et al., 1997). 
Moreover, all three mouse cyp4a genes are shown to be physically linked and 
are phylogenetically related to the Cyp4b subfamily (Heng et al., 1997).  The 
present study amplified mouse cyp4x1 cDNA based on the genomic sequence 
of XX-Pac129 on chromosome 4 (see Figure 3.32).  Hence, the cyp4X1 cDNA 
was produced from chromosome 4 and this is consistent with the locations of 
other CYP4 family members.  
Alignment of intron/exon junction sites between mouse cyp4X1 cDNA and 
published mouse cyp4b1 (Acc.No. BC008996) and rat CYP4a1 (Acc. No. 
M57718M33937) was carried out (see Figure 3.33).  The sequence of exon 1 
contains a methionine at the start in all alignments using the published CYP4 
family members discussed above. 
The alignment showed that intron/exon junction sites were in very similar 
positions between mouse cyp4X1 and mouse cyp4b1, whereas, these was 
greater divergence between mouse cyp4X1 and rat CYP4A1 (Figure 3.33). 
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However, the protein sequences of cyp4a10 and cyp4b1 have similar % 
identity to cyp4x1, at 49 and 47% respectively.  Cyp4b1 is the most distant 
member of the cyp4 cluster from cyp4X1, suggesting a greater evolutionary 
distance from cyp4X1 (Figure 3.54).  In summary, neither the position of the 
intron/exon junctions, the % identity, nor the organization of the genes 
immediately provide obvious clues as to the evolution of the mouse cyp4 
family. 
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FiJure 3.54. Cartoon of cyp4 genes on chromosome 4, showing orientation of gene (arrow), 
and the position of the gene in Megabases (Mb). 
 
Figure 3.54 demonstrates that all cyp4a genes are closely linked to cyp4X1, 
head to head on chromosome 4, whereas the cyp4b1 gene is located far away 
from cyp4X1, but is closely linked to cyp4a pseudogene.  
 
4.7 Expression and purification of mouse cyp4X1 in BL21 (DE3) E.coli 
cells 
A full length cDNA encoding mouse cyp4X1 was cloned into pRSET-a for 
expression as a histidine-tagged fusion protein, containing 507 amino acids of 
cyp4X1.  
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pRSET-a-m4X1 plasmid DNA was transformed into BL21 (DE3) and plysS 
E.coli strains and induced using a final concentration of 1mM IPTG (section 
2.2.4.7). 
Figure 3.42 demonstrated that a protein 62 kDa was expressed in cultures 
treated with IPTG.  Cultures grown without the addition of IPTG did not 
express any protein.  This protein is dependent upon IPTG induction, and is the 
predicted molecular mass for the histidine-tagged Cyp4x1 fusion protein; it can 
therefore be concluded that this band is the cyp4X1.  The induced protein was 
produced at a higher level in BL21 (DE3) cells without the plysS plasmid.  
Cultures of BL21 (DE3) cells treated with IPTG produced a strong band of 
induced protein (62 kDa), whereas the BL21 (DE3) plysS cells produced a 
fainter induced protein (62 kDa) band.  
Figure 3.42 demonstrates that the majority of induced protein was found in the 
pellet fraction (insoluble protein) and hence the insoluble protein was pelleted 
and resuspended in 8M urea, 0.1% SDS.  The cyp4X1 protein was soluble in 
the urea/SDS solution, but still had several faint bands of contamination after 
centrifugation.  The solution was diafiltered on YM10 exclusion membranes 
prior to purification using His.Bind Nickel affinity column (Figure 3.44). 
In the eluted fractions, the majority of the protein was recombinant mcyp-4X1 
at 62 kDa, in addition to several minor lower molecular weight bands.  The 
faint band at ~ 110 kDa was possibly due to protein aggregation, whereas the 
lower molecular weight bands were possibly due to proteolysis.  The results 
presented here show that the protein was highly purified and resolved at the 
same molecular weight before and after purification. 
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4.8 Expression of cyp4X1 in aorta tissue 
It has been reported (Savas et al., 2005) that human CYPX1 RNA is expressed 
in aorta tissue and these authors suggested it might contribute to the oxidation 
of arachidonic acid.  Furthermore, Irizar and Ioannides (1995) demonstrated 
that the expression and inducibility of P450 protein in rabbit aorta by using 
polyclonal antibodies to CYP4A1.  This study shows that the rabbit aorta 
expresses a CYP4A immunoreactive protein; noticeably, it has a different 
mobility to CYP4A1.  It is tempting to speculate that this antiserum shows 
cross-reactivity with the CYP4X1 protein.  Hence it may be that the CYP4X 
proteins play an important role in regulation of cardiovascular blood pressure.  
In order to study the expression of cyp4X1 in aorta tissue, RNA was extracted 
as described in section 2.2.3.9.  An RNase protection assay was performed and 
ciprofibrate was used to determine if the cyp4X1 gene was inducible by 
treatment of mice with peroxisome proliferators.  Figure 3.37 shows expression 
and induction of this gene in both treated and untreated mice.  The RNase 
protection assay showed that a specific protected band was produced in total 
aorta tissue and no protected band was present in the negative control.  It is 
known that CYP4X1 is expressed in the aorta in humans and induced by the 
PPARĮ agonist Wy14643 in HepG2 cells (Savas et al, 2005).  However, 
nothing is known about regulation of cyp4X1 expression in mouse aorta.  
In the present study protected bands were observed in both ciprofibrate treated 
and untreated mice, at a similar level.  The aortic cyp4X1 protein was not 
inducible by peroxisome proliferators in this study.  This data shows for the 
first time that expression of cyp4X1 has been demonstrated in the aorta in 
 198
AL-Anizy M                                                                                        Discussion 
mice.  Furthermore, the experiment demonstrated no induction effect of 
ciprofibrate in treated mice in aorta.  
The data presented here are otherwise consistent with previous reports and 
support the hypothesis that CYP4X1 might contribute to the oxidation of 
arachidonic acid in mice.  
 
4.9 Expression and induction of cyp4X1 in brain tissue in mice 
Cytochrome P450s have been shown to be involved in the biosynthesis and 
metabolism of neurosteroids, vasoactive eicosanoids, retinoid, cholesterol and 
in the metabolism of neurotransmitters (Hedlund et al., 2001; Compagnone et 
al., 2000; Whl et al., 1993; Roman et al., 2002; White et al., 2000; Lund et al., 
1999; Hiroi et al., 1998; Bronheim et al., 1995).  A recent study has 
demonstrated that CYP4x1 is expressed in rat brain (Bylund J. et al., 2002).  
However, nothing is currently known about its expression in the brains of mice.  
In order to study cyp4X1 gene expression in mouse brain tissues, samples were 
analysed using a sensitive RNase protection assay.  
Mice were also treated with ciprofibrate to study the induction effect of this 
agent.  Expression of the cyp4X1 gene was first identified in the brain samples 
prior to studying the induction effect (Figure 3.34).  The probe length in the 
experiment was 424 b.p. and the marker was 124 b.p.  The data in Figure 3.34 
showed that a specific protected band at 177 b.p was seen in the brain sample, 
whereas no band was seen in the control sample (Liver).  Two high molecular 
weight bands were also produced: since these were the same length as the full 
length probe, they did not correspond to the fragment size of protected RNA, 
and were not considered to reflect specific protection of the probe. 
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The size of the protected fragment in the mouse brain sample was shorter than 
the full-length probe, which showed that RNase treatment removed 247 b.p. of 
unprotected probe.  This indicated that cyp4X1 was expressed in brain tissue, 
but not in liver.  The detection of cyp4X1 expression in brain tissue is 
noteworthy, because of the low content of total P450 in brain.  Furthermore, 
most of the P450 isoform detected in the brain are also expressed at high levels 
in extracranial tissues (Bylund et al., 2002; Hedlund et al., 2001), but mouse 
cyp4x1 is not found in the liver.  It had been reported previously that CYP4X1 
had a unique localization to the rat brain, whereas the data presented in section 
3.3.9 demonstrated that mouse cyp4X1 was also expressed in the aorta.  The 
physiological functions of the 4X1 genes are not yet known.  However, the 
data presented here together with previous studies suggest that the 4x1 gene 
may be physiologically important enzyme in neuron function. 
It is known that cyp4a genes are regulated by PPARĮ (Bell et al, 1993) and the 
availability of PPARĮ knock-out mice that do not contain a functional PPARĮ 
gene offers an ideal system to study any role of PPARĮ in the expression of 
mcyp4X1. Hence, expression of cyp4x1 expression in wild type and knock-out 
mice was also investigated. Figure 3.35 shows expression of mcyp4X1 in total 
brain RNA extracted from wild type and knock-out mice. 
This study has found that both wild type and knock-out mice express cyp4X1 
at a similar level.  This was surprising, because expression of the cyp4a 
subfamily is regulated by PPARĮ (Bell et al., 1993), and suggests that the 
cyp4X1 gene is regulated not by PPARĮ, but by alternative mechanisms.  
The induction effects of peroxisome proliferators on the cyp4X1 gene were 
also investigated.  It has been reported that ciprofibrate induces mitochondrial 
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3-hydroxy-3-methylglutaryl-CoA synthase (mHS) in the brain, and that it must 
therefore be bioavailable in the brain (Cullingford et al., 2002).  Figure 3.38 
shows the induction effect of these agents on the expression of cyp4X1 in 
mouse brain.  None of the peroxisome proliferators tested caused significant 
induction of cyp4X1.  This indicates that cyp4X1 gene is not induced by 
ciprofibrate and this consistent with the fact that ciprofibrate induced only the 
CYP4A subfamily. 
In summary, the mouse cyp4x1 gene is expressed in the brain, but not in the 
liver.  However, mouse cyp4X1 expression is not uniquely localized in the 
brain, but is also found in the aorta.  There was no difference in cyp4X1 
expression levels between wild type and PPARĮ knockout mice, and cyp4X1 
expression was not induced by peroxisome proliferators.  
 
4.10 Tissues distribution of cyp4X1 expression and induction 
Several mouse tissues were isolated and RNA was extracted in order to study 
the tissue distribution of cyp4X1 gene expression. Figure 3.36 shows the 
evidence for cyp4X1 expression in mouse lung, heart, and kidney tissues.  
Protected bands were produced after probe hybridisation in these tissues.  
The protected signals were detected only after prolonged exposure of 
autoradiography (four days).  Therefore, the cyp4X1 gene may be expressed in 
these tissues but at very low levels.  
Because the protected fragment was detected at very low levels and only after 
prolonged exposure times, it cannot be said for sure that cyp4x1 is expressed in 
these tissues.  Cyp4X1 is definitely expressed in brain and aorta but further 
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study of the other tissues is necessary to obtain convincing proof of more 
widespread cyp4X1 expression. 
 
4.11 Sensitivity of mouse cyp4X1 antisera 
The next aim of the study was to produce antisera against mouse cyp4X1 and 
characterise this antisera using recombinant and native mouse cyp4X1 proteins. 
Antisera were successfully produced, as discussed below. 
Antiserum against human CYP4X1 (A gift from Dr. Bell) was initially tested 
against recombinant mouse cyp4X1protein, and the minimum detection limit 
obtained was 100 ng (Figure 3.45).  The antisera against human cyp4X1 
therefore had low and insufficient sensitivity against the mouse recombinant 
protein.  There is only 79.2% identity between the mouse and human 
cyp4X1proteins, which explains the low level of cross-reactivity between 
them.  For studies of mouse cyp4X1, a mouse-specific antiserum was therefore 
required.  
Antisera against mouse cyp4X1 were produced using two rabbits (denoted 
"189" and "190").  Sensitivity against the antigen was improved with 
increasing numbers of immunizations in rabbit 190, and the minimum 
detection limit obtained was 1 ng, whereas repeated immunization in rabbit 189 
failed to improve its sensitivity beyond 3 ng. 
When antisera against mouse cyp4X1 were blotted against recombinant 
antigen, a clear band at 53 kDa was detected in each track as expected (Figure 
3.47 A).  The primary sequence of the cyp4X1 cDNA predicts a protein of 
62,808 Da, which is slightly higher than the observed molecular size of the 
recombinant mouse cyp4X1 (53 kDa).  This is consistent with the literature, 
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since most P450s run at 52-55 kDa on SDS-PAGE gels yet have a predicted 
molecular mass of ~60 kDa.  The antisera from rabbit 190 consistently detected 
a single band at 53 kDa, as expected.  However, the antisera from rabbit 189 
detected a single clear band at 53 kDa in only one of the samples tested (Figure 
3.47 B).  When 10 ng of antigen was probed, a single band was detected, as 
expected, but lower quantities of antigen (3, 1, and 0.3 ng) consistently 
produced streaky, indistinct bands.  The reasons for this are not known.  
 
4.12 Selectivity of mouse cyp4X1 antisera 
Once the sensitivity of the antisera had been determined, the selectivity was 
tested.  This testing was carried out using brain and liver tissues from mice, 
since cyp4X1 RNA was known to be expressed in brain but not liver, as 
discussed above. 
The specificity of the antisera for mouse cyp4X1 was tested by 
immunodetection using microsomal and cytosolic preparations from mouse 
brain and liver (Figure 3.48 A). 
Western blots of microsomal and cytosolic extracts were probed with both 
immune and pre-immune sera.  When immune sera were used to probe mouse 
brain microsomes and cytosol, a strong band was detected at 53 kDa, but this 
band was not detected in liver preparations.  Several other bands were also 
detected in both brain and liver fractions.  However, only the 53 kDa band 
detected in brain extracts failed to appear after probing with preimmune serum. 
This indicated that the immune serum was able to discriminate between 
cyp4X1 and other proteins.  Pre-immune sera did not detect cyp4X1 at 53 kDa 
so this demonstrates that the 53 kDa band is specific.  The size of the protein 
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detected (~ 53 kDa) by mouse cyp4X1 antisera in brain microsomes and 
cytosol was slightly lower than that of the purified recombinant protein, 
consistent with the presence of a 49 amino acid N-terminal fusion on the 
recombinant protein. 
The data presented here in the current study show that highly sensitive and 
selective antibodies were present in the mouse cyp4X1 antisera.  However, in 
addition to detecting the 53 kDa cyp4X1 band, antisera detected several minor 
bands.  These were also detected by pre-immune sera and were therefore due to 
non-specific interactions.  In order to prove that the minor contaminating bands 
were due to non-specific antibodies present in the antisera, antisera were 
blocked by incubation with an excess of purified recombinant cyp4X1 protein. 
Normal and blocked cyp4X1 antisera were used to probe brain microsomes.  
Only normal antisera detected the 53 kDa cyp4X1 band, but both antisera 
detected the minor bands, indicating that these minor bands were due to the 
presence of non-cyp4X1 specific antibodies in the antisera.  
The detection of cyp4X1 in both brain microsomes and cytosol was surprising, 
because CYP450 is usually found in the microsomes, but not in the cytosol. 
To check this finding, double centrifugation was carried out at 111000xg for 
thirty minutes and one centrifugation at 111000xg for one hour to obtain pure 
cytosol. Although the cyp4X1 protein was still present following double 
centrifugation for thirty minutes and one centrifugation for one hour, the band 
was less intense and no lower molecular weight bands were present (Figure 
3.49 and 3.50).  This result suggests that the detection of cyp4X1 in the cytosol 
may be an artefact caused by homogenisation or failure to completely remove 
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microsomes during centrifugation. Further investigation is therefore required to 
reliably determine the cellular localization of cyp4x1 in the mouse brain.  
The total content of P450 in rat brain tissue is approximately 100 pmols/mg 
microsomal protein ((Bhagwat,et al 1995).  In this study, the calculated amount 
of cyp4X1 protein in brain was ~200 pmol/mg, which demonstrates that the 
cyp4X1 content in brain is potentially a major component of the total brain 
cytochrome P450 (Figure 3.52).  It is important to note that all of the 
immunoreactive protein is not necessarily present as functional holoenzyme.  
However, the very high levels of cyp4X1 present strongly suggest an important 
role of this P450 in brain function. 
 
4.13 Cyp4X1 protein localization 
It has been reported that CYP4X1 has a unique localization specific in the rat 
brain (Bylund et al., 2002).  In the same study it was suggested that CYP4X1 
was mainly expressed in neurons.  In the present study it was found that the 
cyp4X1 protein is localized in the cytoplasm of cerebellar cells in mouse brain 
tissue (Figure 3.53).  A negative control in the absence of primary antiserum 
showed no immunostaining, demonstrating that positive staining, in the test 
samples was due to the presence of cyp4X1 protein.  Furthermore, the fact that 
Purkinje cells did not stain for cyp4X1 demonstrated that there was specific 
staining by the antisera in cerebellar cells.  
In Figure 3.53 (panel B), it was not absolutely confirmed that the stained cells 
were neuron cells, but based on their size and shape this was a reasonable 
conclusion.  To confirm that the stained cells were neurons and not glial cells, 
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double labelling experiments using GFAP and NF antibodies would be 
required.  
Blood vessels were also stained indicating that vascular endothelial cells also 
contained cyp4X1 protein.  This result was surprising because it was the first 
time that cyp4X1 was seen in the blood vessels, but it supports, the hypothesis 
that this P450 may play an important role in neurovascular function.  
The data presented here show that the cyp4X1 protein is expressed in brain 
tissue, and characterised the localisation of this protein to specific cell types.  
Given the high-level expression of this P450, it is of great interest to determine 
the function of this P450. 
 
4.13 Future work  
The present study has characterized anti-human CYP4Z1 antisera and showed 
that they are capable of detecting <1ng of recombinant antigen.  However, the 
antibody against CYP4Z1 has not been tested against human tissue, due to a 
shortage of human tissue (e.g. aorta, heart).  It is of interest to raise human 
CYP4Z1 antibody against human tissue in order to test antibody specificity and 
selectivity against a native human CYP4Z1.  
To date, nothing is known of the function and expression of this P450.  It is of 
interest to investigate the site expression and function of human CYP4Z1.  The 
present study showed that mouse cyp4X1 is expressed in brain tissue, but not 
other tissues (e.g liver).  However, nothing is known the function of this P450. 
For studying of 4X1 functions, its endogenous substrate needs to be 
determined.  Furthermore, it has been reported that this P450 may have an 
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important role in regulation of the blood pressure.  Hence, it is of interest to 
investigate the enzyme activity of cyp4X1.  
The present study showed the expression of mouse cyp4X1 in mouse tissues, 
but not in human tissues.  It is of interest to investigate the expression of the 
4X1 gene in human tissues. 
The present study showed that mouse cyp4x1 is expressed in brain tissue, but 
nothing is known about mouse cyp4x1 localization.  It is of interest to 
investigate the localization of 4X1gene in mouse brain tissues.  
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